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GUIDANCE 
 
HIV and AIDS remain a major issue in global health. Although the incidence of new infections seems 
to decrease or at least stabilize worldwide, the prevalence of HIV infection represents a huge health 
burden, as the World Health Organization (WHO) estimates that currently 37 million people are 
infected. In Belgium, a similar  trend is seen: there remains a significant incidence of new infections in 
the last years, adding to an increasing prevalence with improved survival. This translates into about 
14.700 people living with HIV (PLHIV) in medical care in Belgium in 2014. 
Cha(lle)nges 
Fortunately, the image of a gaunt and mortally ill AIDS patient no longer corresponds with reality, at 
least in high-income countries. Since the advent of highly active antiretroviral therapy (HAART) or 
continuous antiretroviral therapy (cART), with significantly improved survival, HIV has changed from a 
lethal into a chronic disease. The care focus shifted from keeping the patient alive to keeping the patient 
as healthy as possible, with good quality of life, as long as possible. Hence, the goal is to achieve a 
normal physical and mental health. This evolution entails new challenges for the medical world and for 
the patients, but also for  society. Firstly, the management of a chronic disease requires additional and 
different skills and expertise from health care providers. These include a multidisciplinary approach and 
a long-term vision in which the quality of life of the patient is central. Secondly, the challenges for 
PLHIV are manifold. The vast majority  is confronted with lifelong medication intakes under strict 
adherence requirements. Probably even more challenging is the still ongoing stigmatization of PLHIV. 
This problem can only be addressed in society as a whole. 
 
Aims of the PhD thesis 
In this study, five main goals were identified: 
1. To conduct a literature review on determinants of health-related quality of life (HRQoL) in PLHIV 
2. To assess HRQoL over time and to search for determinants of HRQoL over time, in a single center 
sample of PLHIV from an AIDS Reference Center in Belgium 
3. To assess adherence and its determinants in PLHIV, in the same single center sample 
4. To assess knowledge levels on HIV in university students  
5. To assess disclosure and adherence of PLHIV at the workplace 
Clinical and policy implications will be discussed. 
 
Outline of the PhD thesis 
The introduction will provide the reader some general backgrounds about the key concepts in this 
thesis: HIV, epidemiology, HIV care in Belgium, HRQoL, adherence, disclosure and HIV stigma. 
Secondly, the methods used through the project are described. In the third section, research results 
concerning HRQoL and adherence, experiences from PLHIV in the workplace and HIV-related 
knowledge in a sample of university students are presented. Finally, a global discussion and conclusion is 
given. 
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LEIDRAAD 
 
Hiv en aids staan nog steeds hoog op de wereldagenda. Hoewel het aantal nieuwe infecties stabiel blijft, 
en zelfs een dalende trend vertoont, blijft de hoge prevalentie van hiv een groot gezondheidsprobleem. 
De wereldgezondheidsorganisatie (WHO) schat dat wereldwijd 37 miljoen mensen besmet zijn met het 
virus. In België is een gelijkaardige evolutie merkbaar: de hiv-incidentie blijft hoog en de prevalentie 
neemt toe door de verbeterde overleving. In België worden er ongeveer 14.700 personen met hiv 
medisch opgevolgd in 2014.  
Nieuwe uitdagingen 
Gelukkig is het beeld van een uitgemergelde en doodzieke aidspatiënt ondertussen zeldzaam geworden, 
zeker in hoge-inkomenslanden. Dankzij de huidige antiretrovirale therapie is hiv geëvolueerd van een 
dodelijke naar een chronische ziekte. Vroeger was de behandeling van hiv erop gericht de patiënt in 
leven te houden, nu wil men hem gezond houden en een goeie levenskwaliteit bieden, en dat zo lang 
mogelijk. Men streeft dus naar een normale fysieke en mentale gezondheid. Die evolutie brengt nieuwe 
uitdagingen met zich mee voor de medische wereld, voor de patiënt maar ook  voor de maatschappij. 
Ten eerste vergt de opvolging en behandeling van een chronische ziekte bijkomende vaardigheden en 
expertise van gezondheidszorgverstrekkers, zoals een multidisciplinaire aanpak en een langetermijnvisie 
waarin de levenskwaliteit van de patiënt centraal staat. Patiënten zelf worden geconfronteerd met 
levenslange medicatie, waarbij een strikte therapietrouw noodzakelijk is. Maar misschien nog moeilijker 
is het stigma dat personen met hiv nog steeds ervaren. Dit vormt een belangrijke maatschappelijke 
uitdaging. 
Doelstellingen van het doctoraat 
Het doctoraat beoogde vijf doelen: 
1. Het verrichten van een literatuurstudie over determinanten van gezondheidsgerelateerde 
levenskwaliteit bij personen met hiv 
2. Het meten van de gezondheidsgerelateerde levenskwaliteit over de tijd en het bepalen van de 
determinanten ervan in een studiepopulatie van personen met hiv afkomstig uit een 
aidsreferentiecentrum in België 
3. Het meten van therapietrouw en het bepalen van determinanten ervan in dezelfde studiepopulatie 
4. Het meten van de hiv-kennis bij universiteitsstudenten  
5. Het bevragen van de bekendmaking van de hiv-status en de therapietrouw op het werk 
Mogelijke implicaties voor de klinische opvolging en voor het beleid zullen worden besproken. 
 
Overzicht van het doctoraat 
In de inleiding kan de lezer kennismaken met de kernconcepten in het doctoraat: hiv, epidemiologie, 
hiv-zorg in België, gezondheidsgerelateerde levenskwaliteit, therapietrouw, bekendmaking van hiv en hiv-
stigma. In het volgend hoofdstuk komt de methodologie doorheen het doctoraat aan bod. Het derde 
deel stelt de resultaten van het doctoraatsonderzoek voor: studies betreffende de levenskwaliteit en 
therapietrouw bij personen met hiv, ervaringen van personen met hiv op het werk en kennis over hiv bij 
universiteitsstudenten. Het proefschrift wordt afgesloten met een globale discussie en conclusie. 
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1. INTRODUCTION 
 
1.1.  What is HIV 
 
1.1.1. History 
 
HIV is the abbreviation of Human Immunodeficiency Virus, a virus affecting the human immune 
system. AIDS stands for Acquired ImmunoDeficiency Syndrome, a syndrome caused by HIV infection. 
Although the terms are often mentioned in the same breath, they have a different meaning, as thanks to 
HAART (highly active antiretroviral therapy), not all people infected with HIV will develop AIDS (see 
1.1.2). 
The first report heralding the AIDS epidemic was published in June 1981 by the U.S. Centers for 
Disease Control and Prevention. They reported on a rare lung infection (Pneumocystis carinii 
pneumonia) in five young gay men (men who have sex with men – MSM). The week following the 
publication, they received additional case reports of MSM presenting with similar infections and of 
MSM affected by an aggressive form of cancer (Kaposi sarcoma). By the end of 1981, 270 cases of MSM 
with severe immune deficiency had been reported [1].  
In 1982, the term ‘AIDS’ was used for the first time. In 1984, the virus leading to AIDS was discovered 
and in 1986 it was officially called the ‘human immunodeficiency virus’ (HIV) [1]. In 1987, the first 
antiretroviral agent (zidovudine, AZT)  was approved by the U.S. Food and Drug Administration. 
However, these first antiretroviral regimens, either in mono- or dual therapy with nucleoside analogues, 
were not truly effective [2] and could not prevent that in 1994, AIDS had evolved into the first cause of 
death for people between 25 and 44 years in the U.S. In 1995, the first ‘protease inhibitor’ (see 1.1.6) 
was approved, heralding the start of the HAART era [1]. With these triple drug regimens consisting of 
two nucleoside analogues and a protease inhibitor, AIDS mortality was reduced drastically and HIV-
infection evolved into a chronic disease [3-6]. 
1.1.2. HIV in the world 
 
Worldwide, an estimated 37 million people are living with HIV/AIDS and 2 million individuals were 
newly infected with HIV in 2014 [7]. An estimated 40 million people have died of HIV/AIDS-related 
causes since the beginning of the epidemic [8]. The vast majority of new infections (95%) occur in 
people living in low- and middle-income countries. Sub-Saharan Africa is the most affected region, with 
nearly 1 in every 20 adults living with HIV. Seventy-one percent of all people who are living with HIV in 
the world live in this region [8]. 
In the last decade, new global efforts have been launched to address the epidemic. Thanks to prevention 
(e.g. condom use, male circumcision) HIV incidence rates are declining in a small but growing number 
of countries. In spite of these decreases in incidence rates, prevalence remains high, among others due to 
increased availability of HAART in low and middle income countries as well. In 2014, 15.8 million of 
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people living with HIV (PLHIV) were receiving antiretroviral therapy, more than a 30-fold increase since 
2003. However, in sub-Saharan Africa, still 60% of PLHIV do not have access to HAART [7]. 
1.1.3. Pathophysiology 
 
As a retrovirus, HIV uses the biochemistry of specific human target cells and key viral enzymes to 
transcript its viral RNA into viral DNA, to be integrated into the human genome, from which new viral 
copies can be synthesized. CD3/CD4 positive T-helper lymphocytes are the particular target for HIV [9]. 
The life cycle of HIV consists of the following phases [9, 10] (Figure 1):  
1. Binding to CD4 and additional chemokine receptors (CCR5 or CCX4) on the surface of the CD4-
cell. 
2. Fusion of the virus outer surface (‘envelope’) and the CD4-cell lymphocyte membrane. The virus 
enters the cell. 
3. Reverse transcription: the viral enzyme reverse transcriptase mediates the transcription of viral RNA 
into viral DNA. 
4. Integration: the viral enzyme integrase mediates the integration of viral DNA into the DNA in the 
nucleus of the CD4-cell. 
5. Transcription and translation: use of CD4-cell machinery to synthesize long HIV protein chains. 
6. Assembly: the viral enzyme protease cuts the protein chains into smaller HIV proteins. They 
combine with HIV RNA to form new viruses. 
7. Budding: the new virus pushes itself outside the host cell with the production of new infectious 
virions able to infect previously uninfected CD4-cells. 
 14 
 
 
Figure 1: The HIV life cycle, from [11]. Binding to co-receptors CCR5 or CCX4 is not visualized in this figure. 
There are two types of HIV: HIV-1 and HIV-2. HIV-2 is mainly found in western Africa and is less 
virulent than HIV-1. Within HIV-1, 4 groups (M, N, O and P) have been identified and within group 
M, 9 subtypes have been found (A, B, C, D, F, G, H, J and K). Within HIV-2, 8 groups have been 
identified (A-H) [9, 12]. 
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1.1.4. Transmission 
 
HIV can be transmitted by blood, sperm, vaginal fluid and mother milk. Modes of infection include: 
both homosexual and heterosexual transmission, mother-to-child transmission (MCT, during pregnancy, 
delivery or breastfeeding) and parenteral transmission (prior to systematic screening of blood donors and 
products through blood transfusion, or with intravenous drug use, or accidental exposure with needle 
stick injuries in health care workers) [10]. Prevalence and incidence of these different modes of 
transmission show regional variability [13]. Globally, unprotected sexual intercourse is the main mode of 
transmission [13]. A recent review provides estimates of HIV transmission risks for different exposure 
routes, summarized in Table 1 [14]. 
Table 1: Estimates of per-act probability of acquiring HIV from an infected source 
Exposure route Risk per 10.000 exposures to 
an infected source 
95% Confidence Interval 
Parenteral exposure   
Blood transfusion 9250 8900-9610 
Needle-sharing injection drug use2 63 41-92 
Percutaneous needle stick 23 0-46 
Sexual exposure1   
Receptive anal intercourse3 138 102-186 
Insertive anal intercourse 11 4-28 
Receptive penile-vaginal intercourse 8 6-11 
Insertive penile-vaginal intercourse 4 1-14 
Receptive oral sex Low 0-4 
Insertive oral sex Low 0-4 
Vertical transmission   
Mother-to-child transmission4 2260 1700-2900 
1: Assumes no condom use 
2: Estimate most applicable for the US epidemic, derived from five estimates from three different studies 
3: Ejaculation inside the rectum or withdrawal before ejaculation can increase and decrease the risk, respectively 
4: Without ART use – risk <1% among women treated with ART achieving virological suppression and baby 
treated post-partum (4 weeks) with ART 
As evidenced by the 95% confidence intervals, there undoubtedly exists a wide range in the estimates of 
per-act probability of acquiring HIV from an infected source. However, the estimates clearly rank the 
relative risk according to the setting and/or risk behavior. Furthermore, transmission risk increases 
significantly in each setting in the presence of other sexually transmitted diseases (syphilis, herpes, 
gonorrhea, chlamydia …) or with high viral load (amount of viral particles in the blood) in the infected 
source [14].  
1.1.5. Clinical stages 
 
Acute HIV infection [9, 15] 
Following acquisition of HIV, and an incubation period of on average two to four weeks (but less than 
three months), acute HIV infection can manifest itself through an acute retroviral syndrome. This 
occurs in probably half of new infections and is characterized by fever, myalgia, headache and nausea. 
This flu-like disease is not always recognized as acute HIV infection. In patients with or without acute 
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retroviral syndrome, seroconversion occurs in this time frame, with the appearance of specific HIV-
neutralizing antibodies in the blood. In this acute stage of infection, the viral load can be very high, 
exceeding 105 copies of viral RNA per milliliter due to high level viral replication. This is associated with 
a higher risk of transmission than in the subsequent clinical latency stage. In acute infection, CD4 cells 
drop significantly with uncontrolled infection.  
Clinical latency stage [10] 
With the induction of specific HIV-neutralizing antibodies and specific cytotoxic CD3CD8 T-suppressor 
cell responses, aimed at killing HIV-infected cells, HIV-infection is partially controlled. This results in 
lower viral load values and partial restoration of CD4 cells. This degree of immunologic control can be 
outspoken (in long-term nonprogressors) or even quasi complete (in elite controllers, characterized by 
undetectable viral load in the absence of any ART) [16-18]. 
AIDS [10, 19] 
This stage occurs when the immune system is severely affected by uncontrolled infection. Viral 
replication in this stage is high again. An AIDS diagnosis is given when there are less than 200 CD4-cells 
per microliter of blood (normal values vary between 500-1600 cells per microliter), or when a patient 
presents with an AIDS-defining condition. These comprise opportunistic infections, AIDS-defining 
malignancies or AIDS wasting. Examples of opportunistic infections include oral and esophageal 
candidiasis, cerebral toxoplasmosis, pneumocystis jirovecii pneumonia within a long list.  AIDS-defining 
malignancies include non-Hodgkin lymphoma, Kaposi sarcoma, invasive cervical cancer a.o. AIDS 
wasting, finally, is characterized by unintentional and progressive weight loss, often accompanied by 
weakness, fever, night sweats, nutritional deficiencies, vomiting and diarrhea.  
The three clinical stages of HIV and their associated evolutions in viral load and CD4 cell count are 
shown in Figure 2. The average interval between seroconversion and the development of AIDS, the 
clinical latency period, amounts to eight years, with however significant interindividual variability.  
 
Figure 2: Clinical stages of HIV-infection [20] 
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1.1.6. Treatment 
 
From monotherapy to triple therapy 
As yet HIV infection can not be cured, with an exception confirming this rule (through a complex 
procedure of CCR5-32 deleted autologous bone marrow transplantation [21]). However, current 
treatment options turned HIV into a chronic manageable disease. The last 30 years have witnessed a 
tremendous evolution in treatment options. Before 1996, only nucleoside analogues (nucleoside reverse 
transcriptase inhibitors, or NRTIs) were used. These consisted initially of AZT (zidovudine, Retrovir) 
monotherapy and later bitherapy through combination with 3TC (lamivudine, Epivir), ddI (didanosine, 
Videx) or d4T (stavudine, Zerit) as additional nucleoside analogues. These strategies were not potent 
enough to stop viral replication and were only able to slow down disease progression [2]. The 
introduction of protease inhibitors into a triple cocktail of HAART allowed a switch to a strategy of 
earlier initiation of treatment (the “hit early, hit hard” philosophy) and has proven to be a true game 
changer. Since the introduction of these regimens, AIDS-related mortality has sharply declined as well as 
the occurrence of AIDS-defining conditions and HIV-related morbidity, with and upon condition of 
timely initiation of HAART and strict observance of the high requirements for adherence [3, 4]. 
HAART nowadays still consists of three or more antiretroviral medications, targeting different steps in 
the replication cycle of the virus [10]. Over the years, new drug classes have emerged and currently, there 
are six classes of antiretroviral medication. These can be categorized according to their mechanism of 
action and interference in the biologic sequence of HIV replication in infected cells, as:  
1. Entry inhibitors 
2. Fusion inhibitors 
3. Nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) 
4. Non-nucleoside reverse transcriptase inhibitors (NNRTI) 
5. Integrase inhibitors 
6. Protease inhibitors (PI) 
 
These steps are visualized in the HIV life cycle in Figure 3. 
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Figure 3: Six classes of HIV medication targeting different steps in the HIV replication cycle, from [9] 
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In any HAART regimen, strict adherence is required in order to achieve continuous virological 
suppression, which is the aim of therapy. A typical profile of the dynamics of viral replication control, 
following the initiation of HAART, is given in Figure 4. Failing to achieve this high standard of near to 
100% adherence, is associated with the risk of selection of resistance. Possible approaches to improve 
adherence and prevent the emergence of resistance include development of new drugs with better 
tolerance, safety profile and reduction of pill burden. 
 
Figure 4: Effect of treatment on viral load and CD4 count [20] 
 
Resistance 
Resistance to antiretroviral therapy occurred already in the early years of antiretroviral therapy, and has 
remained a significant problem in management of HAART. Resistance results from HIV-replication 
mistakes, resulting in mutated viruses. By chance, those mutations can be successful and the viruses 
carrying the mutation can be resistant (not responding) any longer to antiretroviral treatment [10]. 
Resistance mutations may burn a complete drug class. Furthermore, there are differences in genetic 
barrier (proneness to develop resistance), which is low for NNRTI and NRTI, but high for protease 
inhibitors [22]. Replication errors occur most frequently when antiretroviral treatment is not potent 
enough to control/stop the replication, e.g. due to insufficient potency (e.g. in mono- or dual therapy) 
or non-adherence [23]. Transmission of drug-resistant viruses is a threat for public health, since patients 
infected with those viruses have more limited treatment options from the start [24]. It is recommended 
to perform genotypic resistance testing before initiating therapy in order to detect baseline resistance 
[25].  
Pill burden and side-effects 
In the beginning of the HAART era, antiretroviral regimens consisted of a large number of pills and 
multiple intake moments. The daily number of pills could rise to more than 20, which represented a 
serious burden to patients. Regimens consisting of a reduced number of pills were associated with better 
virological outcomes – presumably due to a better adherence and less treatment fatigue [26]. Over the 
years, pill burden and dosing frequency have been significantly reduced by new drug formulations, in 
particular with the advent of fixed-dose combination preparations [25, 27] (Figure 5). In 2006, the 
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approval of Atripla – the first once daily fixed-dose combination, or ‘single tablet regimen’ (STR) – 
symbolized a new breakthrough: HIV infection could now be treated by one pill per day. Further 
simplification regimens were developed, for example boosted PI monotherapy or nucleoside free 
regimens in order to address specific issues of NRTI toxicity [28-30]. The reduction in pill burden, 
together with the remarkable decrease in toxicity of newer drugs (mitochondrial toxicity with fatigue and 
muscle weakness, polyneuropathy…), positively influenced long-term adherence and thus clinical 
outcomes for patients [27]. It is estimated that combinations of the different currently available 
antiretrovirals may allow to cover a normal life span of an individual infected e.g. at 20 years of age, 
provided longevity of any regimen is not limited by toxicity or development of resistance. 
 
Figure 5: Example of the decrease in pill burden and/or dosing frequency of HAART over the years 
 
1.2. HIV in Belgium 
 
1.2.1. The HIV epidemic in Belgium 
 
The most recent report of the Scientific Institute of Public Health on HIV/AIDS epidemiology in 
Belgium showed a decrease in the number of new HIV infections. In 2014, 1.039 people were infected 
(minus 8% compared to 2013). This turns out to be the lowest number of new infections since 2008 
[31]. In total, 14.719 PLHIV are in medical care in Belgium, this number continuously grows [31]. The 
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numbers are based upon the report of the seven Belgian AIDS Reference Labs, which are responsible for 
the confirmation tests of HIV (measuring new infections) and the follow up viral load tests 
(measurement of the number of people followed in Belgium).   
More than two thirds of the newly infected PLHIV with the Belgian nationality report having acquired 
HIV in Belgium. Among people with other nationalities, this is approximately 20%; more than half of 
them do not know where having acquired HIV. 
More than half of the PLHIV in Belgium have the Belgian nationality, 80% of them are males. In this 
group, homosexual transmission is most prevalent. Thirty percent of PLHIV in Belgium is of Sub-
Saharan African origin, with 33% of male gender and most prevalent heterosexual transmission. The 
HIV epidemic in Belgium is mainly concentrated in two populations: Belgian MSM and Sub-Saharan 
African women infected via heterosexual contact (Figure 6). 
 
 
Figure 6: Evolution of  the number of patients, grouped per nationality and assumed mode of transmission [31] 
 
Male-to-female ratio among PLHIV in Belgium is 1.78. Mean age is 46 years and 43 years for males and 
females, respectively. 
For the first time also data on treatment, viral load and CD4-count of the PLHIV in Belgium were 
collected and analyzed. It seems that for the period 2007-2013,  89.4% of the 8579 patients from whom 
data were available, were on antiretroviral therapy. This number increased gradually, starting from 75% 
in 2007. Almost 95% of the patients who were at least six months on HAART in 2012-2013 achieved 
an undetectable viral load by the end of the year. Mean CD4-count was 578 cells/mm³, which is 
relatively high and mainly due to earlier start of HAART and greater proportion of PLHIV on HAART 
in Belgium. 
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1.2.2. The organization of HIV care in Belgium 
 
Most of the 14.719 PLHIV in medical care in Belgium are followed in one of the eleven Belgian AIDS 
Reference Centers (ARCs). The centers are located in Antwerp (Institute of Tropical Medicine), Brussels 
(Saint Luc University Hospital, Saint Peter’s Hospital, University Hospital, Erasmus Hospital), Bruges 
(Saint John General Hospital), Ghent (University Hospital),  Leuven (University Hospital), Liège 
(University Hospital), Charleroi (University Hospital) and Mont-Godinne (University Hospital).  
In the ARCs, multidisciplinary care is provided to PLHIV by a team of physicians, nurses, social nurses 
or welfare workers, psychologists and dieticians. On a regular basis (most often, every three months), 
PLHIV visit the center for follow-up. Patients with a recent diagnosis or patients who recently started 
medication, are seen more frequently. Physicians assess the overall health status of the patients, screen 
for possible HIV symptoms or side effects of ART, check the immunological and virological parameters 
as markers for disease progression or control under medication and determine the further medical work 
plan. Nurses perform additional investigations (e.g. blood sampling) and give therapy counseling 
(although this is sometimes performed by a therapy counselor, or by social nurses). The key task for the 
social nurses is to provide psychosocial support in accepting the diagnosis and living with the disease. 
They also help patients with administrative and insurance issues. Physicians and social nurses may refer 
patients to a psychologist for specialized psychological support and follow-up; or to a dietician when 
specific problems arise (for example, involuntary weight loss, overweight/obesity and metabolic 
complications due to ART, dyslipidemia) [32].  
In ARCs, part of the care to PLHIV is financed through a convention between the centers and the 
National Sickness and Invalidity Insurance Institution (RIZIV/INAMI). Costs of consultations with 
physicians and investigations are paid by the patient and health insurance, on the other hand, 
consultations with other health care professionals (social nurse, psychologist, dietician) are covered by 
the convention [33]. ART is free for PLHIV, as this initiated medication is fully reimbursed by the 
health insurance. Patients without Belgian health insurance can not join the convention. According to 
their residence status, financial aspects of health care are organized (for example through urgent medical 
assistance, by Public Centers for Social Welfare / Auxiliary Fund for Sickness and Disability). 
Nevertheless, this group of patients represent a proportionally even more important effort within the 
multidisciplinary team, as they evidently are more prone to stigmatization, lower HRQoL and lower 
adherence. Hence this patient segment requires more psychosocial support and often more intense 
medical follow-up. 
On 1 August 2014, a new (temporary) convention was initiated with a significant reduction in the 
financial support of ARCs. A closed envelope system was introduced, and the maximum envelope set at 
the budget of the previous year (2013), minus 20%. ARCs are enforced to register all their activities 
rigorously, in order to justify the budget and staffing. Medio 2016, results of this temporary convention 
will be evaluated and the convention formula revised accordingly. There is a logic in reducing the 
financial support per patient as a majority of patients under stable medication intake and prolonged 
viral suppression pose few(er) medical and psychosocial problems. This should allow a more systematic 
devolution of medical follow-up to primary care, with the ARC in a backup position rather than a 
primary caregiver role. However, this rationale is not applicable for PLHIV without Belgian health 
insurance and equitable financial support is required. Moreover, a delicate balance will be necessary, in 
order to preserve the financial integrity of the specialized ARC units, most often embedded into 
university services of general internal medicine, that are already financially vulnerable. This financial 
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vulnerability is due to the mere absence of possibilities of generating income from technical medical acts 
(in contrast to other hospital departments and subspecialties) and the low remuneration for purely 
intellectual consultative services. A further reduction of this source of HIV convention related income 
may disrupt this balance and negatively impact on quality of care and ARC capacity, mainly in the 
availability of dedicated personnel. 
 
In October 2013, a national HIV Plan was launched in Belgium. It was developed by the Federal Public 
Service Health, supported by other policy domains (e.g. education, justice…) and overarches the federal 
and regional policies [34]. Four strategic pillars were formulated: prevention, screening and linkage to 
care, treatment of PLHIV and quality of life of PLHIV. The principles were further specified by means 
of concrete actions, aimed at different target groups and stakeholders. MSM and Sub-Saharan African 
migrants were identified as priority groups for prevention and screening interventions, aimed at earlier 
diagnoses. After some hesitation to adopt the plan after the government change in 2014, a number of 
actions described in the plan (such as facilitation of access to HAART irrespective of CD4 count, 
demedicalized testing,...) may effectively be implemented in the near future. 
1.2.3. Follow-up 
 
In the continuum of care from detection of undiagnosed cases to treatment five stages are identified: 
- HIV testing and diagnosis: to identify PLHIV is the first step. People who are not aware of their 
seropositivity are not accessing the care and they can unknowingly transmit the virus. 
 
- Linkage to care: After HIV diagnosis, PLHIV are connected to HIV healthcare providers for 
treatment and counseling. 
 
- Retention to care: HIV treatment is a lifelong process and regular HIV care is established. 
 
- Provision of ART: ART is the recommended treatment to control HIV infection. 
 
- Achieving viral suppression: A good adherence to ART will suppress HIV replication. This is 
the ultimate goal of individual care and will also contribute to the reduction of transmission 
(‘Treatment for prevention’ [35, 36]) 
Ideally, this process would be a continuum, however, in reality it is rather a ‘cascade’ of care. At every 
stage, the target population is not fully captured and seropositive people drop out at different stages. 
In the U.S., 82% of PLHIV is diagnosed, 66% linked to care, 37% retained in care, 33% prescribed 
ART and finally, 25% achieves viral suppression [37] (Figure 7). Black Africans are least likely to be 
retained in care (62% vs. 67% of Hispanics and 71% of Caucasian people) and to achieve viral 
suppression (21% vs. 26% and 31%, respectively). Younger age is also negatively associated with 
retention to care and viral suppression. 
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Figure 7: Linkage to care in different countries 
For France: more than 74% are linked to care and more than 60% is prescribed ART (exact percentages 
unknown)  
 
Data from four European countries (France, United Kingdom, Denmark and Netherlands) are, 
however, more positive, with significantly higher numbers of patients linked to care and prescribed 
ART, and 50-60% PLHIV achieving viral suppression [38] (Figure 7). 
In Belgium, finally, the percentages are even higher, but this should be interpreted with caution because 
results were calculated starting from the diagnosed PLHIV instead of all PLHIV in Belgium [39]. As 
such, of the diagnosed patients, 90.3% enters care, 82% retains in care, 72.4% is prescribed ART and 
69% has achieved viral suppression. An important factor associated with failure to enter or retain into 
care in Belgium is foreign origin. MSM are more likely than other transmission groups to be retained in 
care. The number and percentage of undiagnosed PLHIV in Belgium is unknown, but data from the 
Belgian sexually transmitted infections sentinel network indicate that people younger than 40, 
heterosexuals and people with origin other than Belgium, Europe or Sub-Saharan Africa are more likely 
to be ignorant about their HIV status [39]. However, two explorative HIV-prevalence studies provide 
some interesting quantitative insights on ignorance of HIV in Belgium. The studies were conducted 
among the two principal HIV-infected populations in Belgium: MSM and Sub-Saharan African 
migrants. The first study found an HIV-prevalence of 6% (35/578) among MSM in different venues 
(cruising venues, regular gay clubs/venues and young MSM venues) [40]. Five of them (14.3%) were 
unaware of their seropositivity. Overall, 121/613 (19.7%) men were unaware of their HIV-status. The 
second study, among Sub-Saharan African migrants, found an HIV-prevalence of 6.1% (44/717) in 
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females and 3.1% (22/717) in males [41]. More than half of the participants (53%) did not report their 
HIV-status. This could be due to unawareness, but also to underreporting of HIV positivity in a 
population where HIV-stigma is dominant, resulting in significant denial. 
 
1.3. Health-related quality of life 
 
1.3.1. General considerations 
 
Concept 
 
Health-related quality of life (HRQoL) comprises the aspects of overall quality of life that influence 
health. It is multidimensional and subjective, and there is no standard definition of the concept. 
HRQoL may include general health, physical symptoms and toxicity, physical, emotional, role, social, 
cognitive and sexual functioning [42]. A related concept is ‘well-being’, which reflects positive aspects of 
a person’s life such as positive emotions, resilience and life satisfaction. HRQoL is also reflected in 
participation, which is considered an outcome of a person’s functioning within his or her current social 
and physical environment [43]. 
The assessment of HRQoL has different dimensions [44]. First of all, it is a valuable patient-reported 
outcome that often correlates better with functional capacity and well-being than physiologic measures. 
HRQoL reflects the impact of a particular condition in an individual. HRQoL measures are able to 
capture the different responses of patients and enable a patient-tailored approach. The impact of a 
certain symptom or side-effect on patients’ HRQoL can, for example, be perceived differently by 
different individuals and may require a different approach. 
Secondly, longitudinal HRQoL assessments provide information about the evolution of a medical 
condition. This is especially important in the management of chronic diseases. The natural evolution 
can be tracked, but also the effects of pharmacologic and other treatments. However, it is important to 
note that people, over the course of a chronic condition, may develop a response shift in their self-
evaluation of HRQoL, due to changes in internal standards, values, or conceptualization of HRQoL 
[45].  
Thirdly, HRQoL is used as an outcome measure in economic evaluations of health interventions. In 
economic evaluations, differences in costs of an intervention are weighed against the possible differences 
in health benefits. Health, however, is not easy to quantify and different measures, each with their 
strengths and limitations such as life years gained, disability adjusted life years and quality adjusted life 
years are being used. 
Assessment of HRQoL 
HRQoL can be assessed by different types of self-report questionnaires [46]. Table 2 classifies them 
according to three features: type of score, target group and weighting.  
The type of score can be an index or a profile. The former summarizes the information into one single 
score, while the latter combines the information into a profile, consisting of different subscales. The 
 26 
 
former can be used in cost-effectiveness analyses as it enables a simple comparison between HRQoL of 
different persons and at different time points in a longitudinal follow-up. The latter on the other hand, 
is more detailed and more nuanced. HRQoL is then expressed as scores on different HRQoL domains. 
Some instruments combine both types of scores. The EuroQol generates both a profile score (problems 
reported on its dimensions) and an index score (utility derived from the profile score), and SF-36 data 
can be transformed into health states for which utilities are available [47]. 
A second subdivision can be made according to the target group of the instrument. Some instruments 
were developed for use in different populations and diseases and are broadly applicable. They allow to 
make comparisons among populations and diseases. However, it seems that generic instruments have a 
lower responsiveness to change than disease-specific instruments because the latter include or give more 
weight to health domains important for people living with a specific disease [48]. Concurrently, this is 
the main strength of disease-specific instruments and it increases the face-validity of the instrument for 
patients and other stakeholders (i.e. the perception that it really measures HRQoL). 
Finally, a distinction is made based on weighting. Instruments providing a utility score are preference-
based (cfr. economics: every decision of an individual is a comparison between the utility or "useful-ness" 
obtained from different options). Health utilities are needed to calculate ‘QALYs’ (Quality Adjusted Life 
Years). This concept combines a time and quality dimension and is frequently used to assess and to 
compare impact of different diseases (or treatments) on HRQoL [49].  
The utility of a health state can be derived by three preference-based methods: time-trade off, standard 
gamble and a visual analogue scale [50]. In the time-trade-off method, people can choose between staying 
in a certain ill health state, or being restored to perfect health but with a shorter life expectancy. The life 
expectancy is then varied until the patient considers both options as equivalent. The standard gamble 
procedure implies a choice between staying in the ill health state or a treatment which has a chance of 
curing them, or killing them. The chance is varied until equivalent options are obtained. The visual 
analogue scale is the simplest: people are asked to rate the ill health state on a scale (mostly from 0, 
death, to 1, perfect health). As such, when a large representative sample of a population are asked to rate 
ill health states, average utilities for the ill health states are developed. 
Quality of life instruments using equal weighting attach an equal weight to each item used to calculate 
HRQoL. This may lead to the (fictive) situation where someone who reports having problems with 
mobility and no problems with depressive mood, social functioning and cognition is given the same 
HRQoL score as someone who reports having problems with depressive mood and no problems with 
mobility, social functioning and cognition. Both have one out of four domains impaired and because all 
domains are given equal weights, this results in an identical HRQoL score. The advantage of this 
method is that it is easier to determine HRQoL scores than by preference-based methods. Preference-
based methods are time-consuming and as preferences can change over time, the process should be 
repeated periodically.  
The choice for one instrument or another depends mainly on the purposes of the assessment [51]. For 
cost-effectiveness calculations, for example, an instrument with an index score is obligatory. Clinical 
follow-up, on the other hand, may require a more detailed instrument resulting in profile scores. 
Generic instruments are appropriate to compare HRQol of different populations (cross-sectional 
comparisons), while disease-specific instruments allow to detect changes in HRQol of one specific 
population (longitudinal comparisons) because they include distinct items important for that 
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population. The choice for an instrument with a utility score versus equal weighting is rather 
conceptual: the former uses human (population’s) appreciation of HRQoL, while the latter uses a 
mathematical calculation.  
Table 2: Classification of HRQoL instruments [46].  
MOS-SF-36 = Medical Outcomes Study-Short Form 36 items, WHOQOL = World Health Organization Quality of 
Life, MOS-HIV =  Medical Outcomes Study – HIV health survey, ADDQoL = Audit of Diabetes Dependent 
Quality of Life, AIMS = Arthritis impact measurement scales 
Measure Features Examples 
Type of score   
Index score Useful for cost-effectiveness 
Only one score 
EuroQol [52], Quality of Well-Being 
Scale [53] 
Profile Not appropriate for cost-effectiveness 
More detailed 
EuroQol, MOS-SF-36 [54], 
WHOQOL [55] 
Target group   
Generic Broadly applicable 
Allows comparisons between groups 
Less responsive to change 
EuroQol, Quality of Well-Being Scale 
Specific More face validity 
Responsive to change 
MOS-HIV [56], ADDQoL [57], AIMS 
[58] 
Weighting   
Utility Preferences from patients or community 
Obtaining weights is difficult 
EuroQol, Quality of Well-Being Scale 
Equal weighting Easier to use Karnofsky performance status [59], 
WHOQOL 
 
1.3.2. HRQoL in HIV 
 
As HIV evolved into a chronic disease, investigating HRQoL in PLHIV gained importance. The first 
scientific papers on HRQoL were published in the early nineties and designs vary from observational 
studies, over interventional studies to validation studies of new or existing HRQoL instruments. Until 
the end of 2015, according to Web of Science, approximately 800 articles were published containing 
‘HIV’ and ‘quality of life’ as title words.  
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In general, HRQoL in PLHIV has increased over the years, mainly due to better treatment options [60]. 
Nowadays, life-expectancy in U.S.A. and Canada for PLHIV is almost equal to the general population, 
in particular for timely diagnosed people and starting ART early (>350 CD4 cells/µl) [6, 61].  
However, life-expectancy is not the only parameter determining HRQoL of ill people. The additional 
question remains on the intrinsic quality of the life years gained. Fortunately, ART side-effects and 
toxicity have drastically been reduced since the early years of HAART [62]. However, a recent study in 
the UK found that HRQoL in PLHIV remains impaired, despite the numerous clinical advances. Their 
sample of PLHIV – mainly consisting of Caucasian MSM with good clinical parameters – reported a 
utility score of 0.74 versus 0.82 in the general population. They reported significantly more problems on 
all HRQoL domains, the difference on anxiety/depression being the most distinct [63]. Although people 
with certain other chronic diseases report lower utilities (0.53, 0.56, 0.62 in rheumatic disorders, 
chronic fatigue and COPD, respectively [64-66]), the significant difference with the general population 
indicates that PLHIV still suffer from HIV-related difficulties [64]. However, HRQoL differences can 
also emerge from pre-existing differences between PLHIV and the general population (e.g. other socio-
demographic profile, more pre-existing psychiatric morbidity [68, 69]). 
Many HRQoL instruments are being used in PLHIV and opinions vary on which instrument is the most 
suitable [70]. Sometimes, a combination of instruments is recommended [71, 72]. Table 3 lists some of 
the most used instruments along with their properties. 
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Table 3: Seven HRQoL instruments used in PLHIV and their properties 
 MOS SF-36 [73] EuroQol-5D [52] Quality of Well-
being scale [53] 
MOS-HIV Health 
Survey [55] 
Functional 
assessment of HIV 
infection [74] 
HIV/AIDS 
Quality of Life [75] 
Multidimensional 
QoL 
Questionnaire for 
HIV/AIDS [76] 
Number of items 36 5 50 35 44 42 40 
 Range 0-100 0-1 0-1 0-100 0-176 0-100 12-84 
Subscales 8: physical 
functioning, 
physically related 
role limitations, 
social functioning, 
pain, vitality, 
mental health, 
emotionally related 
role limitations, 
general health 
perceptions 
5: mobility, self-
care, usual 
activities, 
pain/discomfort 
and anxiety/ 
depression 
5: self-care, 
mobility, 
institutionalization 
social activities, 
symptoms/ 
Problems 
10 (+ health 
transition): general 
health perceptions, 
pain, physical 
functioning, role 
functioning, social 
functioning, 
mental health, 
energy/fatigue, 
cognitive function, 
health distress and 
quality of life 
5: Physical well-
being, functional 
and global well-
being, emotional 
well-being/living 
with HIV, social 
well-being, 
cognitive 
functioning 
9: Overall 
function, sexual 
function, 
disclosure worries, 
health worries, 
financial worries, 
HIV mastery, life 
satisfaction, 
medication 
concerns, provider 
trust 
10: mental health, 
physical health, 
physical 
functioning, social 
functioning, social 
support, cognitive 
functioning, 
financial status, 
partner intimacy, 
sexual functioning, 
medical care 
Target sample Generic Generic Generic PLHIV PLHIV PLHIV PLHIV 
Internally 
consistent 
Yes Yes / Yes Yes Moderate Moderate [77] 
Valid in HIV Yes [78] Yes [79] Yes [80] Yes Yes Yes Yes 
Reliable in HIV Yes [78] Yes [79] / Yes Yes Yes Yes 
Sensitive to change 
in HIV 
Yes [71] Moderate [79] / Yes Yes / Yes 
Method Self-administered Self-administered Interview or self-
administered 
Self-administered Self-administered Self-administered Interview or self-
administered 
Extra   Previously called 
‘Health status 
index’ and ‘Index 
of well-being 
Ceiling effects Based on concerns 
of PLHIV 
Based on concerns 
of PLHIV  
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1.4. Adherence 
 
1.4.1. General considerations 
 
Concept 
Adherence is the act of doing what is required; in medicine, the term refers to following a medical 
advice. Terminology and definitions are, however, subject to discussions among researchers. The term 
‘compliance’ for example, was previously commonly used but has been replaced due to its negative 
connotation, as it is suggestive of obedience and submission of the patient to the doctor. This as such 
refers to the more paternalistic classic medical ethics with the caregiver as primary focus, versus the 
current participatory ethics with patient empowerment [81]. Words as ‘concordance’ or ‘agreement’ 
emphasize the patient-physician relationship, but are not quantifiable [82]. Therefore, ‘adherence’ is 
nowadays widely used [81].  
Non-adherence is a major problem and concern in medicine and it negatively impacts public health (e.g. 
translating into more hospital admissions, slower healing processes). Especially in chronic diseases, 
adherence may be low [81], e.g. asthma or diabetes type [83, 84]. 
Adherence is often used to describe only one aspect of ‘following a medical advice’, namely the 
medication-taking behavior. Recently, a taxonomy was developed which distinguishes three components 
of adherence: initiation, implementation and discontinuation [82] (Figure 8). This taxonomy helps to 
distinguish different forms of non-adherence: never (or late) initiation of the therapy, suboptimal intake 
of the medication doses or early discontinuation of the therapy. 
 
Figure 8: Visual representation of a taxonomy for adherence, from [82] 
This taxonomy parallels the ‘Stages of change’ model developed by Prochaska and Diclemente [85]. 
Continued adherence is then considered the ‘change’ towards the health behavior. In the model, shown 
in Figure 9, five stages and degrees of readiness are defined:  
1. Pre-contemplation (not ready): The person has no intention to start the healthy behavior in the 
near future. He/she is unaware of the need to change. 
2. Contemplation (getting ready): The person has the intention to change in the near future. The 
weighting between pros and cons of changing can produce ambivalence which can cause people to 
remain in this stage for a long period.  
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3. Determination (ready): The person is ready to start taking action in the immediate future, he/she 
has already taken small steps which could help incorporate the behavior in his/her daily life. 
4. Action: There are overt modifications in the person’s lifestyle, however, he/she is fighting against 
relapse. 
5. Maintenance: The person is less tempted to relapse and is increasingly confident about continuing 
the change. 
 
Figure 9: Stages of change model of Prochaska and Diclemente [85] 
Assessment of adherence 
Adherence can be measured through various methods. Unfortunately, none of the methods is ideal as 
they only provide an estimate of the true medication-taking behavior [86]. Table 4 lists the different 
methods, along with their most important advantages and disadvantages. Above all, adherence 
assessment should be a systematic item of each patient-caregiver contact and adherence difficulties 
should be explored, in order to detect improvement tools. 
Self-report is most frequently used. Patients are asked about their adherence through interviews, 
questionnaires or written documentation (e.g. diaries) [87]. This method is easy and fast but has two 
disadvantages. First, its subjective nature renders it prone to social desirability. Patients may report a 
higher adherence than in reality in order to please health care providers [88]. Secondly, patients may 
have difficulties to recall their adherence during a preceding period (recall bias) [88]. Nevertheless, self-
report measures have a strong correlation with more objective measures, and with virological response 
[88, 89]. 
A less subjective way of assessing adherence is pill count, often performed in clinical studies. Patients are 
asked to bring their pill packages (since the last visit) and the number of pills in the packages are 
counted by the health care provider. Adherence is then calculated by comparing the number of pills 
taken out of the packages and the number of pills that should have been taken. The biggest pitfall of this 
 32 
 
method is the uncertainty whether the pills were actually taken. The patient could have thrown the pills 
away (‘medication dumping’) [90]. Further, pill counting can be perceived as intrusive or paternalistic by 
the patient [91].  
Pharmacy refill records can be used to assess regularity of medication acquisition [87]. Actual refill data 
are compared to expected refill data, based on medication prescriptions. When a patient refills too late, 
it is assumed that he or she is either missing doses or is not taking medication. This method is less 
intrusive than pill-count and data can be made available from electronic databases. However, these 
databases should be shared, as patients can refill their medication in different pharmacies. Another 
limitation refers to the possible gap between refilling and actually taking medication [87]. 
Electronic monitoring is another variant of pill count. Electronic monitoring devices are medication 
containers provided with a chip, registering every time the container is opened. As such, real time data 
are collected on whether and when the container has been opened [92]. This method can reveal patterns 
of non-adherence which cannot be detected by pill count (e.g. non-adherence only in the morning, 
increased pre-appointment use) [84]. Comparable to pill count, medication dumping remains possible. 
Another disadvantage relates to the difficulty to combine the devices with pill boxes [93, 94]. Patients 
who take different medications, need different devices instead of a single pill box and mostly, there are 
no visual cues (days of the week, morning/noon/evening) on the device. 
Therapeutic drug monitoring (TDM), a biochemical measure, is the most objective method. Serum 
medication levels are registered and as such, this is a direct way to measure adherence [95]. Therapeutic 
drug monitoring has, however, not entered everyday clinical practice because of some limitations. First, 
it can only provide information on adherence during a short time period (days before the blood 
sampling) [96], they are prone to pharmacokinetic variability among patients  and they are expensive 
[97]. TDM can also be prone to bias, as patient pre-knowledge of planned TDM may entice a temporary 
improvement in pill intake, from a perspective of social desirability in the patient-caregiver relationship. 
Furthermore, there remains an issue of pharmacokinetic variability and TDM is expensive in particular 
[86]. In Belgium there is no reimbursement for TDM of antiretroviral drugs. 
 
Table 4: Different methods to measure adherence, their advantages and disadvantages 
 
Method 
 
 
Advantages 
 
Disadvantages 
Self-report Easy to administer Recall bias 
Prone to social desirability 
Pill count More objective Medication dumping 
Intrusive 
Pharmacy records Less intrusive Medication dumping 
Need for shared database  
Electronic monitoring Detailed Medication dumping 
Difficult to combine with a pill box 
Therapeutic drug monitoring Objective 
 
Not representative for longer 
periods 
Expensive 
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1.4.2. Adherence in HIV 
 
The pharmaceutical treatment of HIV can vary from one pill to five or more pills per day, whether or 
not requiring different intake moments. In order to achieve the treatment goals, i.e. undetectable viral 
load, improvement of the immunological function and a good quality of life, a proper adherence is 
mandatory. This means that PLHIV have to take all medications, have to take them on time and, 
sometimes, have to take into account special dietary recommendations [98]. 
Generally, in HIV treatment a threshold of 95% adherence (thus 95% of all pills appropriately taken) is 
applied. Adherence levels below 95% are associated with an increased risk of virological failure [99, 
100]. However, the threshold is no longer absolute and different researchers found that lower adherence 
levels could also be sufficient to achieve or to maintain virological control [101, 102]. This is called 
‘forgiveness’. In general, a longer elimination half-life favors greater forgiveness, for example in NNRTI- 
or boosted PI-regimens [101]. 
Suboptimal adherence can have several negative effects, for the patient as well as for his environment 
[87]. A insufficiently high dosage of medication cannot control viral replication, neither restore immune 
function, and so it will negatively impact the patient’s health. Moreover, the risk for transmission is 
higher with persistent viral replication. 
 
1.5. Living with HIV and with others: stigma and disclosure 
 
1.5.1. Stigma 
 
Stigma is defined as: “The phenomenon whereby an individual with an attribute which is deeply 
discredited by his/her society is rejected as a result of the attribute. Stigma is a process by which the 
reaction of another person spoils normal identity.”[103]  
Stigma can stem from physical (e.g. dwarfism), personal (e.g. mental illness) or social (e.g. racial 
minorities) deviations from the standard [103]. External stigma, the degree to which PLHIV experience 
stigma, should be differentiated from internal stigma, which refers to the degree to which PLHIV 
themselves endorse the negative beliefs and feelings about HIV [104]. 
Despite many efforts, worldwide stigma and discrimination remain major obstacles to an effective 
response to the HIV epidemic [13]. In 1987 already, Jonathan Mann, the founding Director of the 
World Health Organization’s former Global Programme on AIDS considered stigma to be ‘as central to 
the global AIDS challenge as the disease itself’ [105].  
Manifestations of stigmatization can be manifold. Research from Wallonia reported on the experience 
of stigma by 340 PLHIV in the social, medical and professional setting [106]. More than one third 
(35.7%) of the participants had been confronted with derogatory or clumsy gossip, 16.2% insulted or 
criticized and 10% reported that some people did not want to touch them since they know they are 
seropositive. Further, one fifth reported to have experienced a feeling of discomfort among health care 
providers, 15% has heard disparaging comments and 13.1% had been refused care on minimal one 
 34 
 
occasion. Less PLHIV (6.5%) experienced problems in their professional life, partly because 58.4% did 
not reveal their status at work.  
Four underlying reasons for stigmatization of PLHIV have been identified. First, HIV is perceived to be 
a highly contagious disease. Second, HIV is perceived as a serious condition, as some people still 
associate HIV with AIDS and death. Third, some people think PLHIV are responsible themselves for 
having acquired the disease. Fourth, HIV is sometimes associated with perceived norm-violating 
behaviors such as sexual risk behavior, homosexuality and intravenous drug use. As shown in Figure 10, 
these considerations create fear and anger towards PLHIV and few feelings of pity, leading to 
stigmatization. 
 
Figure 10: Underlying reasons for the stigmatization of PLHIV, from [107] 
 
The reasons for stigmatization, however, are founded on misconceptions and ignorance about HIV 
[108]. Increasing awareness and knowledge about the disease can reduce stigmatization [109, 110]. 
Interventions aimed at reducing HIV-related stigma almost always contain an informational part, 
sometimes combined with skills building or contact with PLHIV [110]. These interventions have been 
shown to be able to change attitudes towards PLHIV. However, interventions to reduce stigmatization 
on the long-term, especially in developing countries,  should be undertaken at a higher level. These 
should be based on social processes and positive community participation [110, 111] 
HIV-uninfected people may ‘use’ emotional prejudices and cognitive stereotypes about HIV and may 
even discriminate PLHIV in their behavior. This can lead to social distancing from PLHIV, avoidance to 
take an HIV-test and it negatively influences policy support for PLHIV (for example, leading to less 
pressure for governments to establish or to amplify anti-discrimination laws) [104, 110, 112, 113]. 
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Figure 11: HIV Stigma Framework. It summarizes the different mechanisms and outcomes of stigma, for HIV-
infected as well as HIV-uninfected people [104]. 
 
Mechanisms for HIV-infected people include enacted (experience of stigma), anticipated (belief that 
stigma will occur) and internalized (PLHIVs endorsement of negative beliefs about HIV) stigma. 
Research differentiating between those three mechanisms is scarce. Primarily, internalized stigma was 
studied. Many PLHIV experience internal stigma: according to Lee et al (2002), more than 60% reports 
being embarrassed about the disease and approximately three quarters find it hard to disclose their 
serostatus [113]. In South-Africa, more than one in three participants indicated feeling dirty, ashamed, 
or guilty because of their HIV status [114]. Heterosexuals encountered a higher level of internal stigma, 
possibly because they are afraid to be associated with homo-or bisexuality and/or because enacted stigma 
in the homosexual community has been reduced by support and advocacy campaigns in the past. 
Stigma is negatively associated with mental health [115], social support [116] and people experiencing 
more stigma report more HIV symptoms [113]. Moreover, stigma has been associated with decreased 
HRQoL [66, 117] and non-adherence [115, 118]. Finally, it deters people from seeking medical care and 
to disclose their serostatus [112, 119, 120]. 
Stigma can be assessed in both infected as uninfected people. Examples of HIV stigma questionnaires 
for PLHIV are the HIV stigma scale [121], the Internalized AIDS-related stigma scale [122] and the 
People living with HIV stigma index [123]. A critical discussion on stigma questionnaires developed for 
PLHIV and their psychometric properties is given by Stevelink et al. [124]. Literature on measuring HIV 
stigma from the perspective of uninfected people is, however, more diverse and only few instruments 
were implemented across multiple contexts. Examples of instruments measuring HIV stigma in 
uninfected people are the AIDS attitude scale [125] and more specific instruments such as the tool of 
Kalichman (South-Africa) [126] and Redipath (Asia Pacific) [127], or a recent questionnaire especially 
developed for health facility staff [128]. 
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Reducing stigma is one of the main goals of the Belgian HIV plan: “Reducing all forms of stigma and 
discrimination, especially when they based on serological or health status.” This is then concretized in 
four actions [34]:  
1. Within the target groups (MSM and Sub-Saharan African migrants): Developing campaigns, 
instruments and policies which stimulate a non-discriminatory and non-stigmatizing environment 
within the target groups. 
2. Within society: Developing campaigns, instruments and policies which stimulate a non-
discriminatory and non-stigmatizing environment for PLHIV, LGBTQI (Lesbian, Gay, Bisexual, 
Transgender, Queer, Intersex) and migrants. 
3. Within detainees: Reducing stigmatization of detainees who use drugs. 
4. Within health care professionals: Integration of HIV testing in routine testing for other diseases. 
 
1.5.2. Disclosure 
 
Disclosure refers to the process of announcing the seropositive status to other persons. This is a very 
important issue for PLHIV, as they are repeatedly confronted with disclosure decisions over the course 
of a lifetime [129]. The disclosure process is often complex, with many possible courses and many 
influencing factors. Disclosure can be seen as a continuum, from telling nobody to sharing seropositivity 
with everyone from the onset. Most often disclosure is partial and limited. 
The disclosure process model, as proposed by  Chaudoir and Fisher, offers a good framework to 
understand disclosure and its influencing factors [129]. It was developed to define disclosure among 
people living with a concealable stigmatized identity, such as HIV (but also mental illness, victims of 
assault…). It describes both the decision-making process and the outcome process of disclosure and it 
has five components: antecedent goals, the disclosure event itself, mediating processes, outcomes, and a 
feedback loop (Figure 12).  
The first component in the model are goals of disclosure. Disclosure has been defined as a functional 
behavior, allowing to pursue personal goals [130]. Disclosure takes place when the person thinks the 
goal(s) can be achieved, i.e., after selecting the confidant, evaluating the risks/benefits and choosing a 
strategy [131]. Empirical research shows that PLHIV disclose their status for different reasons: to 
strengthen a relationship, to fulfill a moral duty to inform the confidant in order to protect the 
confidant from exposure to HIV etc. [129] However, there also exist barriers against disclosure, which 
can also be interpreted as goals, for example a desire to keep the diagnosis private, avoidance of social 
rejection and of causing sorrow. Goals can thus be approach-focused or avoidance-focused. People with 
approach goals are pursuing positive outcomes, give more attention to positive cues and have a positive 
state. In contrast, people with avoidance goals are preventing negative outcomes, give more attention to 
negative cues and have a negative affect. 
A second component is the disclosure event itself. The content of disclosure can vary in depth (degree to 
which the diagnosis is considered to be intimate), breadth (number of different aspects related to living 
with HIV) and duration (short or long conversation). The emotional content may be high if the person 
expresses his/her feelings about the disease, or low if the person focuses on factual information about 
the disease. Secondly, the reaction of the confidant is a part of the disclosure event. This can be 
influenced by the content and can in turn influence the content. Chaudoir and Fisher also emphasize 
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the effect of goals on the disclosure event. The approach- or avoidance-focused goals influence the 
number of events, the ability to communicate efficiently and the attention paid to respectively positive 
or negative stimuli during disclosure. 
Disclosure can lead to different outcomes. Individual outcomes can be divided in psychological (distress, 
self-esteem, psychiatric illness), behavioral (sexual behavior, adherence to ART) and health (general well-
being, immune recovery, virological suppression or failure) outcomes. Those individual outcomes have 
been studied most. Secondly, dyadic outcomes, such as liking each other, intimacy and trust, relate to 
the relationship between the discloser and the confidant. Finally, there are social contextual outcomes, 
such as effects on cultural stigma or norms for disclosure. Those outcomes will obviously not be 
achieved by a single disclosure event, but rather by an increase of the ‘phenomenon’ of disclosure by 
PLHIV in society.  
There are mediating processes between (the) disclosure event(s) and outcomes. The most studied is 
‘alleviation of inhibition’. Actively hiding an HIV diagnosis, or feigning seronegativity, affects one’s 
psychological and physiological health. HIV disclosure, therefore, may lead to positive outcomes such as 
less distress and better immunological outcomes [132, 133]. Probably, people with avoidance-focused 
goals would benefit more from this process, as they are more likely to experience negative psychological 
and physiological consequences prior to disclosure. The second mediating process, social support, is also 
crucial to understand outcomes of disclosure. Receiving social support has an important impact on well-
being and its absence can be harmful to psychological health. Additionally, social support or rejection 
can have implications for dyadic relationships (liking, intimacy, trust). It is thought that people with 
approach-focused goals will benefit more from disclosure by obtaining social support. The third 
mediating process is called ‘Changes in social information’. Disclosure changes the information in the 
relationship between the discloser and the confidant and this may mediate individual (taking ART in 
the presence of the confidant), dyadic (change in sexual behavior) and social contextual (becoming 
member of a support group, reducing stigma) outcomes. 
Finally, the model includes a feedback loop. When disclosure events elicit positive outcomes, they may 
increase the likelihood of future and further disclosure, in contrast to negative outcomes after 
disclosure. 
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Figure 12: Disclosure processes model, from [129] 
 
Although this model is supported by scientific evidence, it has some limitations. First of all, the 
distinction between approach- or avoidance-focused goals is not so easy to make. In many cases, the goals 
can be combined, or can differ from situation to situation. Secondly, the model mainly relates to 
voluntary disclosing or not-disclosing. Sometimes, people may feel obliged to disclose their seropositivity 
(for example, after condom rupture, or when filling a medical questionnaire for insurance or 
occupational medicine) [134, 135]. One could argue that in such situations the same either approach- or 
avoidance focused goals enter into play and the model would remain valid. Lastly, the model does not 
identify factors outside the disclosure process which nevertheless influence disclosure, for example 
medical aspects (having to take ART or not, presence of symptoms), the personality of the individual 
(open versus inhibited), the type and severity of stigma in the environment of the person (from 
punishments and ostrasizements over travel restrictions to anti-discrimination laws, but also the post-test 
counseling received from health care providers)… [136-141].  
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2. RESEARCH QUESTIONS AND METHODOLOGY 
 
2.1. Health-Related Quality of Life studies 
 
 What are the main determinants of HRQoL in PLHIV? 
 What are the current levels and determinants of HRQoL in PLHIV in a real life setting in Belgium? 
The first research questions focus on determinants of HRQoL in PLHIV. For this purpose, first, a 
narrative literature review was performed. Subsequently, current levels and determinants of HRQoL in 
PLHIV were assessed in a real-life setting in Belgium. To achieve this aim, the HIV CARE Study was 
initiated in the summer of 2011, in a single center design, namely the AIDS Reference Center (ARC) 
within the department of General Internal Medicine of the University Hospital Ghent, Belgium. This is 
one of at that time nine ARCs devoted to specialist HIV care. In the center, approximately 1.300 
PLHIV are followed by a multidisciplinary team of HIV clinicians, (social) nurses, psychiatrists and 
psychologists.  
Population 
The HIV CARE Study was addressed towards all PLHIV and thus aimed at including a representative 
study sample. It was decided to divide the study in two parts: one part in which every patient could be 
included, and another part for Caucasian, Dutch-speaking people between 18 and 55 years only. For the 
first part, study documents were available in Dutch, French and English. There were no exclusion 
criteria except mastery of one of those three languages. The restriction to Caucasian, Dutch-speaking 
PLHIV in the second part of the study was applied because of the emphasis on psychological and thus 
cultural and age-related variables. 
Recruitment of patients started at the 1st of January 2012. Most of the patients were enrolled during the 
first year (n = 237, study sample of manuscripts 3.2, 3.3). More than 60% of this sample also 
participated to the follow-up study (n = 148, manuscript 3.4). 
The study was approved by the Ethical Committee of the Ghent University Hospital (Registration 
number: B670201112850). 
Questionnaires 
Data were collected through self-report questionnaires and searches in the electronic patient record. An 
overview of the questionnaires used is shown in Table 5. For HRQoL, we used the EuroQol instrument, 
as well as the Medical Outcomes Study-HIV instrument. As such, we combined the advantages of both 
an index score and a profile score, and both a generic and a disease-specific instrument.  
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Table 5: Questionnaires used in the HIV CARE study. The questionnaires assessing HRQoL, adherence, 
depressive symptoms and neurocognitive complaints are included in the appendix. 
* Only for participants of the second part of the study 
Instrument Measure 
EuroQol-6 Dimensions (EQ-6D) [1] HRQoL 
Medical Outcomes Study-HIV (MOS-HIV) [2] HRQoL 
Simplified Medication Adherence Questionnaire (SMAQ) [3] Adherence 
CASE Adherence Index [4]   Adherence 
Beck Depression Inventory II (BDI-II) [5] Depressive symptoms 
3 neurocognitive screening questions [6] Neurocognitive complaints 
Utrechtse Copinglijst* [7] Coping 
Checklist Individual Strength* [8] Fatigue 
Fatigue Severity Scale* [9]  Fatigue 
The Illness Cognition Questionnaire* [10] Illness cognitions 
Epworth Sleepiness Scale* [11] Sleepiness 
Pittsburgh Sleep Quality Index* [12] Sleep quality 
Minnesota Multiphasic Personality Inventory (MMPI-2)* [13] Personality 
 
Flowchart 
To fluently implement the study in the department, a flowchart was made. During meetings, the 
employees were informed about the study and their possible contribution. The flowchart was developed 
with special attention to the normal course of a consultation at the center, the contribution of all 
employees, the convenience for the patient and finally the acquisition of high-quality data. 
Normal course 
The original course of a consultation at the ARC was complemented by additional study steps. For 
example, nurses delivered the questionnaires because most patients are systematically seen by the 
department nurses for counseling and/or appointments. 
Contribution of all employees 
Both the physicians and the nurses were closely involved in the study. The physician was in charge of the 
recruitment by explaining the study to the patient. The nurse’s role was also crucial: they delivered and 
collected the questionnaires, and they were responsible for the interview on CASE Adherence Index and 
neurocognitive screening questions. 
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Patient convenience 
The study did not change the normal course of a consultation for the patient, except reading and 
signing the informed consent and afterwards filling in the questionnaires. To ensure privacy, no 
references or logos related to HIV/AIDS were placed on the questionnaires. Participants of the second 
part of the study could fill in the second questionnaire bundle at home. A stamped and addressed 
envelope was included, so little effort was required to return the questionnaires to the center.  
Acquiring high-quality data 
Most importantly, the process had to be feasible for the contributors. Therefore, both the physicians and 
the nurses were involved in drafting the flowchart. Its final version was clearly communicated to all, 
especially regarding responsibilities and practical matters. To keep all contributors informed, regular 
feedback and updates of the study were given. 
 
2.2. Adherence study 
 
 How is adherence and what are its determinants in a real-life setting in Belgium? 
In view of the utmost importance of adherence to achieve long term virological suppression as a key 
condition to ensure long term prognosis, this research question was addressed, again in a sample of 
patients in clinical follow-up in a single ARC in Belgium (HIV CARE Study). 
Adherence was measured through self-report, for purposes of simplicity and to avoid deviations from 
routine care (associated with electronic devices or therapeutic drug monitoring).  
 
2.3. Study of HIV-related knowledge among university students 
 
 How is HIV-related knowledge in Belgian university students? 
This study was set up as knowledge is an important prerequisite to understand a disease and lack of 
knowledge is associated with increased stigmatization. Students of Ghent University were asked to 
participate. This sample is presumed to represent a better educated segment of the general population, 
with higher a priori likelihood of good knowledge levels on the subject. A questionnaire about HIV-
related knowledge was developed and distributed during university courses in different faculties. More 
details about the study can be found in 3.5. After publication of the results, a press release was sent out 
and different media reported on our study. 
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2.4. Disclosure study in collaboration with Sensoa 
 
 How are the levels of disclosure and associated perceptions on HIV in the workplace in Belgium? 
In 2013, after obtaining the first HIV CARE results concerning determinants of HRQoL, it was decided 
to further elaborate on the topic ‘HIV in the workplace’. Indeed, it was found that the majority of the 
study population had a job, which positively influences HRQoL. The topic was a good opportunity to 
expand the study outside the ARC of Ghent. Sensoa, the Flemish expertise center for sexual health, was 
chosen to be the primary partner in this project and an official cooperation was established from June 
2013 onwards. The collaboration was profound and both parties were equally involved in the 
development of an online questionnaire, the recruitment of the patients (apart from the HIV CARE 
sample) and the interpretation of the results of the project ‘HIV in the workplace’. The project resulted 
in a paper (see 3.6) and a press release on the occasion of World AIDS Day 2013 (1 December). The 
press release was jointly written by the investigators and the experts of Sensoa.  
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Abstract  
 
Introduction: As infection with the Human Immunodeficiency Virus (HIV) has evolved to a chronic 
disease, perceived health-related quality of life (HRQoL) is becoming a prominent and important 
patient-reported outcome measure in HIV care. Literature discusses different factors influencing 
HRQoL in this population, however, currently no consensus exists about the main determinants. In this 
review a clear, up-to-date overview of the determinants influencing HRQOL among people living with 
HIV is provided. 
Methods: All studies published before July 2013 that identified determinants of HRQoL among people 
living with HIV in high-income countries, were considered in this narrative review. PubMed, Web of 
Science and The Cochrane Library were consulted using the keywords ‘determinants’, ‘quality of life’, 
‘HIV’ and ‘AIDS’. To be included, studies should have reported overall health and/or physical/mental 
health scores on a validated instrument and performed multivariable regression analyses to identify 
determinants that independently influence perceived HRQoL. 
Results: In total, 49 studies were included for further analysis and they used a variety of HRQoL 
instruments: Medical Outcomes Study Short Form-36 or variants, Medical Outcomes Study-HIV, HIV 
Cost and Services Utilization Study measure, Multidimensional Quality of Life Questionnaire, HIV 
Targeted Quality of life instrument, Functional Assessment of Human Immunodeficiency Virus 
Infection, HIV Overview of Problems Evaluation System, EuroQol, Fanning Quality of Life scale, 
Health Index and PROQOL-HIV. In this review, the discussed determinants were thematically divided 
into socio-demographic, clinical, psychological and behavioural factors. Employment, immunological 
status, presence of symptoms, depression, social support and adherence to antiretroviral therapy were 
most frequently and consistently reported to be associated with HRQoL among people living with HIV. 
Conclusions: HRQoL among people living with HIV is influenced by several determinants. These 
determinants independently, but simultaneously impact perceived HRQoL. Most HRQoL instruments 
do not capture all key determinants. We recommend that the choice for an instrument should depend 
on the purpose of the HRQoL assessment.   
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Introduction 
 
Since the HAART (highly active antiretroviral therapy) era, HIV has been added to the increasing list of 
chronic diseases [1, 2]. Still, daily and strict intake of antiretroviral medication is required to achieve or 
to maintain virological and immunological control [3, 4]. However, these are not the only outcomes that 
should be taken into account. In chronic diseases, assessing health-related quality of life (HRQoL) has 
become an integral part of follow-up. HRQoL measurements provide valuable feedback about 
therapeutic interventions and they are indispensable in cost-effectiveness analyses [5]. HRQoL measures 
can also identify determinants of HRQoL among people living with HIV (PLHIV), which is vital to 
maximize HRQoL. Although different studies identified factors associated with HRQoL, there is no 
consensus about the main determinants. In addition, a variety of HRQoL instruments are currently 
being used in PLHIV. In this review, we examined determinants reported to be associated with HRQoL 
in PLHIV and we critically discuss the use of HRQoL instruments. 
Methods 
 
A narrative review was performed. The global search strategy was to search the databases PubMed, Web 
of Science and The Cochrane Library using the (Mesh)terms ‘determinant(s) ‘quality of life’, ‘HIV’, 
’AIDS’ as title words. Articles in this review are 1) investigating HRQoL in HIV-infected (adult) 
individuals 2) published prior to July 2013, 3) full text available in English, 4) conducted in high-income 
countries, 5) reporting HRQoL as one total score and/or as a physical and mental score, 6) using a 
validated HRQoL instrument and 7) applying quantitative methodology and multivariable regression 
analysis to identify determinants of HRQoL. Titles and abstracts were reviewed to verify those criteria. If 
all inclusion criteria were fulfilled or if this was still unclear, the manuscript was fully read. In case the 
full text revealed that not all requirements were present, the manuscript was still excluded from further 
consideration. Additional literature was obtained through searching references in the manuscripts 
(snowball method). 
A priori, a framework with four categories of determinants was made: socio-demographic, clinical, 
psychological and behavioural determinants. Those categories were chosen by analogy with the reporting 
of research on HRQoL performed in our hospital department [6]. In particular, our research assesses 
three of the categories through a self-report questionnaire, consisting of a sociodemographic part, a 
psychological part (assessment of depressive symptoms, social support, satisfaction with care) and a 
behavioural part (assessment of adherence and substance use). Clinical parameters on the other hand 
are assessed via the electronic patient record. While reading and interpreting the manuscripts, the 
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categories were further subdivided. Results and conclusions from manuscripts were then allocated to 
one or more determinants. The review was further elaborated by addressing every determinant separately 
and rereading all manuscripts that were relevant for that determinant. 
In addition to the manuscript, an extensive table is provided in which methodological features (study 
design, sample, instrument) and main results of all included studies are provided (Additional table 1). 
Results 
 
In total, 49 studies were included for further analysis. The instruments used to measure HRQoL were 
various: Medical Outcomes Study Short Form-36 or variants, Medical Outcomes Study-HIV, HIV Cost 
and Services Utilization Study measure, Multidimensional Quality of Life Questionnaire, HIV Targeted 
Quality of life instrument, Functional Assessment of Human Immunodeficiency Virus Infection, HIV 
Overview of Problems Evaluation System, EuroQol, Fanning Quality of Life scale,  Health Index and 
PROQOL-HIV (Additional table 1). 
Determinants of HRQoL were divided into four categories: socio-demographic, clinical, psychological 
and behavioural factors. For purposes of intelligibility and conciseness, only determinants of overall 
health outcomes, as well as physical and mental health scores were commented. Factors associated with 
subscales of HRQoL were not discussed. 
1. Socio-demographic characteristics 
Gender 
There was no general agreement about gender differences in HRQoL [7]. If differences were found, 
women mostly reported lower HRQoL than men [8-10]. Different explanations were given: women 
would be more likely to report their unfavourable physical states than men because men are expected to 
adopt a more stoic attitude [10, 11], items on physical subscales would be different for men and women 
[10], and/or women would have more feelings of guilt [12]. Gender differences in HRQoL could also be 
a consequence of gender differences in mental illnesses. Mood disorders, anxiety disorders and 
psychosomatic disorders are more prevalent in females, possibly contributing to the HRQoL difference 
[11]. Controlling for clinical and socio-demographic factors could eliminate gender differences [7].  
In contrast, some studies found that females had a better mental health [13] or reported better overall 
health [14]. Better coping strategies in females and a higher proportion of anxious men in that sample, 
respectively, were proposed as explanations for those findings. At last, Mrus and colleagues observed no 
difference towards overall health change between the genders and they suggested that health change, 
instead of health status, may be a better measure to evaluate HRQoL longitudinally [11]. 
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Age 
Older age was generally associated with lower physical health [13, 15-19] and with a greater decline in 
physical health over time [9] most likely due to physical senescence. The relationship with mental health 
was less distinct. There could be a positive relationship between younger age and better mental health 
[19] while older age was associated with a decrease in mental health after six months in another study 
[20]. As most studies were not able to find any association, it seems that mental health is less age-
dependent.  
Family situation 
A stable relationship conceivably contributes to a good HRQoL. This was shown, though only for 
physical health, in two studies [18, 21]. Conflicting results were found with respect to changes in 
HRQoL over time. In women, being single was associated with an improvement in HRQoL after 4 
months, whereas being married was associated with a decline [22]. Being chronically ill possibly causes 
more health distress and anxiety in married women, since the illness can interfere with their role as a 
spouse. However, a stable partner was also found to be positively associated with mental health after one 
year [9].  
Concerning parenthood, a similar picture emerged. Children bring happiness, however, ill parents will 
be more worried about their health because of them. PLHIV may be more confronted with their 
constraints through the process of bringing up children [9]. Accordingly, in two studies, parenthood was 
negatively associated with physical health over time [8, 9].  
Socio-economic status: education, employment, income 
There was a joint consent that socio-economic status has an impact on HRQoL [9, 14, 15, 17, 18, 20, 
23-27]. Employment influenced both physical and mental health status, or overall health [14, 17, 23, 24, 
28] although the effect on physical health was twice as big [25]. Employment was a positive predictor for 
good physical health after 3-4 years [26]. Employment constitutes a big part of the daily life of people. It 
can provide structure, a social support network, role identity and meaning [29]. The exact association 
between employment and HRQoL, however, remained unproven. Probably this is a bi-directional 
relationship: good HRQoL could be a requirement to be able to work (selection hypothesis), or work 
could be a source of well-being (causation hypothesis) [25, 27]. 
There were indications for an association between financial situation and HRQoL [15, 18, 23]. A low 
versus middle- or high income was associated with a lower mental and overall health [23]. Yet, income 
may be not the best measure to assess financial situation. Data concerning expenditures, family 
composition, financial insecurity and financial worries could provide useful additional information [30]. 
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Education has also been linked to HRQoL and the relationship would be linear (i.e. higher education 
associated with higher HRQoL) [23]. An education of less than five years was negatively associated with 
mental health after six months [20] and with physical health change after 12 months [9]. It is possible 
that a lower education is a proxy of a lower socio-economic status in general, but it could also represent 
a poorer ability to understand the therapy recommendations [20]. This leads to less informed, less 
involved and less empowered patients which affects their HRQoL [31, 32].  
2. Clinical and disease-related factors 
Virological and immunological status 
A better virological status was associated with a better overall [33], physical [14, 18, 34] and mental 
health [14], although a reasonable amount of studies did not find an (independent) association [8, 13, 
15, 20, 27]. 
On the other hand, the relationship between immunological status and HRQoL was better corroborated 
by scientific evidence: a higher CD4-cell count was associated with a better physical health [15, 16, 20, 
21, 34, 35]. It was also a predictor for better physical health scores on follow-up measurements [20, 36, 
37]. However, physical health improved more in patients who started ART at CD4 <200 cells/µl than in 
patients with 200-350 cells/µl or >350 cells/µl, because their physical health at baseline was worse [38]. 
Current guidelines recommend nonetheless to start ART early (i.e. 350-500 celles/µl), because there is 
evidence that this results in reduced progression to AIDS and reduced mortality [39]. In another study, 
CD4 count was negatively associated with HRQoL at baseline, but positively after 12 months [40]. It is 
possible that PLHIV with a high CD4-count at baseline, wanted to go back to their excellent health and 
therefore considered their actual health status as dissatisfying. Over time, PLHIV develop other 
perceptions and expectations about HRQoL and may consider their health status acceptable [40]. 
Three studies have found an additional relationship with mental health. A lower CD4 cell count was 
then associated with a lower mental health score (MHS) (cross-sectional and at 12 months) [9, 18, 35]. 
This could be due to the faster disease progression in PLHIV with low CD4-counts, which leads to 
distress [9]. 
Staging and time since diagnosis 
Regarding disease stage, a clear effect on physical health has been established: as HIV evolves to a 
further stage, physical health diminishes. The poorest physical health is seen in people with AIDS [18, 
23, 25] and AIDS negatively influenced future physical health in follow-up studies [9, 26, 36]. In 
contrast, the effects on mental health were variable. A longer time since diagnosis was associated with 
both lower [14] and higher mental health [25]. A lower mental health over time could arise in cases 
 62 
 
where longitudinal follow-up resulted in a successful control of HIV. PLHIV may then experience 
difficulties to report mental problems because they are expected to feel fortunate because of their good 
health [14]. On the other hand, a longer duration could facilitate the development of effective coping 
strategies which could enhance mental health [40]. For health care providers, it is important to monitor 
mental health continuously, irrespective of the physical condition of the patient.  
ART treatment 
The effect of ART-treatment on HRQoL has been described as a balance between reduced HIV-related 
symptoms and better life-expectancy on the one hand and medication side-effects on the other hand 
[41]. In people with an acceptable health status prior to ART-initiation, these side-effects could even 
overrule  the benefits [21]. Encountering few ART-related side-effects contributed to normal physical 
and mental health [21]. Sexual dysfunction is an example of a side-effect – although frequently seen  
without iatrogenic cause – which was found to have a significant impact on HRQoL [42]. 
Recent studies mainly showed a positive effect of ART-treatment on HRQoL. This could be due to the 
continuous improvements in ART-therapy leading to less side-effects and to possibilities of combination 
preparations [43, 44]. ART treatment was independently associated with a higher physical health [17] 
and interruption of ART treatment was associated with lower mental health [15]. 
In some studies, no HRQoL-differences between ART-treated and non-treated PLHIV were observed [8, 
14, 18], or only at bivariate level [20]. Maybe non-treated PLHIV had a better health, through which 
treatment was (still) not required [14].  
Presence of symptoms 
The negative influence of HIV-related symptoms on HRQoL was supported by scientific evidence and 
generally, a relationship with both physical and mental health was found [20, 23, 25, 26, 28, 45, 46]. 
Long-term studies found the same results [9, 36]. In the HIV Cost and Services Utilisation Study, there 
was an inverse linear relation between number of symptoms and SF-36 scores. Each additional symptom 
(out of 13), was associated with a nearly 1.5-point decrease in physical and mental health [23]. 
Furthermore, symptom status was a stronger predictor for HRQoL than functional status, health 
perceptions, age, sex, biological and physiological markers [47]. 
Lipodystrophy was found to be an influential HIV-related symptom [48]. It affected both physical and 
mental health [48] and was associated with lower mental health after one year [9]. In time trade-off 
preference measurements, PLHIV would even give up a life year to avoid lipodystrophy [49]. It was 
although possible that only in PLHIV perceiving a moderate to severe body alteration, HRQoL is 
affected [50]. Lipodystrophy is a highly visible symptom, and it could also affect the self-esteem and 
social contacts of PLHIV [48]. Similar negative effects of weight loss have been reported [14].  
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Comorbidity 
A negative effect of comorbidity burden on HRQoL, especially on physical health, was supported by 
cross-sectional studies [15, 51] and a longitudinal study [40]. Regarding specific comorbidity, comorbid 
hepatitis B was associated with a lower physical health and hepatitis C negatively influenced physical 
health after one year [9]. On the other hand, HRQoL was the same among PLHIV, people infected with 
hepatitis C and people infected with both HIV and hepatitis C [17]. PLHIV with a GB virus C infection 
reported even a better quality of life than PLHIV without GB virus C infection [52]. Authors reasoned 
that patients’ HRQoL could be more affected by socio-economic and psychological factors than physical 
illnesses as HIV or hepatitis C, as the latter have become manageable diseases [17], or they may be a 
more favourable course of HIV infection in patients with GB virus C infection [52]. 
3. Psychological factors 
Depression and anxiety 
Depression strongly interferes with daily life and the negative impact on HRQoL was obvious [8, 46, 53, 
54]. Some authors did only find an association with mental health, and not with physical health [9, 15, 
16, 55] although depression can also cause physical problems (e.g. less appetite, sleep disorders…). Not 
only the presence, but also a history of depression was associated with poorer HRQoL [17]. Depression 
also mediated the relationships between coping styles, social support and HRQoL [16, 53], which will be 
discussed further on. 
The prevalence of anxiety disorders in PLHIV is higher than in the general population and it is 
associated with depressive symptoms [14, 56]. Anxiety was found to be associated with a diminished 
physical and mental health [18]. 
Coping styles, locus of control and religion 
Coping styles are highly relevant in PLHIV, looking at the stress resulting from HIV diagnosis and 
treatment, as well as multiple possible other stressors [53]. Studies examining the effect of coping styles 
on HRQoL have often found that the effect was indirect, namely via the intermediate determinant 
depression [16, 53]. An active coping style has also been found to be directly associated with a better 
HRQoL [35, 40]. People adopting an active coping style undertake actions to enhance their current state 
and this coping style is generally thought to be effective in reducing stress [57] and the impact of life 
stressors on mental health [19]. Coping styles are also associated with health locus of control (HLOC). 
People with an internal HLOC believe that health outcomes result directly from one’s own behaviour 
whereas people with an external HLOC believe that others– other persons, fate, or luck– determine the 
outcome [58]. An internal HLOC was a predictor of a better physical health and a powerful others 
HLOC predicted a lower mental health [26]. However, somewhat contrary to that, a higher level of 
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spirituality/religion (which could be associated with an external HLOC) has been found to be correlated 
with the perception of a better life then before the HIV diagnosis. It seems that religious/spiritual 
coping could also be an effective coping style [59]. Nevertheless, religious coping could be ineffective 
too, by arousing feelings of punishment by God, or being ostracised [60]. 
Social support 
Social support could directly influence health outcomes, or it could serve as a buffer to reduce the 
influence of stressors on health outcomes [61].  Many studies found positive relations between the 
presence of social support and both physical and mental health  [13, 25, 53]. Furthermore, a higher 
social support at baseline was predictive for a better mental health after 12 months [40]. 
In the study of Jia et al (2004), social support had a mainly indirect role in HRQoL, mediated by 
depression [53]. This suggests that enhancing social support could reduce depressive symptoms, which 
then could improve HRQoL. 
It seemed that the more people PLHIV have to talk to (i.e. providing social support), the better the 
mental health was [15]. By studying different types of social support (emotional and tangible social 
support), Friedland et al were able to distinguish different patterns [62]. Emotional social support (e.g. 
empathy, affection, caring) positively influenced HRQoL and tangible social support (e.g. financial and 
material assistance) negatively influenced HRQoL. People who received more tangible social support 
perceived themselves as more ill and as having a lower HRQoL [62]. Associations between social support 
and HRQoL over time seemed to vary. Possibly, social support becomes more important at difficult 
times [63]. 
Neuropsychological status 
Cognitive problems lead to difficulties in every day practices, such as remembering names of new people, 
concentrating during a conversation or finding solutions for unexpected problems [64]. These will most 
probably affect HRQoL. In a study in HIV positive women, neurocognitive performance together with 
emotional distress accounted for most of the variance of HRQoL [65]. The validation study of the 
Quality of Well-being scale for HIV patients also revealed a significant influence of neurocognitive 
impairment [54]. In another study, neurocognitive impairment reduced physical health, but not mental 
health [55].  
Other (health care, disclosure, stigma) 
The way PLHIV perceive health care service has also shown to be important for the patient’s HRQoL 
[18, 20]. Poor satisfaction with information from health care providers was independently associated 
with a lower mental health [20]. Inadequate communication with the physician could lead to 
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misunderstanding, uncertainty and a lack of trust in the caregiver [20]. Therefore, communication is 
considered one of the core competencies of physicians [66]. Some PLHIV even experience rejection by 
the medical staff, especially people infected through drug use. Wrong attitudes could hinder a good 
physician-patient relationship, which is crucial for physical HRQoL [18].  
Experiencing stigma negatively influenced HRQoL [28] and discrimination from family, friends or at 
work negatively influenced mental health [18]. Disclosing seropositive status was found to have negative 
effects on both physical and mental health [18]. The latter relationship, however, remained unclear, 
because disclosure could also be beneficial for the patient’s mental and physical health (mainly through 
social support) [67]. However it could potentially be related to the fact that people with worse HRQoL 
have to disclose their seropositive status because of the symptoms, and may feel forced to do so instead 
of voluntarily doing so. PLHIV should be prepared and supported by health care professionals before 
their decision whether or not to disclose and before they are confronted with stigma and discrimination 
in order to be able to better cope with these difficulties [46]. 
4. Behavioural factors 
Smoking 
Relationships between smoking and HRQoL are not extensively studied yet [68]. Two studies suggested 
that smoking negatively influenced HRQoL [16, 68]. Among HIV-positive veterans, current smokers had 
the lowest HRQoL as compared to former and never smokers [68]. Current smokers were more at risk 
for pulmonary diseases and respiratory symptoms, which may affect their physical health [68]. However, 
smoking was also found to be negatively associated with mental health [16]. Psychiatric comorbidity was 
found to be highly prevalent in smokers – or the other way around, since patients reported that smoking 
helps them cope with depressive symptoms and anxiety [69]. 
Alcohol use 
The effect of alcohol use on HRQoL in PLHIV was scarcely or only superficially studied [70]. In none of 
those studies among PLHIV, an independent association between alcohol use and HRQoL was found  
[8, 18, 70] except for one. In that study, not using alcohol was a predictor for a lower physical health. A 
causal relationship between light to moderate alcohol use and a better physical HRQoL is, however, not 
very plausible. Light to moderate alcohol use could rather be seen as an expression of  risk behaviour for 
which a certain degree of functional status is required [15].  
Drug use 
Quality of life in HIV-positive drug users has been relatively more studied than in tobacco and alcohol 
users, because IDU is a risk factor for HIV-transmission. Current drug use was associated with lower 
mental health [15, 70, 71]. HRQoL in former users of illicit drugs was not worse than in persons who 
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never used drugs [70]. For IDU the same was found: being an IDU was associated with a lower physical 
health [13], whereas being a former IDU was associated with a better physical and mental health [21]. 
Impact of drug use on HRQoL could be direct, via the physical deterioration caused by the drugs [13] or 
indirect, via associated psychiatric disorders [71]. 
Adherence 
In a review of twelve studies considering the relationship between adherence to ART and HRQoL, ten 
showed an association with HRQoL [72]. Three of them applied a prospective design and are thus more 
indicative for a causal relationship [72]. More adherent PLHIV probably had better virological and 
immunological outcomes and could therefore have a better HRQoL.  
Reporting concerns and difficulties about taking medication, was associated with poor mental health 
[13, 73]. These difficulties could originate in a low self-efficacy, a high pill burden, difficulties to 
incorporate the medication moments in daily activities, experiencing side-effects...  
Life style and sexual risk behaviour 
Not surprisingly, physical activity was associated with a better physical health [16, 74, 75]. Healthy 
nutrition and a good stress management were associated with both physical and mental health [74]. 
Associations between unsafe sex and HRQoL were contradictory: in one study, there was no 
relationship to either physical or mental health and in another study [74], having unsafe sex with casual 
partners was associated with poor mental health [76]. 
Discussion 
 
This review presents an overview of socio-demographic, clinical, psychological and behavioural factors 
associated with HRQoL in PLHIV. Many determinants have been found, and it is not clear which 
determinants are the strongest predictors for HRQoL. Nonetheless, there seems to be a consensus about 
the effect of socio-economic status, immunological status, presence of symptoms, (psychiatric) 
comorbidity, social support and adherence to ART. 
These partly correspond to determinants of HRQoL of people living with other diseases. In patients 
with Crohn’s disease, epilepsy, Parkinson’s disease and aneurysmal subarachnoid haemorrhage, 
advanced disease stage (cfr. immunological status) was found to be predictive for impaired HRQoL [77-
80]. Disability (cfr. presence of symptoms) was a determinant of HRQoL in patients with Crohn’s 
disease, Parkinson’s disease and aneurysmal subarachnoid haemorrhage [77-79]. Depression was 
negatively associated with HRQoL in patients with epilepsy, Parkinson’s disease and aneurysmal 
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subarachnoid haemorrhage [78-80]. Presence of comorbidities was associated with lower HRQoL in 
patients with epilepsy, lung cancer and in long-term survivors of colorectal cancer [80-82].  
Literature about HRQoL in PLHIV consisted mostly of cross-sectional studies, however some 
longitudinal and interventional studies were found as well. Overall, there was a great diversity of 
instruments to measure HRQoL in PLHIV. Both generic (regularly SF-36) and disease-specific (MOS-
HIV, HCSUS, HAT-QOL …) instruments were used (see Table 1). It is impossible to point out the best 
HRQoL instrument for PLHIV, since that choice mainly depends on the purpose of the assessment. For 
example, cost-effectiveness analyses require a HRQoL instrument that provides an index score while 
clinical routine management requires an instrument that provides information about HIV-specific 
aspects influencing HRQoL in PLHIV. Up till now, however, many HIV-specific instruments omit some 
of those aspects (e.g. stigma, coping and resilience, body image…) and literature concerning those 
determinants is rather scarce [35, 83, 84]. Instruments developed in cooperation with PLHIV (e.g. 
FAHI, HAT-QOL, HOPES, PROQOL) try to minimize that limitation. HRQoL instruments in PLHIV 
have been compared and discussed by many researchers, mainly by means of two-by-two comparisons in 
a selected population. Two studies provide a more general overview: Clayson et al. brought three generic 
(SF-36, EuroQol and Health Utilities Index) and two HIV-specific (MOS-HIV and FAHI) instruments 
forward as appropriate for use in clinical trials [85]. Their conclusions were based upon assessment of 
content, practicality and psychometric properties. Following their criteria, generic instruments should 
also be able to provide preference-based index scores and they should have normative population data. 
Grossman et al. suggest the SF-12 and MOS-HIV as the most appropriate tools [86]. They made a trade-
off between the brevity of the instrument and the usefulness of the information provided.  
The heterogeneity of HRQoL instruments was also present in the types and numbers of possible 
determinants that were analysed. Moreover, the detail by which these determinants were studied, varied 
from one single question to a whole battery of tests and interviews. Although this makes it difficult to 
compare results, it permits to 1) state that a certain factor is associated with HRQoL, independently of 
many other variables and 2) describe this effect more profoundly.  
This is a narrative review, and this method has several limitations. The literature search was not 
integrally documented, and is as such impossible to reproduce and the inclusion of the studies could be 
subject to personal bias. Nonetheless, we reported transparently about the search method and aimed at 
composing a review as complete and as consistant as possible. The latter is also the reason for including 
only papers that used quantitative, multivariable regression analyses. Thereby, we do not want to detract 
from the great value of papers using other methodologies (especially qualitative research). 
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Conclusion 
 
HRQoL in PLHIV is influenced by many concurrent factors. From the evidence studied here we can 
conclude that there is a consensus about the influence of socio-economic status, immunological status, 
presence of symptoms, (psychiatric) comorbidity, social support and adherence to ART. Various 
instruments can be used to assess HRQoL in PLHIV, however, all have limitations. The choice of 
instrument should depend on the purpose of the HRQoL assessment. 
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Table 1: Overview of HRQoL instruments used in the reviewed manuscripts.  
Name of the instrument  
(and abbreviation) 
Generic or  
HIV-specific 
instrument 
Measurements 
Medical Outcomes Study Short Form-36 or 
variants (SF-12, SF-8) 
SF-36 [87] 
Generic 8  subscales 
Physical health summary 
Mental health summary 
Medical Outcomes Study-HIV 
MOS-HIV [88] 
HIV-specific 11 subscales 
Physical health score 
Mental health score 
 
HIV Cost and Services Utilization Study tool 
HCSUS  [89] 
HIV-specific 10 subscales 
Physical health 
Mental health 
Overall health 
 
Multidimensional Quality of Life 
Questionnaire for people with HIV/AIDS 
MQoL-HIV [90] 
 
HIV-specific 10 subscales 
Global score 
HIV targeted Quality of life instrument 
HAT-QOL  [91] 
HIV-specific 9 subscales 
Global score 
 
Functional Assessment of Human 
Immunodeficiency Virus Infection 
FAHI  [92] 
HIV-specific 4 subscales: 
Physical well-being 
Emotional well-being 
(Social well-being)* 
(Functional well-being)* 
 
HIV Overview of Problems Evaluation System 
HOPES  [93] 
 
HIV-specific 6 subscales 
Global score 
EuroQol Generic Global score (utility) 
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EQ  [94] 
 
Fanning Quality of Life Scale [95] HIV-specific Global score 
 
Health Index  
HI   [96, 97] 
Generic Physical well-being 
Mental well-being 
 
PROQOL [98] HIV-specific 7 subscales 
(+ 1 on treatment impact) 
Global score 
*Determinants of the  FAHI-subscales ‘social well-being’ and ‘functional well-being’ were not considered 
in this review. 
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Additional table: Overview of the included articles.  
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Country, 
setting Sample Measures Study design Main findings 
Airoldi et al 
2010 
Italy, 
multicenter 
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77.4% m, mean 45.8y, 39.2% 
homosexual, 15.6 IDU, 556 mean 
CD4, all undetectable, all on ART SF-36 
Longitudinal 
(Baseline, 
1,2,4,6 
months) Better HRQoL after switch to single tablet regimen 
Armon et al 
2012 
USA, 
monocenter 
159 
90.6% males, median 43 (39-49)y, 
68.6% white, 16.4% black, 13.2% 
Hispanic, 18.9% IDU, 62.3% 
homosexual, 92.5% ART, 1.4 (IQR 
1-2) VL, 455 (IQR 275-735) CD4 
MOS-HIV  
(+ Brief COPE Inventory) 
Cross-
sectional 
MH: public or no insurance +, mental illness -, number of non-HIV 
medications taken -, CD4 cell count +, maladaptive coping behaviors -, 
adaptive coping behaviors. / PH: maladaptive coping behaviors - 
Blalock et al 
2002 
USA, 
monocenter 
200 
75% m, median 40 y, 23% 
Caucasian, 70% African American, 
5% Hispanic, 75% HAART, all 
CD4 < 200 
MOS-30  
(+ Brief Symptom Inventory + Structured 
Clinical Interview for DSM-IV non-patient 
version HIV) 
Cross-
sectional HRQoL: employment + 
Bouhnik et al 
2006 
France, 
multicenter 
(102) 
591 
all males, all homosexual, 43y 
mean, 12% ≤ 200 CD4, 63% 
undetectable VL (<400), 81% on 
ART SF-36 
Cross-
sectional MH: unsafe sex - 
Briongos-Figuero 
et al 
2011 
Spain, 
monocenter 
150 
74.7% m, 44.3 ± 8.3 y, 8% 
immigrants, 18.7% homosexual, 
38% IDU, 9.3% CD4<200, 23.3% 
undetectable, 84% on ART MOS-HIV 
Cross-
sectional 
PH: female gender - and hospitalization -, parenthood -, depression -  MH: 
depression -, chronic hepatitis C - 
Burgoyne et al 
2004 
Canada, 
monocenter 
41 
85% m, mean 38.8y, 315 mean 
CD4, 3.9 mean VL, 83% on ART SF-36 (+ MOS Social Support Survey) 
Longitudinal 
(Baseline, 2, 
4 years) 
Stability in quality of life over 4 years  
HRQoL: perceived social support +, symptoms -, immunologic status +, 
virological status +  
Call et al 
2000 
USA, 
monocenter 
158 
87% m, 39 ± 8.6y, 64% Caucasian, 
73% homosexual, 8% IDU, 69542 
median VL , 144 median CD4, 
75% on ART SF-36 
Cross-
sectional PH: viral load -, after controlling for CD4 cell count 
Cederfjall et al 
2001 
Sweden, 
monocenter 
189 
70.9% m, 37-42y, 41.3% 
homosexual, 15.9% IDU, 81% on  
ART, 18.5% <200 CD4 
Health Index  
(+ HIV symptom scale, Sense Of Coherence 
scale, Well-being Scale, Interview Schedule 
for Social Interaction) 
Cross-
sectional HRQoL: Sense Of Coherence + 
Corless et al 
2013 
USA, Puerto 
Rica, Africa, 
multicenter 
(13 clinics) 
702 
61.6% m, 43.4 ±  9.3y, 23.4% 
white, 33% African American, 
30.7% Hispanic, 71.4% on ART 
HAT-QoL (+ Stressful Life Events Scale + 
Revised Sign and Symptom Checklist) 
Cross-
sectional 
HRQoL: medication adherence concerns -, total physical and 
psychological symptoms - 
 78 
 
Crothers et al 
2005 
USA, 
multicenter 
(3) 
867 
99% males, mean 49-53y, 33-39% 
white, 50-55% African American, 
319-377 mean CD4, 2.3-3.1 mean 
VL, 78-84% on ART SF-12 
Cross-
sectional PH: current smoking - 
Fleming et al 
2004 
USA  
(1 center) 
and Jamaica 
(1 center) 
299 
 (53 HIV, 110 HCV, 136 
HIV/HCV) 69-77% males, mean ± 
45 y, 8% MSM in HIV/HCV and 
HCV - 53% in HIV, 73-89% IDU 
in HIV/HCV and HCV - 2% HIV, 
17-22% <200 CD4, 46-54% <50 
copies VL SF-36 
Cross-
sectional 
HRQOL for the group of HIV/HCV coinfected patients was similar to 
that of HRQOL in patients with either HCV or HIV alone.  
PH: age -, unemployment -, no ART use - 
MH: being immigrant -, IDU -, functional status +, depression - 
Friedland et al 
1996 
Canada, 
multicenter 
(5) 
120 
89.2% m, mean 37y, 74.8% 
homosexuals, 13% IDU 
Fanning QoL scale (+ Evans QoL 
questionnaire + Index of Well-being + 
Interpersonal Support Evaluation List + 
Social Support Inventory for People with 
AIDS + Ways of Coping Questionnaire + 
Recent Life Changes Questionnaire (health 
status) + Symptom Checklist)  
Cross-
sectional 
HRQoL: income -, perception-oriented coping +, tangible social support -
emotional social support + 
Gibson et al 
2011 
Canada, 
multicenter  
758 
82% m, 47 ±10y, 64% Caucasian, 
67% homo/bisexual, 74% 
undetectable VL, 58% <500 CD4 
SF-36  
(+ National Population Health Survey 
(NPH) Stress Questionnaire + Pearlin 
Mastery Scale + Medical Outcomes Study 
Social Support Survey (MOS-SSS) + Brief 
COPE) 
Cross-
sectional PH, MH: number of stressors - 
Hays et al 
2000 
USA, 
multicenter 
(unknown) 
2864 
77% m, 39 ± 9 y, 49% white, 33% 
African American, 15% Hispanic, 
49% homosexual, 24% IDU HCSUS tool (based on SF-36) 
Cross-
sectional 
PH: income +, unemployment -, AIDS-, symptoms –  
MH: age +, education +, income +, unemployment -, CD4 cell count +, 
symptoms - 
Herrmann et al 
2013 
Australia, 
monocenter 
102 
85.3% m, 46 (37-53.8)y, 78.4% 
Caucasian, 52.9% homosexual, 
5.9% IDU, 75.5% undetectable 
VL, 530(376-733) CD4 cell count, 
85.3% on ART PROQOL-HIV 
Cross-
sectional 
HRQoL: age>45y +, unemployment -, depression -, sexual dysfunction -, 
gastrointestinal symptoms -, malaise -, morphological symptoms -, other 
symptoms - 
Holzemer et al 
2009 
USA, Puerto 
Rica, Africa, 
multicenter 
(14 clinics) 
726 
54.6% m, 42.7 ± 9.5y, 21.0% 
white, 29.7% African American, 
27.6% Hispanic,  15.4% African 
Continent, 40.9% AIDS, 70% on 
ART 
HIV/AIDS Targeted Quality of Life 
instrument  
(+ Revised Sign and Symptom Check-List for 
Persons with HIV Disease + Perceived 
Stigma Scale + CES-D) 
Cross-
sectional HRQoL: symptoms -, depression -, stigma - 
Jia et al 
2004 
USA, 
multicenter 
(3) 
226 
all males, 45.7 ± 8.7y, 54.9% white, 
31.9% homosexual, 8% IDU, 
25.3% CD4<200 
HCSUS tool (+ Social Support Appraisal 
Scale + Coping with HIV questionnaire + 
CES-D + Patient Medication Adherence 
Questionnaire-7 + Charlson Co-morbidity 
Cross-
sectional 
PH, MH and overall HRQoL: social support +, depressive symptoms - MH 
and overall HRQoL: effective coping +  
The effects of social support and coping were mainly through the 
intermediate factor of depressive symptoms. 
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Index) 
Jia et al 
2005 
USA, 
multicenter 
(3) 
197 
all males, 45.8 ±8.4 y, 55.8% white, 
mean CD4 426 ± 284 
HCSUS tool  
(+ Coping with HIV questionnaire + Social 
Support Appraisals Scale + CES-D) 
Longitudinal 
(Baseline, 12 
months) 
PH 12m: CD4 cell count +  
MH: depression –  
Jia et al 
2007 
USA, 
multicenter 
(3) 
197 
all males, 45.8 ± 8.4y, 55.8% white, 
426 ± 284 
HCSUS tool  
(+ Coping with HIV questionnaire + Social 
Support Appraisals Scale + CES-D) 
Longitudinal 
(Baseline, 12 
months) 
PH: interaction effect of CD4 and time (at baseline -, at 12m +), 
comorbidity –  
MH: social support + 
Korthuis et al 
2008 
USA, 
multicenter 
(14) 
951 
68% m, 31% white, 51% black, 
14% Hispanic, 69% on ART HCSUS tool 
Cross-
sectional 
PH and MH: current illicit drug use – 
MH appeared to be more severely impacted by illicit drug use than PH. 
Kowal et al 
2008 
Canada, 
monocenter 
97 
84% m, 39.4 ± 8.7y, , 71% 
Caucasian, 368.9 ± 199.9 CD4 
count 
SF-36  
(+ Center for Epidemiological Studies-
Depression Scale (CES-D) + Coping 
Inventory for Stressful Situations)  
Cross-
sectional 
PH: physical activity +, CD4 cell count +  
MH: smoking -, depressive symptoms - / Depressive symptoms mediated 
the relationship between coping styles and MH. 
Liu et al 
2006 (ref 15) 
USA, 
multicenter 
(4) 
636 
all males, 43.3y (IQR 39.0-48.2), 
84% white  SF-36 
Longitudinal 
(Baseline, 
every 6 
months) 
PH: age -, socioeconomic status +, number male sexual partners -, no 
alcohol drinking -, more advanced HIV disease stage-  
MH: outpatient visits -, antiretroviral drug interruption -, recreational drug 
use -, social support + 
Liu et al 
2006 (ref 41) 
USA, 
multicenter 
(4) 
68 
all males, mean 43y, 84% white SF-36 
Longitudinal 
(Pre-
seroconver 
sion, post-
seroconver 
sion, post-
initiation 
ART) 
PH decreased significantly after seroconversion and after starting HAART 
< 2 years . After 2 years of HAART use, PH was relatively stable, but 
further decreased after 4 years on HAART  
PH: age -, income +  
MH declined, though not significantly, after seroconversion and then 
started to increase after longer HAART use.  MH: depression - 
Lorenz et al 
2006 
USA, 
multicenter 
(unknown) 
2267 
70.7% m, 51% white, 31.2% 
African American, 14.4% Hispanic, 
47.2% homosexual, 23.4% IDU 
2 questions SF-36:  
‘‘How would you rate your current health, 
overall?’’  
‘‘How would you rate your quality of life, 
overall?” 
Longitudinal 
(Baseline, 18 
months) 
HRQoL increases for people with decreasing number of symptoms, 
HRQoL decreases for increasing or unchanged number of symptoms 
Mrus et al 
2005 
USA, 
multicenter 
1178 
82.9% m, 36.2 (±0.6)- 39.2 (±0.3) y, 
30-56% white, 15-48% black, 17-
21% Hispanic, all CD4 <200 
AIDS Clinical Trials Group QoL 601-602 
Health Survey (adaptation of SF-21) 
Longitudinal 
(baseline, 24 
weeks, 40 
weeks) 
Women reported poorer HRQoL than men in the domains of physical 
functioning, pain, and energy/fatigue. Changes in domain scores over 
time and in response to treatment did not differ. 
Murri et al 
1997 
Italy, 
monocenter 
213 
66.6% m, mean 36y, 25.4% 
homo/bisexual, 43.6% IDU, 38% 
<200 CD4, 71.8% on ART MOS-HIV 
Cross-
sectional HRQoL: symptoms -,  number of daily pills - 
Murri et al 
2003 
Italy, 
multicenter 
809 
68.1% m, 36 (IQR 32-40)y, 14.7% 
homosexual, 48.2% IDU, 38.1% 
CD4<200, 39.7% undetectable VL, 
89.9% on ART MOS-HIV 
Longitudinal 
(Baseline, 6 
months) 
PH baseline:  CD4 cell count +, hospitalization -, symptoms –  
MH baseline: hospitalization -, symptoms - and satisfaction with 
information from providers +  
PH 6 months:  more advanced stage of HIV infection -, baseline CD4  cell 
count +, PH + and symptom score –  
MH 6 months: age -, baseline MH +, symptom score - and education + 
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Nieuwkerk et al 
2007 
The 
Netherlands, 
multicenter 
(22) 
256 
3 groups: <200 (n = 106), 201-350 
(n = 65), and >350 CD4 (n = 68) 
96-88-93% m, 39.4 ± 7.7-40.3 ± 
10.2-40.4 ± 8.4 y. 70 (IQR 20-140)-
271 (IQR 230-320)-450 (IQR 390-
635) CD4, 5.2 (IQR 4.8-5.5)-5.0 
(4.5-5.3)-4.8 (4.4-5.0) VL  MOS-HIV 
Longitudinal 
(Baseline, 
every 6 
months) 
PH improved more among patients who started HAART with <200 CD4 
than among those with >200  
No difference on physical QoL between patients who started HAART with 
201 to 350 CD4 cells/mL versus those with >350 CD4 cells/mL  
No difference in impact on mental QoL between the 3 groups. 
Osowiecki et al 
2000 
USA, 
monocenter 
36 
all females, 37.9 ± 6.7y, 428.2 ± 
225.2 CD4  
MQoL HIV (+ Profile of Mood States + 
neurocognitive measures) 
Cross-
sectional HRQoL: neurocognitive performance +, severity of emotional distress - 
Perez et al 
2005 
Spain, 
multicenter 
(4) 
320  
73.4% m, mean age 39.7 (±8.6), 
46.9% IDU, 471.5 ±291.1 mean 
CD4, 61.6% undetectable VL, all 
on ART 
MOS-HIV  
(+ Duke-UNC-11 Functional Social Support 
Questionnaire + GHQ-28 - psychiatric 
morbidity) 
Cross-
sectional 
PH: psychological morbidity -, social support +, intravenous drug use -, 
hepatitis B -, CD4 count +, manual job +, older age –  
MH: social support +, only one additional pill +, difficulty in taking the 
medication -, female gender + 
Perez et al 
2009 
Spain, 
multicenter 
(4) 
540 
73.4%m, 38-41y, 32.6-52.7% IDU, 
65.1-68.4% undetectable VL, 
448.6-544.5 average CD4, all on 
ART 
MOS-HIV  
(+ Duke-UNC-11 Social Support 
Questionnaire + Goldberg’s questionnaire 
(psychiatric morbidity) 
Cross-
sectional 
PH, MH: no differences among genders after controlling for clinical and 
demographic variables 
Preau et al 
2005 
France, 
multicenter 
(47) 
309, 80% m, 38.8 ± 9.2 y, 14% 
IDU, 26% ≤ 200 CD4, 4.2 ± 1, 
62% on ART 
SF-36  
(+ Multidimensional Health Locus of 
Control Scale) 
Longitudinal 
(Baseline, 44 
months) Internal HLOC beliefs were associated with improved physical HRQoL. 
Preau et al 
2007 (ref 18) 
France, 
multicenter 
(102) 
2235 
73.6% m, 42.4 ± 9.4 y, 15.5% 
immigrants, 45.1% homo/bisexual, 
16.1% IDU, 470 (IQR 314–644) 
CD4, 80% on ART  
SF-36  
(+ Hospital Anxiety and Depression Scale) 
Cross-
sectional 
PH: < 47 years -, stable relationship +, financial difficulties -, 
uncomfortable housing conditions -, detectable VL -, AIDS-defining events 
-, adverse HIV treatment reactions -, rejection by medical staff -, disclosure 
of seropositivity -, HAD scores -, psychoactive drugs –  
MH: financial precariousness -, CD4 count +, adverse treatment reactions -
, disclosure of seropositivity, discrimination -, HAD scores -, psychoactive 
drugs - 
Preau et al 
2007 (ref 21) 
France, 
multicenter 
(unknown) 
243 
67% m, 37-38 (35-41)y, all IDU, 
7% CD4 <200, 80% ART 
SF-12  
(+ Life Experience Survey Scale + CES-D) 
Longitudinal 
(Baseline, 42 
months) 
PH: age -, stable partner +, being a former IDU +, CD4 cell count > 500 +, 
financial-related NLE -, HAART self-reported side effects –  
MH: social support from partner +, being a former IDU +, violence-related 
NLE -, HAART-related side effects -  
Protopropescu  
et al 
2007 
France, 
multicenter 
(unknown) 
1000 
77.3% m, 37.1 (±0.3) y, 74.6% 
born in EU, 43% homosexual, 
17.4% IDU, median CD4 293 
(IQR 154-440), all on ART SF-36 
Longitudinal 
(baseline, 1 
year, 5 years) 
Positive change in PCS and MCS over the first 12 months, stable trend in 
the maintenance phase of the treatment, from M12 to M60  
PH and MH: CD4 count +, side-effects -,  poor housing conditions -  PH: 
older age -  higher education +, parenthood -, more advanced disease stage 
-, HCV coinfection -, homosexual transmission +   
MH male gender +, stable partner +, IDU -, symptoms of lipodystrophy -, 
antiretroviral naivety - 
Rajagopalan et al 
2008 
USA 
(unknown) 
1124 
78.7% m, median 40-49y SF-8 
Cross-
sectional 
PH and MH: lipoatrophy - 
Rao et al 
2007 
USA, 
multicenter 
273 
87% m, 39 (±8.7) y, 59% Hispanic, 
FAHI  
(+ Woodcock Language Proficiency Battery– 
Cross-
sectional HRQoL (functional health status): female gender -  
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(4) 61% ≤ 200 CD4, 70% on ART Passage Comprehension subtest) 
Rodriguez-Penney 
et al 
2013 
USA, 
multicenter 
(unknown) 
141 
81-82% m 
SF-36  
(+ Charlson Co-morbidity Index (CCI) + 
Reading subtest of the Weschler Test of 
Adult Reading + HIV Dementia Scale + 
Profile of Mood States) 
Cross-
sectional 
PH: comorbidity -, depression –  
MH: depression - 
Rueda et al 
2011 
Canada, 
multicenter 
(unknown) 
361 
94% m, 42 ± 9y, 85% Caucasian, 
396 ± 263 CD4, 55% undetectable 
VL (<500 copies) 
MOS-HIV  
(+ neuropsychological tests) 
Cross-
sectional 
PH, MH: employment +  
Employment status had a greater impact on PH than on MH 
Sarna et al 
1999 
USA, 
multicenter 
(6) 
33 
all females, mean age 34.4 ± 7 y, 
14% white, 27% Hispanic, 52% 
black, 327.9 ± 268.2 CD4 HOPES 
Longitudinal 
(Baseline, 2 
months, 4 
months) 
HRQoL improved over a 4 month period, married women seemed to be 
more vulnerable to disruptions in HRQoL over time 
Schroecksnadel et 
al 
2008 
Austria, 
monocenter 
152 
65.1% m, median 37y 
Multidimensional QoL questionnaire for 
HIV/AIDS  
(+ BDI) 
Cross-
sectional HRQoL: haemoglobin +, viral load -, depressive symptoms - 
Sherbourne et al 
2000 
USA, 
multicenter 
(unknown) 
2864 
77% m, mean 39 ± 9 y, 49% white, 
33% African American, 15% 
Hispanic, 49% homosexual, 24% 
IDU 
HCSUS tool (+ Composite International 
Diagnostic Interview (psychiatric 
conditions)) 
Cross-
sectional 
PH and MH: probable diagnosis of any mood disorder -,  
Heavy drinking was not associated with HRQoL  
Probable drug dependence was associated with poorer HRQoL, but most 
of the effect disappeared after controlling for presence of a probable mood 
disorder. 
Soussa et al 
1999 
USA, 
multicenter 
(3) 
142 
80% m, mean 38 ± 8.7y,  56% 
homosexual, all AIDS or ≤ 200 
CD4 
MOS-30  
(+ HIV problem checklist (symptoms) + HIV 
quality audit marker (functional status)) 
Cross-
sectional HRQoL: Symptoms -,  functional status +, general health perceptions + 
Szaflarski et al 
2006 
USA, 
multicenter 
(4) 
449 
86% m, 43.3 ± 8.4y 45.2% 
Caucasian, 50.1% African 
American, 76.5% on ART  
HAT-QoL (+the Duke Religion Index 
(DUREL), Functional Assessment of 
Chronic Illness Therapy—Spiritual Well-
Being—Expanded (FACIT-Sp-Ex) scale, rief 
RCOPE (religious coping) + HIV Symptom 
Index + CES-D) 
Cross-
sectional 
HRQoL (feeling that life has improved): spirituality/religion +, also 
indirect effects through healthy beliefs and health status/health concerns 
Tillmann et al 
2004 
Germany, 
monocenter 
250 
82.4% m, 40.4 ± 10.6y, 56.4% 
homosexual, 14.4% IDU, mean VL 
34 234 ± 98 438 copies, mean CD4 
cell count 328 ± 215 EuroQol 
Cross-
sectional 
GB virus C coinfected HIV patients had better HRQoL than HIV patients 
without GB virus C co-infection 
Trepanier et al 
2005 
Canada, 
monocenter 
155 
mean 41.5 ± 8.5, 93% gay/bisexual 
males, 25% < 200 CD4, 51% 
undetectable VL (<500), 79% on 
ART 
MOS-HIV (+ Neuropsychological battery + 
BDI) 
Cross-
sectional 
PH: neuropsychological status +, depression x neuropsychological status 
interaction, no effect of depression  
MH: depression -, no effect of neuropsychological status and the 
depression x neuropsychological status interaction  
Uphold et al 
2007 
USA, 
multicenter 
(3) 
226 
all males, 45.7 ± 8.7, 55% white  
HCSUS tool (+ Health-Promoting Lifestyle 
Profile II (HPLP-II) + Psychiatric 
Epidemiology Research Interview) 
Cross-
sectional PH, MH and overall HRQoL: health behaviours +, stress -  
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Worthington  
et al 
2005 
Canada, 
monocenter 
308 
91% m, mean 41 ± 8 y, 73% 
homosexual, 9% IDU, CD4 438 ± 
286, 82% on ART MOS-HIV 
Cross-
sectional HRQoL: employment +, symptoms - 
Zinkernagel et al 
2001 
Switzerland, 
multicenter 
(2) 
318 
66% m, median 38y, 403 median 
CD4 , 2.15 median VL, 78% on 
ART 
MOS-HIV + EuroQol VAS  
(+ Hospital Anxiety Depression Scale + 
State-Trait Anxiety Inventory) 
Longitudinal 
(baseline and 
every 6 
months) 
MH: higher education +, being employed +, viral load -, female gender +, 
HIV duration - 
 
Multicenter (number) = number of sites, m = males, y = years, VL = viral load, PH = physical health, MH = mental health, + = positive association, - = negative 
association 
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3.2. Socio-economic, behavioural, (neuro)psychological and clinical determinants of 
HRQoL in people living with HIV: a pilot study. 
 
Sophie Degroote, Dirk Vogelaers, Peter Vermeir, An Mariman, Ann De Rick, Bea Van Der Gucht, 
Jolanda Pelgrom, Filip Van Wanzeele, Chris Verhofstede and Dominique Vandijck 
 
Degroote S et al. Socio-economic, behavioural, (neuro)psychological and clinical determinants of quality of life (QoL) 
in people living with HIV: a pilot study. Journal of the International AIDS Society (2013) 16:18643 
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Abstract 
 
Introduction: Due to highly active antiretroviral therapy (HAART), HIV-1 infection has evolved from a 
lethal to a chronic disease. As such, health-related quality of life (HRQoL) has become an important 
outcome variable. The purpose of this study was to identify socio-economic, behavioural, 
(neuro)psychological and clinical determinants of HRQoL among people living with HIV. 
 
Methods: This study was conducted between January 1st and December 31st 2012 at the Aids Reference 
Center of Ghent University Hospital, a tertiary care referral center in Belgium. Validated self-report 
questionnaires were administered to collect socio-demographic data, to assess HRQoL (Medical 
Outcomes Study-HIV), depressive symptoms (Beck Depression Inventory-II) and adherence to HAART 
(Short Medication Adherence Questionnaire) and to screen for neurocognitive dysfunction. 
 
Results: A total of 237 people participated, among whom 187 (78.9%) were male. Mean age was 
45.8±10.7 years and 144 (63.7%, 144/226) participants were homosexual. Median physical and mental 
health score (PHS, MHS) were 55.6 (IQR 48.2-60.6 ) and 52.0. (IQR 44.2-57.9), respectively. 
Multivariable regression analysis revealed that incapacity to work, depressive symptoms, neurocognitive 
complaints (NCC), dissatisfaction with the patient-physician relationship and non-adherence were 
negatively associated with HRQoL. 
 
Conclusions: Socio-economic (work status), behavioural (adherence) and (neuro)psychological 
(depressive symptoms, NCC) determinants independently impact HRQoL among this cohort of people 
living with HIV. Clinical parameters (viral load, CD4 count) were not independently associated with 
HRQoL.  
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Introduction 
 
In Belgium, 12.600 people living with HIV (PLHIV) are medically followed and there is a stable 
incidence rate of three new diagnoses per day [1]. HAART therapy is reimbursed by health insurance 
and more than 80% of the people on HAART have an undetectable viral load [2]. Worldwide, similar 
significant improvements in virological control through HAART emerge, and HIV has developed into a 
chronic disease with reasonable life expectancy [3]. The prevalence of people living with HIV (PLHIV) 
hence still increases [4]. As a result, concerns about lifelong medication use as well as physical and 
mental consequences of a chronic illness became important outcome indicators. In HIV treatment 
decisions, the impact on health-related quality of life (HRQoL) is a particular point of interest [5]. 
Maximizing HRQoL is a key goal in HIV care and therefore it is necessary to identify which factors 
influence HRQoL. Changing or managing these factors by means of targeted interventions should be 
the focus of health care managers and policy makers. 
Studies investigating determinants of HRQoL found associations with clinical [6-9], socio-economic [10-
12], psychological [13-16] and behavioural [17-20] parameters. Those studies mostly examined a specific 
and limited set of parameters within their field of interest. However, few studies [21-23] evaluated 
parameters from different categories simultaneously and none of them included neuropsychological 
parameters. As such, the possible distinctive influence of neurocognitive problems on HRQoL, remains 
unclear.  
This study is the first to investigate HRQoL in Belgium, and the first to incorporate neuropsychological 
parameters in a broad and detailed set of possible determinants of HRQoL.  
Methods 
 
Setting 
The study was conducted at the AIDS reference centre (ARC) of Ghent University Hospital, one of nine 
tertiary care referral centres in Belgium involved in the medical treatment and emotional and social 
support for PLHIV. 1300 PLHIV are currently followed by a multidisciplinary team of physicians, 
(social) nurses, psychologists and psychiatrists. The collaborating AIDS reference laboratory is 
responsible for HIV-diagnosis (serology, viral load, resistance, genotyping) and data collection of blood 
values. 
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Participants 
In order to obtain a representative sample of the HIV population seen in the ARC, all PLHIV 
consulting the ARC during the study period were eligible to participate. There were no constraints 
concerning age, time since diagnosis, treatment or other variables. Treating physicians recruited 
participants during a routine patient visit via informed consent, available in Dutch, French and English. 
The study was approved by the Ethics Committee of Ghent University Hospital and recruitment of 
participants started the 1st of January 2012.  
Instruments 
Patients were asked to fill in a self-developed and validated self-report questionnaire and to participate in 
a short interview with a nurse. Socio-demographic and socio-economic questions, as well as three 
validated instruments (Medical Outcomes Study-HIV – MOS-HIV, Short Medication Adherence 
Questionnaire – SMAQ and Beck Depression Inventory II – BDI-II) were incorporated in the bundle. 
To evaluate HRQoL, the MOS-HIV [24] was used. This instrument contains 35 items which lead to 11 
subscale scores between 0 and 100 (health perceptions, pain, physical functioning, social functioning, 
role functioning, mental functioning, energy, cognitive functioning, health distress, quality of life and 
health transition). Two final scores are then calculated: the physical health score (PHS) and the mental 
health score (MHS).  
In addition, participants were asked to fill in the 6 item SMAQ [25] and the 21 item BDI-II [26]. 
Presence of depressive symptoms in people with chronic illnesses is defined as a score of 17 or more on 
the BDI-II [27]. In a short interview with a nurse, the patient answered three questions to screen for 
presence of neurocognitive complaints (NCC) [28]. Memory, planning and attention problems were 
surveyed. One or more ‘yes’ answers are indicative for neurocognitive complaints.  
Clinical data were obtained through the electronic patient file. 
Analyses 
Data were analysed using the statistical software package SPSS, version 21 (SPSS, Inc., Chicago IL, US). 
Categorical variables are reported as numbers and percentages, continuous variables as medians and 
interquartile ranges (IQR) since they were non-normally distributed. PHS and MHS were separately 
analysed as continuous dependent variables. For bivariate analysis, Mann-Whitney U tests and Kruskal 
Wallis tests were used and correlations were calculated. Multivariable linear regression analysis was 
conducted to potentially identify determinants independently associated with HRQoL. Every variable 
with a p-value ≤0.20 after bivariate analysis, was put into a multivariable linear regression model. 
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Backward conditional procedures were performed manually to identify independent determinants. 
These were sequentially put into a model, based on the enter procedure. Significance of the covariates is 
reported by the p-values, parameter estimates by the unstandardized coefficients (B) and 95% confidence 
intervals (CI). Goodness of fit was reported by the R squared of the model. Statistical significance was 
set at p≤0.05. 
Results 
 
Population 
A total of 237 PLHIV participated in the study. Male-female ratio was 4:1, mean age was 45.8 ± 10.7 
years and 63.7% (144/226) of the participants were homosexual. Almost 90% (209/237) were 
Caucasian and 69.2% (164/237) had employment. At the time of assessment, the vast majority (92.0%, 
218/237) was receiving HAART, and viral load and CD4-count were < 40 copies/ml and >500 cells/µl 
in respectively 74.3% (176/237) and 59.9% (142/237) of participants. Depressive symptoms were 
observed in 22.3% (51/229) of the participants and eighty-six participants (36.3%) had NCC. In this 
sample, there is an underrepresentation of black PLHIV as compared to the PLHIV seen in the center 
(10% vs. 24%) and of people with foreign origin as compared to the total Belgian cohort (10% vs. 49%). 
Male-to-female ratio is higher than the ratio in the total Belgian cohort (4 vs. 1,7). Mean age in the study 
sample (45.8 years) is higher than mean age of PLHIV seen in the center (44.1 years) and mean age of 
the total Belgian cohort (43.1 years). 
QoL 
Median PHS and MHS are 55.6 (IQR 48.2-60.6 ) and 52.0. (IQR 44.2-57.9), respectively. PHS is 
significantly higher than  MHS (p<0.001) and there is a significant correlation between them (0.644; p < 
0.01). The median scores on the subscales, for men and women, are shown in Table 1. 
Table 2 shows the results of the bivariate analysis. A lower PHS and MHS is seen in PLHIV who are 
female (p<0.001 and 0.006), not working (seeking work <0.001 and 0.048, houseman/housewife 0.021 
and  0.015, invalid both < 0.001), living alone (p=0.003 and <0.001), and having an income <€1.500 
(both p<0.001). Lower PHS and MHS are also associated with shorter time since diagnosis (p=0.017 and 
0.040), the presence of depressive symptoms (both p<0.001), neurocognitive complaints (both p <0.001), 
less satisfaction with relationship with physician (p=0.049 and 0.004), dissatisfaction with social support 
(both p <0.001), dissatisfaction with sex life (both p<0.001), and poor adherence (both p<0.001). Black 
ethnicity (p = 0.030) and dissatisfaction with information received about medication (p=0.010) are 
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associated with lower PHS, whereas not being married (divorced p=0.006, single <0.001) and drug use 
(p=0.021) are associated with lower MHS (Table 2). 
Multivariable linear regression analysis shows that presence of depressive symptoms, neurocognitive 
complaints, work incapacity, satisfaction with the patient-physician relationship and non-adherence are 
independently associated with both poor PHS and MHS. Seeking work and being a 
houseman/housewife negatively influence PHS. Dissatisfaction with sex life is associated with lower 
MHS (Table 3).  
Table 1: Results of MOS-HIV: Quality of Life scores for men and women 
                      Median (IQR) 
Total scores Men Women 
Physical health score 57.7 (49.6-60.9) 51.4 (44.2-54.5) 
Mental health score 52.8 (45.1-58.7) 50.4 (41.6-54.9) 
Subscales    
General health perceptions 70 (50-85) 63.9 (45-75) 
Physical functioning 91.7 (75-100) 75 (50-83.33) 
Role functioning 100 (100-100) 100 (50-100) 
Social functioning 100 (80-100)  80 (60-100) 
Cognitive functioning 80 (65-100) 75 (65-100) 
Pain 88.9 (66.67-100) 77.8 (55.56-100) 
Mental health 72 (56-80) 65.20 (56-76) 
Energy 70 (55-80) 60 (45-75) 
Health distress 85 (65-100) 70 (50-90) 
Quality of life 75 (50-75) 75 (50-75) 
Health transition 50 (50-75) 67.1 (50-75) 
 
Table 2: Results of bivariate analyses (Mann-Withney U test, Kruskal Wallis test or Pearson correlation).  
Median and IQR are shown for categorical variables, the correlation coefficient for continuous variables.  
Variable PHS (median and IQR) p-value MHS (median and IQR) p-value 
Sex 
Female 
Male 
 
51.37 (44.19-54.52) 
57.65 (49.60-60.95) 
<0.001  
50.37 (41.64-54.95) 
52.83 (45.09-58.74) 
0.006 
Sexual orientation  (n = 226) 
Heterosexual 
Homosexual 
Bisexual 
 
53.29 (44.56-59.60) 
57.65 (49.65-61.21) 
54.40 (44.64-59.13) 
0.066  
50.80 (43.09-56.40) 
53.02 (45.29-58.71) 
44.94 (41.10-53.54) 
0.155 
Age (correlation) -0.115 0.076 -0.092 0.158 
Ethnicity (n = 236) 
White 
Black 
 
57.16 (49.26-60.87) 
52.27 (44.39-57.41) 
0.030  
52.57 (44.15-58.09) 
50.52 (45.89-55.90) 
0.680 
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Viral load 
<50  copies/ml 
40-400 copies/ml 
401-1000 copies/ml 
> 1000 copies/ml 
 
56.53 (48.22-60.92) 
53.75 (49.55-58.93) 
54.98 (45.74-59.08) 
55.65 (45.60-60.91) 
0.651  
51.92 (45.12-57.99) 
51.53 (43.90-56.47) 
59.49 (54.69-62.54) 
51.87 (41.10-55.90) 
0.238 
CD4 count 
< 200 
200 – 500 
> 500 
 
45.87 (38.42-53.06) 
55.66 (47.53-60.23) 
56.42 (49.70-60.87) 
0.112  
52.93 (47.80-59.87) 
50.94 (44.15-56.16) 
53.33 (44.24-58.19) 
0.602 
ART Treatment 
No 
Yes    
 
54.01 (47.74-58.47) 
56.10 (48.23-60.73) 
0.464  
52.42 (44.25-57.92) 
50.99 (39.50-58.13) 
0.602 
Time since diagnosis (correlation) -0.155 0.017 -0.133 0.040 
Depressive symptoms
 
No
 
Yes 
 
57.69 (51.99-60.95) 
47.82 (39.24-53.37) 
<0.001  
54.69 (50.26-58.89) 
39.76 (34.34-44.00) 
<0.001 
Civil status  
Married 
Cohabitant 
Divorced 
Widow/widower 
Alone 
 
58.68 (53.71-61.41) 
57.17 (48.21-60.87) 
53.06 (45.99-59.08) 
56.54 (51.26-60.22) 
53.74 (47.53-59.96) 
0.095  
55.56 (49.95-60.13) 
52.88 (43.38-60.71) 
50.52 (45.12-54.82) 
44.45 (37.84-52.99) 
50.52 (42.29-56.13) 
0.003 
Domestic situation 
Living with partner/children, family or friends 
Living alone 
 
57.71 (50.52-60.90) 
53.24 (47.08-59.66) 
0.003  
53.47 (46.96-59.85) 
50.37 (41.96-55.75) 
<0.001 
Place of residence 
At home 
Other 
 
56.21 (48.21-60.75) 
53.06 (48.90-57.74) 
0.414  
52.20 (44.07-57.95) 
50.52 (50.25-55.50) 
0.674 
Children 
No  
Yes  
 
57.24 (49.29-60.91) 
53.06 (44.58-59.45) 
0.086  
52.75 (44.19-58.40) 
50.52 (45.04-55.52) 
0.184 
Education  
Primary school (12 years) 
College (15 years) 
College (18 years) 
College of higher education (3 years) 
College of higher education (> 3 years) 
University 
 
53.06 (44.19-58.60) 
53.06 (46.81-59.47) 
57.23 (48.23-60.87) 
55.47 (50.21-60.73) 
58.87(49.93-62.06) 
57.04 (52.96-59.08) 
0.525  
50.52 (41.78-59.19) 
50.52 (43.90-55.03) 
52.80 45.54-60.13() 
51.84(45.89-55.90) 
51.95 (39.99-57.93) 
55.81 (46.81-58.34) 
0.161 
Activity  
Student 
Working 
Job seeker 
Housewife/houseman 
Invalid 
Retired 
 
52.25 (44.19-55.52) 
58.37 (53.06-61.24) 
49.30 (42.81-55.58) 
43.05 (34.76-57.99) 
40.90 (34.81-49.88) 
57.70 (51.65-58.66) 
<0.001  
49.77 (45.89-54.06) 
53.90 (48.98-58.65) 
47.05 (39.99-57.73) 
45.24 (34.44-50.49) 
41.43 (35.96-45.69) 
57.58 (47.80-60.71) 
<0.001 
Income (after taxes) (n = 226)
 
<  € 1500 
≥ € 1500 
 
52.41 (41.67-58.74) 
57.95 (53.06-61.29) 
<0.001  
48.66 (40.66-55.51) 
54.26 (48.79-58.87) 
<0.001 
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Table 3: Multivariable linear regression models for PHS and MHS. 
 
PHS-model  
 
p-value 
 
B 
 
[95% Confidence Interval] 
Constant <0.001 56.04 [53.48; 58.60] 
Depressive symptoms 0.017 -3.19 [-6.62; -1.75] 
Work situation 
Student (vs. working) 
Seeking work (vs. working)  
Houseman/housewife (vs. working) 
 
0.158 
0.001 
0.017 
 
-5.88 
-6.54 
-8.74 
 
[-14.07;  2.31] 
[-10.50;  -2.58]  
[-15.90;  -1.58] 
Smoking  
No  
Yes 
 
58.89 (49.30-59.91) 
54.57 (46.28-61.05) 
0.816  
52.61 (45.21-58.29) 
51.11 (42.95-56.73) 
0.200 
Drug use 
No  
Yes 
 
56.89 (49.26-60.75) 
50.66 (45.44-59.13) 
0.072  
52.78 (45.20-58.09) 
48.41 (38.83-53.63) 
0.021 
Alcohol use
 
No 
≤ 3/day 
> 3/day 
 
54.44 (47.53-60.29) 
58.19 (49.88-61.29) 
57.72 (45.12-59.07) 
0.075  
50.52 (43.93-57.07) 
55.22 (45.75-59.19) 
52.22 (37.16-57.73) 
0.112 
Religion 
Atheist 
Catholic  
Protestant 
Muslim 
Other 
 
57.58 (50.93-60.75) 
57.04 (48.23-60.87) 
50.80 (48.10-54.52) 
53.06 (51.09-63.49) 
53.70 (45.41-59.96) 
0.350  
52.83 (44.19-58.19) 
51.79 (44.25-58.19) 
52.80 (46.01-55.50) 
55.90 (50.52-56.40) 
48.66 (43.90-57.60) 
0.857 
Membership self-help group 
No  
Yes 
 
55.66 (48.23-60.54) 
53.06 (45.99-59.83) 
0.585  
52.57 (44.24-58.02) 
49.31 (44.98-51.25) 
0.248 
Satisfaction relationship physician
 
Very  satisfied 
Satisfied or indifferent  
 
56.81 (49.31-60.80) 
50.93 (45.41-58.96) 
0.049  
53.02 (45.16-58.62) 
46.64 (39.88-53.70) 
0.004 
Satisfied information medication (n = 221)
 
No  
Yes 
 
49.55 (41.30-57.98) 
57.10 (49.33-60.87) 
0.010  
50.25 (40.42-59.65) 
52.49 (45.09-57.92) 
0.558 
Satisfaction support 
 
(Very) Satisfied 
(Very) unsatisfied or indifferent 
 
57.64 (50.25-60.93) 
49.65 (42.04-57.18) 
<0.001  
53.52 (46.64-58.69) 
44.88 (35.96-50.94) 
<0.001 
Satisfaction sex life 
 
(Very) satisfied 
(Very) unsatisfied or  indifferent 
 
58.39 (53.06-61.22) 
51.09 (44.58-57.69) 
<0.001  
55.47 (50.49-59.85) 
45.54 (38.58-52.81) 
<0.001 
Neurocognitive complaints
 
No 
Yes 
 
58.25 (51.65-61.32) 
50.72 (44.20-56.10) 
<0.001  
55.41 (49.83-59.87) 
45.72 (39.61-51.79) 
<0.001 
SMAQ adherent (n = 218)
 
No  
Yes 
 
49.70 (44.19-53.32) 
57.74 (50.80-61.07)) 
<0.001  
48.41 (39.74-52.72) 
53.47 (45.89-58.87) 
<0.001 
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Invalid (vs. working) 
Retired (vs. working) 
<0.001 
0.084 
-11.70 
-3.47 
[-14.74;  -8.67] 
[-7.0;  0.47] 
Neurocognitive complaints 0.007 -2.88 [-4.981;  -0.788] 
Satisfaction with relation physician 0.028 2.85 [0.31;  5.40] 
Non-adherence (SMAQ) 0.001 -4.18 [-6.62;  -1.75] 
R² = 0.426    
 
MHS-model  
 
p-value 
 
B  
 
[95% Confidence Interval] 
Constant <0.001 51.34 [49.01; 53.675] 
Depressive symptoms <0.001 -10.10 [-12.22; 7.98 ] 
Work situation 
Student (vs. working)                  
Seeking work (vs. working)  
Houseman/housewife (vs. working) 
Invalid (vs. working) 
Retired (vs. working) 
 
0.153 
0.517 
0.650 
<0.001 
0.873 
 
-4.74 
-1.04 
-1.32 
-5.90 
-0.26 
 
[-11.25;  1.77] 
[-4.20; 2.12]  
[-7.03;  4.39]  
[-8.34;  -3.45] 
[-3.39;  2.88] 
Neurocognitive complaints <0.001 -4.46 [-6.15;  -2.77] 
Satisfaction with sex life <0.001 3.29 [1.64;  4.95] 
Satisfaction with relation physician <0.001 3.80 [1.77; 5.82] 
Non-adherence (SMAQ) <0.001 -3.61 [-5.56;  -1.67] 
R² = 0.653    
 
 
Discussion 
 
Physical and mental health scores of the MOS-HIV in this cohort of PLHIV are high and comparable to 
those found in HIV patients studied in other countries [10, 21, 29-31]. Scores on the subscales of the 
MOS-HIV are even comparable to those found in a general healthy population, except for a lower score 
for mental health [32]. The good clinical status of our cohort and the high representation of Caucasian 
homosexuals might be a potential explanation. In people with other chronic diseases such as chronic 
fatigue syndrome or rheumatoid arthritis, substantially lower HRQoL scores have been reported [32, 
33]. It seems that HIV does not interfere with daily life to the same extent as these other chronic 
diseases. 
Determinants associated with a lower HRQoL in this study are the presence of depressive symptoms, 
neurocognitive complaints, working situation, satisfaction with the relationship with the physician, 
adherence and satisfaction with sex life. 
It is well-known that depressive symptoms negatively impact perceived HRQoL [16, 23, 34, 35]. In this 
study, depressive symptoms were independently associated with both poor MHS and PHS. Moreover, 
depressive symptoms interfere with all domains as measured by the subscales of the MOS-HIV (except of 
health transition) which emphasises their considerable impact. Systematic and periodic screening for 
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depression, as well as an appropriate treatment if necessary, are imperative to intervene in this 
prominent problem.  
NCC were found to be independently associated with lower PHS, MHS and lower subscale scores 
(except health transition). Neurocognitive impairment has already been shown to be a predictor of poor 
HRQoL [36] and to be significantly associated with lower scores on all HRQoL subscales [37]. This 
might be explained by difficulties in coping with daily activities such as stocking, managing their money, 
planning appointments, etc., which potentially lead to frustration and a loss of independence [36]. 
Medical professionals, family members and PLHIV themselves should be vigilant for these signs. 
Screening and prevention of HIV-associated neurocognitive disorder should become more familiar in 
HIV care in order to determine effective treatment strategies (exclude neurotoxicity if possible, treating 
co-morbidity…)[38]. We could, however, not confirm presence of NCC by a neurocognitive testing 
battery, but it was previously observed that patient-reported measures of neurocognitive functioning and 
results on objective neurocognitive testing correlate significantly [37]. 
Several studies report that employed PLHIV tend to have better HRQoL [10, 12, 39-41]. Employment 
has an important role in the daily life of people. It provides structure, a social support network, role 
identity and meaning [40]. Physical functioning, role functioning, social functioning, pain, mental 
health and health distress were found to be significantly affected by disability. Differences in physical 
health as compared to employed people were also observed in job seekers. They have lower scores in 
physical-, role-, and social functioning and energy.  
The exact association between employment and HRQoL remains unproven. Probably this is a bi-
directional relationship [10, 12]. PLHIV with  good HRQoL can choose to work (selection hypothesis), 
or work can be a source of wellbeing (causation hypothesis)[10]. Working should be encouraged and 
therefore possible internal or external barriers should be addressed [42]. PLHIV could be advised by 
peers, medical professionals and HR- and labour legislation experts about their rights and about 
practical concerns and discomforts. Our research group, in collaboration with the Flemish expertise 
center on sexual health, currently gathers experiences from PLHIV at the workplace. This is a first step 
in developing a framework for employers and employees to inform them and to guide them through 
HIV at the workplace. 
The importance of a good patient-physician relationship is emphasised by its contribution to both 
physical and mental health. It was shown that a good and trustful patient-physician relationship 
contributes to a good adherence [43, 44] and to an undetectable viral load [44]. Mental health improves 
by the feeling of ‘being treated as a person’ and trust in the physician [44, 45]. The perception of 
empathy and a good knowledge about HIV seem to be predictive for satisfaction about the patient-
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physician relationship [46]. Physicians should be aware of this and invest in their relationship with 
PLHIV. 
Furthermore, adherence itself  influences HRQoL. Differences between adherent versus non-adherent 
participants are seen in all subscales of the MOS-HIV which corresponds with the overall conclusion of 
the review on this topic by Geocze, Mucci, De Marco, Nogueira-Martins & Cicero [20]. Out of 12 
studies, ten showed a positive association between adherence and HRQoL. A causal relationship was, 
however, not clear. Adherence to ART could lead to better HRQoL, considering the protective role of 
ART in disease progression and mortality. On the other hand, ART frequently causes serious side effects 
(nausea, diarrhea, lipodystrophy, …), which of course negatively influence HRQoL. Some PLHIV may 
therefore feel the tendency to stop adhering to ART in an attempt to re-establish their HRQoL. Another 
possibility could be that adherence and HRQoL have overlapping determinants. However, it is evident 
that adherence remains a highly important goal and moreover, interventions to improve adherence 
could have additional HRQoL benefits.  
PLHIV who are satisfied about their sex life have a higher MHS than those who are not. In literature, 
studies addressing this relationship are scarce. Most research discusses sexual dysfunction rather than 
sexual satisfaction [47]. However, there is evidence that a good sex life contributes to  good HRQoL in 
the general population [48] and that experiencing sexual problems is associated with poorer quality of 
life in gay men [49]. In our study, dissatisfaction with sex life is associated with significant lower scores 
on all subscales of the MOS-HIV except health transition. Apparently, multiple domains of HRQoL are 
influenced by this presently understudied outcome measure. We recommend to break the taboo about 
sexual problems and to take these complaints seriously. They can be the expression of multiple stressors: 
troubles in the current relationship, loneliness, trauma, physical causes… Accurate identification of the 
cause(s) should lead to the right treatment approach [50]. 
There are several study limitations that need to be addressed. The number of participants is limited. 
Nevertheless, good predictive models for HRQoL were achieved and the number is considered as 
adequate given the great detail in our research. A second limitation is the self-report of depressive 
symptoms and neurocognitive complaints. Formal testing by a psychiatrist or neuropsychologist was not 
done. Because of the cross-sectional design, we were not able to determine causal relationships. 
Furthermore, taking into account the non-normal PHS and MHS, linear regression analysis reveals less 
correct models than median regression analysis would do. Finally, the use of separate models for physical 
and mental health may be artificial, regarding the evidence about a strong, bidirectional relationship 
between them [51]. In fact, in this study, physical and mental health were found to be influenced by 
mainly the same parameters. 
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Behind these limitations, some strengths of this pilot study should be considered. To the best of our 
knowledge, this study is the first to investigate HRQoL among PLHIV in Belgium. Moreover, in 
addition to clinical variables, whose relationship with HRQoL has been the focus of a limited number of 
studies [6, 52, 53], many other (socio-economic, behavioural and psychological) variables were analysed 
and were found to be associated with HRQoL. Calling more attention to non-clinical parameters in HIV 
care, seems to be a relevant approach. 
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Conclusion 
 
PHS is high in this cohort of PLHIV. Not the clinical, but socio-economic (working), behavioural 
(adherence, sex life) and (neuro)psychological (depressive symptoms, NCC) variables significantly  
influence HRQoL, as well as the perceived quality of the patient-physician relationship. Future research 
should focus on interventions to improve HRQoL, in hospital settings (supporting adherence, screening 
for and treating depression and neurocognitive problems, improving patient-physician relationship) and 
abroad (framework for HIV at the workplace, promoting sexual health). 
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Abstract 
 
Introduction: HIV has become a chronic disease in which patient-reported outcomes, such as health-
related quality of life (HRQoL), are vital for good clinical management. Most previous studies on this 
topic identified determinants of HRQoL cross-sectionally. The aim of this study was to identify 
determinants of HRQoL in a longitudinal design. 
Methods: Baseline (T0, n = 237) and follow-up (T1, n = 148) data were collected at time of enrollment 
and 12 months later. The self-report questionnaire consisted of socio-demographic questions and 
validated instruments to measure HRQoL (Medical Outcomes Study (MOS)-HIV Questionnaire), 
adherence to antiretroviral therapy (Simplified Medication Adherence Questionnaire), depressive 
symptoms (Beck Depression Inventory) and three questions examining neurocognitive complaints. 
Mixed linear regression was done to identify determinants of HRQoL, as expressed by the physical and 
mental health score (PHS and MHS) of the MOS-HIV. 
Results: In the mixed models, following determinants were found to be independently associated with 
worse PHS and MHS: presence of neurocognitive complaints, depressive symptoms, being invalid and 
non-adherence. Not having a job was also associated with worse PHS. Having a monthly income of less 
than €1500, not being very satisfied about the relationship with the physician and a higher education 
were determinants of worse mental health. 
Conclusions: Determinants of PHS and MHS show a substantial overlap. Mainly socio-economic and 
psychological variables influence HRQoL over time. 
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Introduction 
 
As of the advent of highly active antiretroviral therapy, the management of HIV (Human 
Immunodeficiency Virus) infection has drastically changed. Whereas the goal was to keep the patient 
alive, initially, currently, it has changed to keep the patient healthy [1]. To do so, purely clinical 
management of HIV is not sufficient. Measures of treatment benefits beyond clinical parameters are 
necessary and can only be obtained by means of patient-reported outcomes. Those may include signs 
and symptoms, functional status, general perceptions or feelings of well-being, adherence, satisfaction 
with treatment, and health-related quality of life (HRQoL)[2]. HRQoL is a subjective perception of 
health status consisting of physical, mental and social wellbeing and is part of the bigger concept 
‘Quality of life’ [3]. The latter includes, among others, family relationships, residential environment, 
social support, economic situation and health [4]. However, although being a main determinant of QoL, 
the contribution of health to QoL can vary and a less favorable health status does not always correspond 
with a lower QoL [5, 6]. Moreover, a reciprocal causal relationship between QoL and health has been 
argued [7]. 
The longitudinal assessment of HRQoL has become increasingly important, especially in chronic 
diseases such as HIV [8]. It can be used to measure the burden of the disease, to detect changes over 
time and to evaluate the effects of new treatments [9]. Moreover, HRQoL is a useful measure in 
economic evaluations [10]. 
HRQoL in people living with HIV (PLHIV) has been extensively studied [9, 11, 12]. One of the main 
goals of the HIV Cost and Services Utilisation Study, a large project in the U.S.A. which started in 
1994, was to collect data on HRQoL of a nationally representative sample of 2.864 PLHIV. A significant 
variability according to disease stage was observed [9]. In 2003, Skevington et al. reviewed no less than 
303 studies on HRQoL in PLHIV and observed a great diversity among the instruments used to assess 
HRQoL [11]. A recent review discussed 49 studies focusing on determinants of HRQoL in PLHIV, 
again, heterogeneity was prominent [12].  
It is well-known that certain factors, such as depression and socio-economic status are associated with 
HRQoL in PLHIV [13-17]. However, longitudinal data on HRQoL are scarce [18], and only a few 
studies focused on determinants of HRQoL over time [19-22]. This gap in literature is remarkable, since 
PLHIV are followed for long periods and therefore, identification of (modifiable) HRQoL predictors is 
of great importance. As such, results of such studies could serve as a starting point to establish quality 
improvement interventions [20]. This study aimed to identify potential baseline determinants of 
HRQoL in a cohort of PLHIV.  
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Methods 
 
Setting and participants 
In a prospective cohort study design, approved by the Ethics Review Board of Ghent University 
Hospital, patients were enrolled between January 2012 and December 2012 at a single center in Belgium 
[17]. In the center, approximately 1300 PLHIV are followed, male-to-female ratio is 3:1, mean age is 
45.3±11.2 years and 23.8% have black ethnicity. More than two thirds of the population has an 
undetectable viral load (67.3%) and 49.5% has a CD4-cell count above 500 cells/ml. The open 
recruitment was done by the treating physician, by means of an informed consent. All PLHIV followed 
at the hospital were eligible for inclusion and study material was available in Dutch, French and English. 
Baseline (T0, n = 237) and follow-up (T1, n = 148) data were collected at time of enrollment and 12 
months later. After approximately one year, all T0 participants were contacted by the principal 
investigator (by telephone or e-mail) to ask if they were willing to participate in the follow-up study. 
Questionnaires, along with a prepaid and addressed envelope, were then sent to those who consented. 
Instruments 
A self-report questionnaire was filled in by the participants. Socio-demographic questions were 
combined with validated instruments to measure HRQoL (MOS-HIV Questionnaire [23]), adherence 
(Simplified Medication Adherence Questionnaire [24]), depressive symptoms (Beck Depression 
Inventory [25]) and three questions examining neurocognitive complaints [26]. HRQoL was measured 
through 35 items, leading to 11 subscales, which were then combined and transformed through a 
specific algorithm to calculate two continuous scores: the physical and mental health score (PHS and 
MHS) [27]. Only PHS and MHS are discussed in this study, not the subscales. 
Analyses 
Data were analyzed by means of the statistical package SPSS, version 22 (SPSS, Inc., Chicago IL, US). To 
determine determinants of HRQoL at both timepoints (i.e. aggregated PHS0 and PHS1 scores and 
aggregated MHS0 and MHS1 scores), bivariate analyses were performed (Student’s T-test, One-way 
ANOVA), as well as Pearson’s correlations. Factors assessed at T0 that were found to be significantly 
related with PHS and MHS at the 0.05 level at bivariate analyses, were used as fixed factors in the linear 
mixed regression models for PHS and MHS, respectively. Stepwise regression was performed. Factors 
were added to the model in order of their bivariate association’s strength with PHS/MHS. Factors were 
removed when they did not significantly contribute to the model (p>0.05). Interaction effects were 
examined if the effect of one factor could depend on the value of other factors included in the model as 
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shown by high correlations of estimates. Significance of the covariates was reported by the p-values, 
magnitude of the effects by the estimates and 95% confidence intervals (CI).  
Results 
 
At the end of the inclusion period (December 2012), 237 PLHIV participated in the study. At T1, 148 
(62.4%) participants had returned the follow-up questionnaire. Among the 89 others, two died, 14 no 
longer wanted to participate, 38 could not be reached and 35 agreed to participate again, but did not 
return the questionnaire. 
A comparison between the two groups revealed that the follow-up group is older (46.9 ± 10.6 years 
versus 44.0 ± 10.72 years, p=0.042), has less depressive symptoms (26/148, 17.6% vs. 26/89, 29.2%, 
p=0.036), is more frequently living at home (3/148, 2.0% vs. 9/89, 10.1%, p=0.006), and is less 
frequently smoking (37/148, 25.0% vs. 39/89, 43.8%, p=0.006) as compared to the group that did not 
participate in the follow-up. 
Patient characteristics 
The majority of the cohort are males (T0: 187/235, 79.6% and T1: 122/148, 82.4%) with a mean age of 
45.9 ± 10.7 years at T0 and 48.0 ± 10.6 years at T1. The vast majority of participants have good 
virological and immunological outcomes with 175 out of 235 (74.5%) having an undetectable viral load 
at T0 and 140 out of 148 (94.6%) at T1). At T0, 60.4% (142/235) have a CD4-count above 500 cells/µl, 
this is 75.7% (112/148) at T1. All sociodemographic characteristics are shown in Table 1. 
Table 1: Patient characteristics at T0 and T1.  
* data available only for patients on HAART 
 T0 T1 
 n % n % 
Gender 
   Male 
   Female 
 
187 
48 
 
79.6 
20.4 
 
122 
26 
 
82.4 
17.6 
Ethnicity 
   White 
   Black 
 
209 
25 
 
89.3 
10.7 
 
134 
14 
 
90.5 
9.5 
Mean age (± SD) 45.9 10.7 46.9 10.6 
ART treatment 
   Yes 
   No 
 
219 
16 
 
93.2 
6.8 
 
137 
11 
 
92.6 
7.4 
Time since diagnosis 9.5 6.4 10.2 6.6 
Viral Load 
   < 40 copies/ml 
 
175 
 
74.5 
 
109 
 
73.6 
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   40-400 copies/ml 
   401-1000 copies/ml 
   > 1000 copies/ml 
38 
3 
19 
16.2 
1.3 
8.1 
26 
2 
12 
17.6 
0.7 
8.1 
CD4-count 
   < 200 cells/µl 
   200-500 cells/µl 
   > 500 cells/µl 
 
5 
88 
142 
 
2.1 
37.4 
60.4 
 
2 
49 
97 
 
1.4 
33.1 
65.5 
SMAQ* 
   Adherent 
   Non adherent 
 
171 
46 
 
78.8 
21.2 
 
110 
27 
 
80.3 
19.7 
Depressive symptoms 
   No 
   Yes 
 
183 
52 
 
77.9 
22.1 
 
122 
26 
 
82.4 
17.6 
Neurocognitive complaints 
   No 
   Yes 
 
147 
83 
 
62.6 
35.3 
 
95 
53 
 
64.2 
35.8 
Civil status 
   Married 
   Cohabitant 
   Divorced 
   Widow/widower 
   Alone 
 
60 
34 
28 
4 
109 
 
25.5 
14.5 
11.9 
1.7 
46.4 
 
41 
21 
16 
3 
67 
 
27.7 
14.2 
10.8 
2.0 
45.3 
Children 
Yes 
No 
Domestic situation 
Living alone 
Living with partner, family, friends 
 
81 
153 
 
95 
140 
 
65.4 
34.6 
 
40.4 
59.6 
 
46 
102 
 
57 
91 
 
31.1 
68.9 
 
38.5 
61.5 
Education 
   Primary school (12 years) 
   College (15 years) 
   College (18 years) 
   College of higher education (21 years) 
   College of higher education (> 21 years) 
   University 
 
16 
42 
76 
52 
24 
24 
 
6.8 
17.9 
32.3 
22.1 
10.2 
10.2 
 
6 
24 
55 
33 
14 
16 
 
4.1 
16.2 
37.2 
22.3 
9.5 
10.8 
Activity 
   Student 
   Working 
   Seeking work 
   Househusband/housewife 
   Invalid 
   Retired 
 
3 
162 
14 
6 
34 
14 
 
1.3 
68.9 
6.0 
2.6 
14.6 
6.0 
 
3 
106 
5 
4 
21 
9 
 
2.0 
71.6 
3.4 
2.7 
14.2 
6.1 
Income per month 
   < €1500 
   ≥ €1500 
 
106 
122 
 
46.5 
53.5 
 
62 
82 
 
56.9 
43.1 
 Sexual orientation 
   Heterosexual  
   Homosexual 
 
77 
144 
 
33.3 
62.3 
 
44 
100 
 
29.7 
67.6 
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   Bisexual 10 4.3 4 2.7 
Smoking  
   No 
   Yes 
 
159 
76 
 
67.7 
32.3 
 
111 
37 
 
75.0 
25.0 
 Alcohol use 
   No 
   <= 3 consumptions/day 
   > 3 consumptions/day 
 
159 
57 
16 
 
68.5 
24.6 
6.9 
 
99 
36 
13 
 
66.9 
24.3 
8.8 
Drug use 
   No 
   Yes 
 
209 
25 
 
89.3 
10.7 
 
135 
13 
 
91.2 
8.8 
Satisfaction relationship physician 
   Very satisfied 
   Satisfied or indifferent 
 
193 
42 
 
82.1 
17.9 
 
121 
27 
 
81.8 
18.2 
Satisfaction information medication* 
   Satisfied 
   Not satisfied 
 
197 
21 
 
83.8 
8.9 
 
126 
11 
 
92.0 
8.0 
Satisfaction social support 
   (Very) satisfied 
   Indifferent 
   (Very) Dissatisfied 
 
176 
38 
14 
 
77.2 
16.7 
6.1 
 
111 
27 
10 
 
75 
18.2 
6.8 
Satisfaction sex life 
   (Very) Satisfied 
   Indifferent 
   (Very) Dissatisfied 
 
131 
56 
45 
 
56.5 
24.1 
19.4 
 
85 
36 
27 
 
57.4 
24.3 
18.2 
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Mixed models 
Bivariate analyses were performed to preselect possible factors to include in the mixed models (Table 2). 
Mixed models consisted only main effects of the fixed factors, since no significant interaction effects 
were estimated. Following factors were found to be independently associated with worse PHS: presence 
of neurocognitive complaints, depressive symptoms, being invalid, not working and non-adherence. All 
those factors, except for not working, were also independently associated with worse MHS, along with 
not being very satisfied with the relationship with the physician, a higher education and a monthly 
income of less than €1500 (see Tables 3 and 4).  
Table 2: Results of bivariate analyses. § = Significant association (p ≤ 0.005) 
Variable PHS (median and IQR) p-value MHS (median and IQR) p-value 
Sex 
Female 
Male 
  
49.60 ± 10.06 
53.90 ± 9.16 
0.001§  
47.64 ± 9.81 
51.48 ± 9.55 
0.003§ 
Sexual orientation  (n = 226) 
Heterosexual 
Homosexual 
Bisexual 
 
51.49 ± 9.73 
54.02 ± 9.20 
50.81 ± 10.57 
0.038§  
49.36 ± 9.77 
51.75 ± 9.39 
46.09 ± 12.41 
0.016§ 
Age (correlation) -0.171 0.001§ -0.121 0.019§ 
Ethnicity (n = 236) 
White 
Black 
 
53.35 ± 9.61 
50.78 ± 7.76 
0.127  
50.75 ± 9.84 
50.94 ± 8.42 
0.912 
Viral load 
<50  copies/ml 
> 50  copies/ml 
 
53.28 ± 8.9.68 
52.61 ± 8.86 
0.546  
51.08 ± 9.73 
49.91 ± 9.60 
0.305 
CD4 count 
< 200 
200 – 500 
> 500 
 
45.15 ± 8.16 
53.09 ± 8.98 
53.32 ± 9.70 
0.113  
46.42 ± 14.44 
49.87 ± 9.25 
51.41 ± 9.79 
0.183 
ART  
No 
Yes    
 
52.33 ± 9.44 
53.17 ± 9.48 
0.663  
49.64 ± 11.32 
50.86 ± 9.58 
0.534 
Time since diagnosis (correlation) -0.189 0.001§ -0.151 0.006§ 
Depressive symptoms 
No 
Yes 
 
55.06 ± 8.12 
45.53 ± 10.50 
<0.001§  
53.83 ± 7.81 
38.99 ± 8.63 
<0.001§ 
Civil status  
Married 
Cohabitant 
Divorced 
Widow/widower 
Alone 
 
54.17 ± 10.05 
52.11 ± 9.73 
51.17 ± 9.11 
57.02 ± 4.29 
53.11 ± 9.22 
0.311  
52.76 ± 9.99 
51.13 ± 10.79 
48.89 ± 9.75 
45.58 ± 9.94 
50.18 ± 8.99 
0.075 
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Domestic situation 
   Living with partner/children, family or friends 
   Living alone 
 
53.57 ± 9.58 
52.41 ± 9.28 
0.245  
51.84 ± 9.81 
49.16 ± 9.34 
0.009§ 
Children 
No  
Yes  
 
53.74 ± 51.79 
51.79 ± 9.94 
0.061  
51.16 ± 10.03 
49.99 ± 8.96 
0.274 
Education  
College (15 y) or less 
College (18 y) 
College of higher education (21 y) or more 
 
51.56 ± 9.88 
53.11 ± 9.47 
52.91 ± 10.04 
0.121  
48.58 ± 9.47 
52.37 ± 9.31 
50.63 ± 9.95 
0.019§ 
Activity  
Working 
Student, job seeker, 
housewife/househusband/retired 
Invalid 
 
56.30 ± 6.68 
50.18 ± 9.64 
40.66 ± 9.77 
<0.001§  
53.24 ± 8.07 
49.31 ± 9.77 
40.15 ± 9.82 
<0.001§ 
Income (after taxes) (n = 226) 
<  € 1500 
≥ € 1500 
 
49.49 ± 10.98 
55.86 ± 7.01 
<0.001§  
47.41 ± 10.75 
53.41 ± 7.97 
<0.001§ 
Smoking  
No  
Yes 
 
53.32 ± 9.11 
52.59 ± 10.30 
0.519  
51.12 ± 9.55 
49.95 ± 10.06 
0.286 
Drug use 
No  
Yes 
 
53.45 ± 9.40 
50.08 ± 9.65 
0.037§  
51.15 ± 9.65 
47.51 ± 9.69 
0.028§ 
Alcohol use 
No 
≤ 3/day 
> 3/day 
 
52.16 ± 10.01 
55.51 ± 7.86 
53.73 ± 7.65 
0.013§  
49.89 ± 9.998 
53.72 ± 7.49 
49.84 ± 10.30 
0.003§ 
Religion 
Atheist 
Catholic  
Protestant 
Muslim 
Other 
 
54.48 ± 8.30 
53.30 ± 9.92 
48.96 ± 8.36 
58.74 ± 6.69 
51.90 ± 9.70 
0.081  
52.10 ± 8.36 
50.48 ± 10.24 
49.96 ± 8.08 
57.15 ± 1.75 
50.20 ± 10.28 
0.473 
Satisfaction relationship physician 
Very  satisfied 
Satisfied 
 
53.68 ± 9.13 
 50.52 ± 10.53  
0.024§  
51.71 ± 9.28  
 46.47 ± 10.46  
< 0.001§ 
Satisfied information medication (n = 221) 
No  
Yes 
 
49.95 ± 10.24 
53.49 ± 9.33 
0.044§  
50.76 ± 10.53 
50.87 ± 9.50 
0.952 
Satisfaction support  
(Very) Satisfied 
Indifferent 
(Very) unsatisfied 
 
54.44 ± 8.71 
49.93 ± 9.84 
45.49 ± 12.27 
<0.001§  
52.43 ± 8.33 
46.33 ± 11.78 
43.07 ± 12.26 
<0.001§ 
Satisfaction sex life  
(Very) satisfied 
Indifferent 
(Very) unsatisfied 
 
55.55 ± 8.29 
50.69 ± 9.79 
48.72 ± 10.24 
<0.001§  
53.96 ± 7.76 
47.42 ± 9.82 
45.45 ± 11.24 
<0.001§ 
 108 
 
Neurocognitive complaints 
No 
Yes 
 
55.75 ± 8.02 
48.50 ± 10.00 
<0.001§  
53.83 ± 7.81 
45.62 ± 10.27 
<0.001§ 
SMAQ adherent (n = 218) 
No  
Yes 
 
49.02 ± 9.50 
54.29 ± 9.11 
<0.001§  
46.79 ± 10.64 
51.94 ± 8.93 
<0.001§ 
 
Table 3: PHS model 
Working is the reference category for ‘activity’. n.a. = not applicable 
Variable p-value Estimate CI 
Intercept <0.001 58.67 [57.37; 59.98] 
Neurocognitive complaints <0.001 -4.19 [-2.17; -6.21] 
Activity    
   Invalid  
   Student, seeking work,    
househusband/housewife, retired 
<0.001 
<0.001 
 
-13.10 
-5.78 
[-16.05;-10.14] 
[-8.36;-3.19] 
   Working n.a. n.a. n.a. 
Non-adherence 0.011 -3.03 [-5.35; -0.71] 
Depressive symptoms 0.012 -3.19 [-5.68, -0.71] 
 
Table 4: MHS model 
Working is the reference category for ‘activity’. Average education is the reference category for ‘education’.  
n.a. = not applicable 
Variable p-value B CI 
Intercept <0.001 59.51 [57.81; 61.21] 
Neurocognitive complaints <0.001 -5.27 [-7.00; -3.54] 
Depressive symptoms <0.001 -10.08 [-12.25; -7.91] 
Activity    
   Invalid  <0.001 -5.81 [-8.46; -3.15] 
   Student, seeking work,  househusband/housewife, retired 0.333 -1.16 [-3.52; 1.20] 
   Working n.a. n.a. n.a. 
Not very satisfied relationship physician <0.001 -3.94 [-6.00; -1.88] 
Non-adherence 0.009 -2.75 [-4.80; -0.69] 
Education 
   Low (≤15 years) 
   High (> 18 years) 
   Average (18 years) 
 
0.171 
0.005 
n.a. 
 
-1.57 
-2.67 
n.a. 
 
[-3.82; 0.68] 
[-4.50; -0.84] 
n.a. 
Income <€1500 0.030 -2.09 [-3.98; -0.21] 
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Discussion 
 
In this study, determinants of physical and mental HRQoL in PLHIV were identified. Two trends 
emerged: the overlap of physical and mental health determinants and the importance of socio-economic, 
psychological and behavioral factors as compared to clinical factors routinely measured in HIV follow-up 
(viral load and CD4-count).  
The overlap between determinants of physical and mental health indicates that both constructs are 
strongly associated. The distinction between physical and mental health can be considered artificial, 
although the scores reflect problems on other HRQoL domains [28]. 
In HIV care, a multidimensional, holistic approach should be applied in order to monitor and possibly 
mediate relevant parameters affecting HRQoL. Our findings could inspire the development of HRQoL 
improving interventions. Especially in chronic diseases such as HIV, a good HRQoL should be pursued 
in order to truly value the increased life-expectancy [29]. As such, modifiable factors associated with a 
decline should be tackled and those associated with an increase should be further elaborated so the 
benefits are spread among all PLHIV.  
Four determinants of physical health were identified; neurocognitive complains, activity, adherence and 
depressive symptoms. Concerning mental health, we have identified seven determinants: depressive 
symptoms, activity, neurocognitive complaints, satisfaction with the relationship with the physician, 
adherence, education and income. These determinants are similar to the determinants of current 
HRQoL previously found at T0 [17]. 
The presence of neurocognitive complaints is associated with a 4 and 5-point decline on PHS and MHS, 
respectively. Their impact, such as memory loss or attention deficits, imply serious difficulties in daily 
living and result therefore in worse physical and mental health [30, 31]. We would recommend a 
periodic screening for neurocognitive complaints, which can be quickly and simply integrated in a 
routine consultation checklist. 
It is well-known that depressive symptoms have a negative impact on multiple domains of HRQoL, 
leading to a decrease in physical and mental health in PLHIV [13, 14]. Chronic illnesses are complicated 
by depressive symptoms through different mechanisms, including more pain, a higher risk for non-
adherence, less social support and changes in the immune system [14]. Health care professionals should 
pay extra attention to the expression of depressive symptoms and to timely refer PLHIV to specialized 
psychological care. 
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Invalid PLHIV had a significantly worse physical health than working people. They miss the health-
related benefits of employment like fulfilling a role in society, gaining social status and developing a 
psychological identity [15, 32]. However, it is still possible that a pre-existing worse physical health 
results in not practicing a job. Mental health also suffers from invalidity, possibly due to the lack of 
structure, social support network, role identity and meaning associated with a job [33]. Those negative 
effects could be alleviated by encouraging volunteer work or even considering progressive return to 
work. The group of students, housewifes/househusbands, job seekers and retired people also present 
with worse physical health, although less distinct than invalid people. They miss the benefits of arranged 
employment as well, at least partly or temporarily.  
Adherence has been found to be related to good HRQoL [34], probably because adherence leads to 
favorable clinical outcomes, which lead to better physical health over time [35]. The relationship with 
mental health may originate in the inherent connection between physical and mental health [36]. Our 
findings confirm the need for prioritization of adherence in HIV care. Self-management techniques 
could be applied to increase the chances for success [37].   
Patients who are very satisfied with the relation with their physician had a better mental health. Such a 
good relationship can be interpreted as a type of emotional social support, which is known to enhance 
future mental health [38, 39]. For some PLHIV, the physician is a confidant, and hence a good 
understanding can promote mental health [40]. Our findings stress the long-term effect of the quality of 
this relationship [40]. It seems useful to include items about satisfaction with care in HRQoL 
assessments [41-43]. 
A lower income may be a proxy for a lower socio-economic status and has already been found to be 
associated with worse mental health, probably due to more distress [9, 16]. Social care for PLHIV is an 
essential part of multidimensional HIV care [44]. 
In contrast, a higher education (as compared to an ‘average’ education, i.e. college 18 years) was found 
to be associated with a lower mental health. This is inconsistent with previous research [9, 22] and with 
the established principle that better socio-economic status is associated with better HRQoL [45]. 
However, as our model also contains activity and income, it is possible that education alone has more 
complicated effects on HRQoL. For example, high-educated people are less distressed, but not less 
dissatisfied [46]. 
The results of this study should be regarded in the light of some limitations. Most importantly, our study 
cohort does not represent all PLHIV followed in our center or the entire Belgian HIV cohort, with 
males having sex with males being overrepresented [17]. At T1, there was a considerable drop-out. 
Moreover, the follow-up cohort consists of less people with depressive symptoms, indicating a selection 
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bias towards people with better mental health. Despite this bias, our findings on determinants of 
HRQoL are sound and consistent with international literature in similar samples, except for the clinical 
determinants [19-22]. Although one year follow-up is a short period in chronic diseases, this study 
contributes to the understanding of determinants of HRQoL over time in PLHIV. A second strength 
refers to the assessment of possible explanatory variables from different fields (clinical,  
(neuro)psychological, socio-economic) in order  to take into account the multidimensional character of 
HRQoL.
Conclusion 
 
This study identified a set of multidimensional determinants for HRQoL over time. Worse physical 
health was predicted by the presence of neurocognitive complaints and/or depressive symptoms, not 
working (i.e. invalidity, job seeking, being househusband/housewife, student, retired) and non-
adherence to antiretroviral therapy. A lower mental health was predicted by the same parameters, 
together with dissatisfaction with the relationship with the physician, higher education and a lower 
income. Assessing these factors helps detecting patients at risk for lower physical and mental health and 
contributes to the development of interventions that increase HRQoL in PLHIV. 
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Abstract 
 
Since the era of highly active antiretroviral therapy (HAART), HIV is considered as a chronic disease. 
Adherence to HAART is crucial for effectiveness. Non-adherence negatively impacts patient outcome 
and the larger economy. However, data on adherence among the Belgian HIV cohort are scarce. 
Therefore, the purpose of this pilot study was to identify determinants of adherence among HIV 
patients treated in Belgium. 
The study was conducted at the AIDS Reference Center of Ghent University Hospital between January 
1st and December 31st 2012. Sociodemographic data were collected, along with the Short Medication 
Adherence Questionnaire (SMAQ), the CASE Adherence Index, the EuroQol-6D, the MOS-HIV, the 
Beck Depression Inventory-II and three neurocognitive complaints (NCC) screening questions.  
To date, 218 patients participated in the study, among whom 173 (79.4%) were male. Mean age was 
46.0±10.6 years and 133 patients (63.9%) were homosexual. 
According to the SMAQ and the CASE, respectively 78.5% and 93.5% of the patients were adherent to 
ART. Logistic regression analysis revealed that smoking, NCC and female sex were independent 
determinants of non-adherence. 
In conclusion, there is an elevated risk for non-adherence in smokers, people experiencing 
neurocognitive problems and women in our sample. The latter could reflect differences between male 
and female HIV patients in Belgium. Adherence improving initiatives should be tailored to these three 
risk groups. 
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Introduction 
 
The HIV epidemic is far from being controlled. Although HIV care has made enormous progress, a HIV 
cure is still lacking. Meanwhile, the number of HIV patients still expands. For Belgium, there are about 
three new diagnoses per day and currently 14.000 patients are infected [1]. For most of them, the 
infection is controllable, due to treatment with highly active antiretroviral therapy (HAART). In the 
HAART era, clinical outcomes for HIV patients are more hopeful, as life expectancy has increased and 
HIV related deaths have declined [2, 3]. However, strict adherence to the therapy is imperative. Non-
adherent patients can encounter clinical progression marked by unfavorable viral loads and CD4 counts 
[4-6]. Consequences of poor adherence not only affect the patient, but also public health by the higher 
chance of multidrug-resistant HIV and wild type HIV and their transmission [7-9].  
As both the individual patient and the general society have  interest in a good therapy adherence, this 
topic should be better explored, especially towards establishing strategies to improve adherence. In 
Belgium, however, adherence to HAART in HIV patients has never been analysed yet. The aim of this 
study was to examine adherence and its determinants in an HIV cohort.  
Methods 
 
Subjects and procedures  
This pilot study was performed at the AIDS Reference Center (ARC) of Ghent University Hospital. This 
is one of the nine tertiary care referral centers for HIV treatment and care in Belgium. The study is part 
of the HIV CARE (Consortium for HIV/AIDS Research) Study, which aims to elaborate the health 
economic aspects of HIV applying a societal perspective. The project was approved by the Ethics 
Committee of Ghent University Hospital and recruitment of participants started from the 1st of January 
2012 onward. 
All HIV patients followed in the ARC are eligible to participate in the HIV CARE Study. Treating 
physicians recruit patients during a routine visit via an informed consent, available in Dutch, French 
and English.  
Based on comprehensive literature research, a self-report questionnaire bundle and a short interview 
were developed and validated. The bundle comprises sociodemographic questions, as well as five 
validated instruments: the Short Medication Adherence Questionnaire (SMAQ, [10]), the CASE 
Adherence Index [11], the EuroQol-6 Dimensions [12], the Medical Outcomes Study-HIV (MOS-HIV, 
[13]) and the Beck Depression Inventory-II [14]. 
 118 
 
The SMAQ was used to assess adherence [10]. This validated instrument consists of six questions; four 
are yes/no questions: (1) Do you ever forget to take your medicine? (2) Are you careless at times about 
taking your medicine? (3) Do you sometimes forget to take your medication? (4) Did you not take any of 
your medicine over the last weekend?, as well as two open questions:  (a) Thinking about the last week, 
how many times have you not taken your medicine? (b) Over the past 3 months, how many days have 
you not taken any medicine at all? A patient is considered to be not adherent if one or more of the four 
first questions were answered affirmatively, if he/she missed more than two doses in the past week or if 
there were more than two days without medication during the past three months. 
On the other hand, the CASE (Center for Adherence Support Evaluation) Adherence Index was utilized 
[11]. It contains three multiple-choice questions: (1) How often do you feel that you have difficulty 
taking your HIV medications on time? (2) On average, how many days per week would you say that you 
missed at least one dose of your HIV-medication? (3) When was the last time you missed at least one 
dose of your HIV-medication? In accordance with the answers chosen, a score between 0 and 16 is 
obtained. A score of 10 or less is generally considered indicative for non-adherence [11]. 
The CASE is part of a short interview with a nurse. Together with this interview, three questions about 
neurocognitive complaints were also incorporated to screen for potential memory, planning, and 
attention problems [13]. In addition, two quality of life measures were performed, by means of the 
EuroQol-6D and the MOS-HIV [14, 15]. The final instrument is the 21 item Beck Depression Inventory 
– II [16]. Presence of depressive symptoms is defined as a score of 17 or more on the BDI-II [17]. 
Clinical data were obtained via the electronic patient file. 
Statistical analysis 
The statistical package SPSS, version 21 (SPSS, Inc., Chicago IL, US) was used for data analysis. For 
bivariate analysis, χ² tests and Mann-Whitney U tests were used. Categorical variables are reported as 
numbers and percentages, continuous variables as a mean ± standard deviation (SD). Multiple logistic 
regression analyses were conducted to identify independent determinants of adherence in patients who 
receive antiretroviral therapy. Variables showing a p-value of ≤0.20 in bivariate analysis, were put into 
the multiple logistic model. Using the backward conditional procedure, independent determinants were 
identified. Subsequently, those were then put into a model, based on the ‘enter’ procedure. Significance 
of the covariates is reported by the p-values, parameter estimates by the odds ratio and 95% confidence 
intervals. Significance was set at p≤0.05. 
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Results 
 
A total of 237 patients participated in the study (period 1st January 2012 – 31st December 2012), among 
whom 218 (92.0%) were treated with HAART. There were 173 (79.4%) males and 45 (20.6%) females. 
Mean age was 46.0 years (±10.6) and 63.9% (133/208) of the participants was homosexual. Twenty-five 
patients (11.5%) were of African origin and 152 patients (69.7%) had a job. The majority of the patients 
is treated with antiretroviral therapy based on protease inhibitors (127/218; 58.3%). On average, the 
patients take 3.7 (± 2.0) pills per day. Viral load and CD4-count were <50 copies/ml and >500/µl in 
respectively 79.8% (174/218)  and 61.0% (133/218) of the cases. Depressive symptoms were present in 
21.6% (47/218) of the patients, neurocognitive complaints in 37.2% (81/218).  
According to the SMAQ, 79.4% (173/218) of the patients were adherent. According to the CASE 
Adherence Index this is 93.6% (204/218). However, only 47.2% (103/218) were fully adherent (i.e. 
maximum score of 16 on the CASE Adherence Index). 
Female gender (p=0.018), a lower income (p=0.024), smoking (p=0.007), drug use (p=0.044), no use of a 
medication aid (p=0.050), neurocognitive complaints (p<0.001) and impaired QoL (p=0.003, p=0.006, 
p=0.039) are significantly associated with non-adherence measured with the SMAQ (Table 1). 
Drug use (p=0.038), presence of neurocognitive complaints (p=0.006), poor physical health (p=0.021), 
dissatisfaction about social support (p=0.039) and dissatisfaction about sex life (p=0.030) are significantly 
associated with non-adherence according to the CASE Adherence Index. 
Multiple logistic regression analysis was performed for SMAQ non-adherence only, since insufficient 
cases (n=14) of CASE non-adherence were observed. The SMAQ model revealed that females, smokers 
and patients experiencing neurocognitive complaints are at higher risk for non-adherence (Table 2). 
Table 1: Results of bivariate analysis of the SMAQ. Only variables associated with adherence at a significance 
level of ≤ 0.2 are shown. These were used in the multiple logistic regression analysis. 
Variable 
 
Adherent 
n=173 
Non-adherent 
n=45 
p-value 
Sex 
   Female  
   Male 
 
30 
143 
 
15 
30 
0.018 
 
Depressive symptoms 
   No depressive symptoms 
   Depressive symptoms 
 
139 
34 
** 
32 
13 
0.180 
 
Ethnicity 
   White 
   Black 
 
156 
17 
* 
36 
8 
0.121 
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Income (n = 207) 
   <  € 1500 (n = 88) 
   ≥ € 1500 (n = 108) 
 
70 
95 
** 
26 
16 
0.024 
 
Smoking 
   No 
   Yes 
 
128 
45 
** 
24 
21 
0.007 
 
Alcohol use 
   No 
   ≤ 3/day  
   > 3/day  
 
118 
47 
8 
* 
34 
7 
4 
0.183 
Drug use 
   No 
   Yes 
 
157 
16 
* 
36 
9 
0.044 
 
Satisfaction sex life 
   (Very) unsatisfied or indifferent 
   (Very) satisfied  
 
70 
103 
* 
25 
20  
0.069 
 
Medication aid 
   No  
   Yes 
 
47 
126 
* 
19 
26 
0.050 
 
Neurocognitive complaints 
  No 
  Yes  
 
119 
54 
** 
18 
27 
<0.001 
 
EuroQol index 
   High 
   Low 
 
140 
33 
 
27 
18 
0.003 
MOS-HIV PHS  
   Good (> pc 25) 
   Poor (≤ pc 25) 
 
138 
35 
 
27 
18 
0.006 
MOS-HIV MHS 
   Good (> pc 25) 
   Poor (≤ pc 25) 
 
137 
36 
 
29 
16 
0.039 
 
Table 2: Mutiple logistic regression model for non-adherence (SMAQ). 
Variable p-value OR                   95% Confidence Interval 
Sex: female 0.016 2.616                1.193 - 5.736  
Smoking 0.008 2.625                1.282 – 5.376 
Neurocognitive complaints 0.001 3.292                1.634 – 6.633 
Hosmer and Lemeshow’s chi square, degrees of freedom and significance are 0.967, 4, 0.915 respectively.  
Area under the curve of the ROC curve is 0.724 [0.642 – 0.807] SE 0.042 
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Discussion 
 
In this HIV cohort, 78.5% (SMAQ) to 93.5% (CASE) of the patients were adherent. The difference 
between the two percentages indicates that adherence largely depends on how it is defined and 
measured. Females, smokers and patients reporting neurocognitive problems have a higher chance for 
non-adherence. 
After multiple regression analysis, being female was found to be an independent determinant of non-
adherence. In literature, there is no consensus regarding the influence of gender on adherence, as 
apparent from the review of Nicastri et al. (2007) on gender differences during HAART [18].  A possible 
explanation for our finding could be that a higher concentration of HAART in females compared to 
males (pharmacokinetic differences) leads to a higher frequency of adverse reactions, which could induce 
non-adherence. Differences in drug regimen or number of pills per day were, however, not observed in 
our cohort. Another possibility could be the practical barriers to adherence experienced by women, for 
example taking care of the household and the children [7, 19]. We should, however, take into account 
our limited number of females (45/218) and the fact that males and females in our cohort differ in 
certain characteristics. Nearly half of the females is black (20/45; 44.4%), while there were only 5 black 
men (2.9%). That may have hindered the analysis of both ethnicity and gender in this study.  
The association between smoking and adherence has received little attention in literature so far. In the 
study of Goujard et al. [20], non-adherence appeared more in smokers compared to non-smokers. In 
another study, smoking was found to be an independent predictor of non-adherence [21]. It is possible 
that smokers present health risk behaviors that can influence medication adherence. Smokers are more 
likely to be risk-takers and non-adherence is consistent with that behavior [22]. A mediating role of 
psychological factors has been argued, as HIV positive smokers report that smoking helps them cope 
with depression, anger or anxiety [23]. 
In previous studies, neurocognitive status and its relation with adherence has already been explored [24]. 
Most of the studies find an association between good neurocognitive function and good adherence. 
Other investigators found subjective cognitive complaints to be associated with non-adherence [25]. In 
our study, patients were asked about problems with memory, planning/reasoning and attention. These 
subjective complaints were indeed independent predictors of non-adherence, which is not surprising, 
since maintaining adherence is challenging. Especially when multiple intake moments are required and 
when a combination of pills should be taken at one intake moment, neurocognitive resources are being 
used. Adherence can therefore easily be affected by lapses in memory or attention. Incorporating intake 
moments into daily routines can be a helpful solution, however, planning and reasoning may sometimes 
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be necessary to cope with unusual or unexpected circumstances such as holidays, pharmacists on leave 
etc. [24]. 
A factor that may help overcome this problems, is using a medication aid. This can be an alarm, a pill 
box, a steady routine or someone who helps to remember the medication intakes. We found that 
patients using a medication aid had a better adherence than those who are not (see Table 1). 
Although strict adherence is generally considered imperative for good viral suppression, we have not 
found a relationship between adherence and viral load [5, 6]. It is, however, plausible that different 
adherence thresholds exist according to the medication scheme [26, 27]. Boosted PI-regimens, the most 
prescribed regimen in our cohort, seem to be more forgiving of suboptimal adherence than NNRTIs 
[28, 29]. Short interruptions of the therapy, which in our study may have been categorized as being not 
adherent, not necessarily lead to virological consequences [30]. 
Some study limitations should be mentioned. A first limitation relates to the number of participants, 
although this number can be justified by the great detail of the study. A second limitation is the self-
report bias. Self-report is subjective, and often overestimates adherence [31]. People tend to choose social 
desirable answers, in particular when questionnaires are administered face-to-face. This can be a part of 
the explanation for the remarkable difference (± 15%) between the SMAQ (written) and CASE 
Adherence Index (interview) .A final methodological limitation is the cross-sectional design, which does 
not allow to determine causal relationships.  
The most important strength of this study is the great number of parameters that were collected in 
relation to adherence. Moreover, to the best of our knowledge, this is the first study to identify 
determinants of adherence in Belgian HIV patients. 
In conclusion, females present a higher risk for non-adherence than males in this Belgian HIV cohort. 
The presence of neurocognitive complaints is a risk factor for non-adherence, as well as smoking. Future 
adherence improving initiatives will be especially conceptualized for this target groups. 
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Abstract 
 
Background: Adolescents are a risk group for acquiring sexually transmitted diseases, including HIV. 
Correct knowledge about transmission mechanisms  is a prerequisite to taking appropriate precautions 
to avoid infection. This study aimed at assessing the level of HIV-related knowledge among university 
students as a first step in developing targeted interventions. We used a self-developed HIV knowledge 
questionnaire, supplemented with socio-demographic and sexual behavior questions. The questionnaire 
was composed of 59 items from different existing questionnaires. It included general statements and 
statements about prevention, transmission and treatment of HIV. 
Results: There were 357 (79.7%) female and 93 (20.3%) male participants and their median age was 20  
(IQR 19-21) years. On average 42/59 (71.2%) questions were answered correctly, 5 /59 (8.5%) were 
answered incorrectly and 12/59 (20.3%) were unknown . The best and worse scores were seen on the 
prevention questions and the treatment questions, respectively. HIV-related knowledge is higher in older 
students and in students with a health-related education. Students with sexual experience, with five or 
more partners and students who have been tested on STDs have a higher HIV-related knowledge. 
Conclusions: Knowledge on prevention and transmission of HIV is fairly good among university 
students and knowledge is higher among students with more sexual experience. They still have some 
misconceptions (e.g. HIV is spread by mosquitoes) and they are ignorant of a substantial number of 
statements (e.g. risk for infection through oral sex). 
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Introduction 
 
In Western countries, half of the adolescents is already sexually active at the age of 18 years [1-3]. There 
is a stabilisation of this number during the last decade, as well as the age at which the first sexual 
intercourse takes place [1, 3, 4]. Adolescents are a particular risk group for acquiring sexually transmitted 
diseases (STDs). Their sex life gets a boost during college days (they gain freedom, go out, meet new 
people…) while low rates of condom use [5] and experimenting with alcohol and drugs [6] pave the way 
for unprotected sex. Young adults have a low health risk assessment: they do recognize peers as being at 
risk for STDs such as HIV, but not themselves [1, 7]. This pattern especially emerges in countries with a 
low prevalence of AIDS [8].  Moreover, HIV infection has become a chronic condition and previous 
research showed that health-related quality of life in people living with HIV in Belgium is comparable to 
the general population [9]. Therefore, the fear of getting infected may become less distinct [10]. 
Consequently, the highest prevalence of STDs in Belgium is seen among 20 to 24-year-old people [5]. 
Among the 1.100 to 1.200 people in Belgium infected by the HIV virus every year, about 10% is 
between 15 and 24 years [11]. Specific education and prevention campaigns are still warranted to reduce 
STD/HIV transmission in this population. 
A first, although unsatisfactory, condition to achieve this reduction, is a good knowledge about the 
transmission of STDs, and HIV in particular. Previous studies have shown gaps in the HIV knowledge 
of young adults [12-17]. Different interventions to improve this knowledge have been described, with 
varying degrees of success [18-21]. Improving knowledge can have different secondary goals: reducing 
sexual risk behavior, improving condom use or establishing better attitudes towards people living with 
HIV (PLHIV) [22-24]. 
In Belgium, an HIV knowledge survey was carried out among the general population in 2008 [25]. This 
was a part of a periodic general health survey with 11.250 participants. The survey included five 
questions concerning transmission, prevention, testing and attitude towards PLHIV. The purpose of this 
periodic survey is to monitor and to follow the knowledge about HIV in order to observe effects of 
prevention programs. The survey of 2008 revealed that in the age category of 15-24 years the HIV-related 
knowledge was lower than in the older group (25 to 54 years). However, this survey is very limited and 
does not register sexual behavior as a possible covariate. 
More recently, Van Rossem et al. [10] compared AIDS knowledge and sexual activity among secondary 
school students from different education types in the Northern part of Belgium. Students from general 
education had better AIDS knowledge and were less sexually active than students from vocational 
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education. Within all different types of education, sexually active students had a better AIDS 
knowledge.  
The aim of this study was to assess HIV-related knowledge and sexual behavior in Belgian university 
students. Following research questions were addressed: 1) Are there gaps in HIV-related knowledge 
among this high-educated population? 2) Is HIV-related knowledge related to socio-demographics 
and/or sexual behavior?  
Methods 
 
Participants 
Participants in the age group between 18 and 25 years were recruited during university classes. Professors 
were asked to provide 10 minutes of their teaching time for this study. A short presentation was given by 
the researcher to give practical information. 
Instrument 
The instrument was composed by items from four previously validated questionnaires. 37/45 items from 
the HIV Knowledge Questionnaire [26] were included in our survey. Eight were not retained because 
they were not relevant for our Belgian population (e.g. lambskin condoms) or because of the overlap 
with the transmission questions. Four questions from the AIDS Risk Behaviour Knowledge test [27] 
were also included. Two questions from the study of Nachega et al. [28] and one item from the HIV 
Knowledge Scale for Hispanics [29] were ultimately added. The latter examines knowledge about which 
bodily fluids can transmit the HIV virus. The format of the questionnaire, including the ‘I don't know’ 
option, was adopted from previous work in our research group [30-32]. The questions were divided into 
four categories: general (12 items), transmission (27 items), prevention (12 items) and treatment (8 
items).  
Statistical analyses 
Data were analysed by means of the statistical package SPSS, version 21 (SPSS, Inc., Chicago IL, US). 
Categorical data are reported as numbers and percentages and continuous data by medians and 
interquartile ranges (IQR) (as non-normally distributed). Total scores on the questionnaire and on the 
four subcategories were calculated. A descriptive analysis of the students’ responses on each of the 59 
questions was done. Differences in terms of total score  between groups were identified by means of 
Mann-Whitney-U or Kruskal Wallis tests, if appropriate followed by post-hoc tests. 
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Results 
 
Participant’s characteristics 
A total of 450 participants completed the questionnaire, among whom 357 (79,3%) females and 93 
(20.7%) males. Median age was 20 (IQR 19-21) years. Participants’ characteristics are shown in Table 1. 
Table 1: Characteristics of the participants 
 n % 
Sex 
Female 
Male 
 
357 
93 
 
79.3 
20.7 
Age 
18 
19 
20 
21 
22 
23 
24 
25 
 
104 
113 
41 
104 
40 
23 
17 
8 
 
23.1 
25.1 
9.1 
23.1 
8.9 
5.1 
3.8 
1.8 
Nationality (n = 448) 
Belgian 
Other 
 
442 
6 
 
98.7 
1.3 
Study (n = 448) 
Educational sciences 
Linguistics and literature 
Pharmaceutical sciences 
Health care management and policy 
Philosophy 
Communication sciences 
Moral sciences 
Other 
 
135 
98 
93 
43 
26 
21 
13 
19 
 
30.1 
21.9 
20.8 
9.6 
5.8 
4.7 
2.9 
4.2 
Religion 
Catholic 
 
270 
 
60.1 
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Jewish 
Muslim 
Buddhist 
No religion 
Other 
1 
3 
2 
168 
5 
0.2 
0.7 
0.4 
37.4 
1.1 
Sexual orientation (n = 448) 
Heterosexual 
Homosexual 
Bisexual 
 
428 
12 
8 
 
95.5 
2.7 
1.8 
Relationship 
Yes 
No 
 
252 
197 
 
56.1 
43.9 
Sexual experience 
Yes 
No 
 
363 
86 
 
80.8 
19.1 
Number of sex partners 
0 
1 
2 
3 
4 
5 
> 5 
 
86 
145 
83 
51 
30 
19 
34 
 
19.2 
32.4 
11.4 
11.4 
6.7 
4.2 
7.6 
Contraception women (n = 292) 
Contraception pill 
Coïtus interruptus 
Condom 
Spiral 
Other 
 
246 
9 
135 
4 
16 
 
84.2 
3.1 
46.2 
1.4 
5.5 
Contraception men (n = 70) 
Contraception pill (female partner) 
Coïtus interruptus 
Condom 
Spiral (female partner) 
Other 
 
28 
1 
49 
2 
1 
 
40.0 
1.4 
70.0 
2.9 
1.4 
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STD 
Yes 
No 
 
6 
441 
 
1.3 
98.7 
Tested on STDs 
Yes 
No 
 
76 
373 
 
16.9 
83.1 
 
Questionnaire scores 
The median total score on the 59 items was 42 (37-46), this corresponds with a percentage of 71.2% 
(62.7%-78.0%). Concerning the subscales, the best score was seen on the prevention items (median 
10/12). Transmission and general knowledge scores  were slightly lower (21/27 and 9/12 respectively) 
and the score on the treatment questions was the lowest (3/8) (Table 2). 
Table 2: Scores on the questionnaire. Number of items is reported in italic. % and spread of % are based on the 
median and the IQR. 
 Median IQR % Spread of % 
Total score (59) 42  37-46  71.2  62.7-78.0 
General (12) 9    8-10 75.0  73.3 – 83.3 
Transmission (27) 21  18-23 77.8  66.7 – 85.2 
Prevention (12) 10  9-11 83.3  75.0 – 91.7 
Treatment (8) 3    2-4 37.5  25.0 – 50.0 
 
The number and percentage of correct, incorrect and ‘I don't know’ answers on each statement is shown 
in an additional file (Additional file 1). Only the most remarkable results will be reported here. Testing 
seems unfamiliar to many students: a majority (292 students, 65.2%) does not know whether HIV is 
routinely tested during pap smears, 216 students (48.4%) do not know that HIV infection can not be 
detected one week after the risk contact and 91 students (20.3%) think that a test lab has to inform the 
partners of a HIV positive person.  
Some misconceptions about transmission exist as well: 168 (37.2%) participants think that HIV can be 
spread by mosquitos and 114 (25.7%) do not know. A minority of 203 (45.5%) students are aware of 
the HIV risk when having oral sex with a HIV positive woman. Finally, 170 (37.9%) students incorrectly 
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think that there is a risk for acquiring HIV by donating blood and only 127 (28.7%) of them know that 
HIV can be transmitted through breast feeding.  
The statements about HIV treatment were rarely correctly answered; mostly ‘I don't know’ was 
indicated. The preventive value of ART after rape and the effect of missing doses on the transmission 
risk of HIV were the questions with the fewest correct answers (29, 6.5% and 31, 6.7% respectively). 
Factors associated with knowledge 
There is a significant positive correlation between total score and age (Spearman’s rho 0.276, p<0.01). 
There are differences according to the education. Students of Health care management and policy 
(median score 46, IQR 42-50) and Pharmaceutical sciences (median score 45, IQR 42-48) have 
significantly higher scores than the others (all p<0.05) and students of Communication sciences (median 
score 37, IQR 32-39) have significantly lower scores than the others (all p<0.049). Students who are 
currently in a relationship, have significant higher scores than single students (43, IQR 38-46 versus 41, 
IQR 36-45, p = 0.027). 
Differences in sexual behavior are associated with differences in the questionnaire total score as well. 
Hence, students with sexual experience have higher scores than students without sexual experience 
(median score 43, IQR 38-46 versus median score 40, IQR 36-45, p = 0.007). Within the group with 
sexual experience, higher scores are seen in students who have been tested on STD’s than those who 
have not (median score 46, IQR 41-50 versus median score 42, IQR 37-45, p<0.001). Differences 
according to the acquisition of STDs were not found (p = 0.401), but this could be due to a limited 
number of participants who acquired STDs. 
The number of sexual partners is also associated with the questionnaire total score. Students reporting 
five of more partners (median score 44, IQR 41-48) have higher scores than students with two, three or 
four partners (median score 43, IQR 38-46, p = 0.018) and than those with one partner (median score 
42, IQR 37-46, p = 0.003). Religion (p = 0.398), sexual orientation (p = 0.727) and contraception 
method (all p>0.05) were not associated with the total questionnaire score. 
Discussion 
 
Although in general, HIV-related knowledge is fairly good in this sample of university students, there are 
several misconceptions. Myths about transmission via insect bites and donating blood seem to be 
persistent and have also been found in studies from other countries [8, 13, 33, 34] as well as in the 
Flemish study [10]. Somewhat contrary to other countries, many Belgian university students do not 
know that the virus can be transmitted via mother milk (e.g. Chinese students: 78.8% correct answers 
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versus 28.7 in this sample, [14]. Knowledge about HIV treatment is poor, probably owing to 
unfamiliarity with this subject. The low score on this category of questions can be justified, and this 
knowledge could be considered less essential. Yet, the possibility of post-exposure prophylaxis should be 
more announced among this risk group. 
In accordance with previous research, we found that older students have a better HIV-related knowledge 
[10, 14, 34, 35]. This is possibly due to personal experiences which lead to more interest in this topic 
[10]. This may also indicate that sexual education in secondary schools is insufficient [35]. More 
probably, however, students gather information gradually through various channels: television, 
magazines, peers… [14]  
Subsequently, the better HIV-related knowledge in sexually active students can be explained by personal 
involvement. This may lead to active information seeking, or becoming more receptive to information 
[10]. It is possible that students who have more lifetime sexual partners, are more aware of the risk for 
STDs. This assumption is supported by additional analyses in this sample. The relative number of 
students using condoms as well as the number of students who already had a STD-test, was linearly 
associated with the number of partners.  
Engaging in sexual risk behavior, is not always associated with inadequate knowledge and vice versa [8]. 
Therefore, it seems that providing information alone is not effective to reduce sexual risk behavior [15, 
18, 36]. Nevertheless, improved knowledge can make students feel more comfortable to talk about the 
topic in a relationship [37]. In their review, Scott-Sheldon et al. concluded that behavioral interventions 
can be efficient to reduce STDs and to improve condom use. Besides education, behavioral 
interventions include motivational training and/or skills training (e.g. partner negotiating, condom 
practice on a model) [38]. Almost two decades earlier, similar strategies were suggested for school-based 
programs in a review of Kirby et al. [39]. Moreover, the programs should have a focus on specific 
behavioral goals, use social learning (e.g. modelling) and  address social and media influences on sexual 
behavior [39]. A last positive feature of intervention programs could be peer-learning. An instructor of 
the same age category can facilitate talking and discussing about sexual behavior and can serve as a role 
model [22]. For adolescents, peers are a main source of information about such topics [15]. 
We found no association between religion and HIV-related knowledge. In Belgium, this is not surprising 
since few people practice their religion [40]. It is not sure whether students reporting to be catholic have 
other values and ideas about (sexual) relationships than students reporting to be non-religious. 
This study has certain limitations. First of all, our sample of university students is not representative for 
all Belgian university students (e.g. only 20.7% males versus ±40% [41]) and did not include all types of 
education. More specifically, no students from the faculties of sciences, engineering and economics were 
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included. Future research could also include adolescents following non-university higher education 
and/or adolescents not following higher education to explore possible knowledge differences according 
to educational level. Secondly, the self-developed knowledge instrument was not validated, but this was 
considered legitimate as it was composed by statements of previously validated questionnaires. Because 
of the detailed and extensive knowledge instrument, sexual risk behavior was assessed only via indicative 
questions such as the number of partners and contraception and not through an additional 
questionnaire. Lastly, the cross-sectional nature of the study does not reveal causal associations or 
predictors of a good HIV-related knowledge. 
Strengths of this study include the detailed information resulting from the rather extensive 
questionnaire. To avoid guessing, students could indicate the option ‘I don’t know’. This distinguishes 
the non-correct answers into misconceptions and doubts. This is interesting since these could be 
addressed differently in campaigns or interventions.  
Conclusion 
 
Knowledge on prevention and transmission of HIV is fairly good among Belgian university students and 
is comparable to those found in other countries. There is, however, room for improvement. Older and 
sexually experienced students have a better knowledge, most likely due to more personal involvement. 
Future interventions should approach both sexually experienced and non-experienced students with 
tailored information and skills. 
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Additional file 
Table 3: Number and % of students who answered correctly, incorrectly or 'I don't know' on the 59 statements 
* = Statement from Nachega et al. [25] 
** = Statement from the Aids Risk Behaviour Knowledge test [24] 
*** = Statement from the HIV Knowledge Scale for Hispanics [26] 
Others: Statement from the HIV Knowledge Questionnaire [23] 
 Correct Incorrect I don't know 
General n % n  % n % 
 
HIV and AIDS are the same thing 
 
 
431/449  
 
96.0 
 
15/449  
 
3.3 
 
3/449  
 
0.7 
There is a cure for AIDS 
 
417/450  92.7 15/450  3.3 18/450  4.0 
AIDS is cause of HIV 
 
366/446  75.3 42/446  9.4 38/446  8.5 
A person with HIV can look and feel healthy 
 
437/449  97.3 2/449  0.4 10/449   2.2 
People who have been infected with HIV 
quickly show serious signs of being infected 
 
360/448  80.4 31/448  6.9 57/448  12.7 
A person can be infected with HIV for 5 years 
without getting AIDS 
 
394/449  87.8 3/449  0.7 52/449  11.6 
Women are always tested for HIV during their 
pap smears 
 
103/448  23.0 53/448  11.8 292/448  65.2 
You can usually tell if someone has HIV by 
looking at them 
 
439/447  98.2 2/447  0.4 6/447  1.3 
Taking a test for HIV 1 week after having sex 
will tell a person if she of he has HIV  
 
179/446  40.1 51/446  11.4 216/446  48.4 
If a persons tests positive for HIV, then the test 
site will have to tell all of his or her partners 
 
204/448  45.6 91/448  20.3 153/448  34.2 
A positive HIV blood test means that the 
person is infected for life * 
 
366/448  81.7 32/448  7.1 50/448  11.1 
HIV can cause death* 252/448   56.2 157/448  35.0 39/448  8.7 
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Prevention       
 
Pulling out the penis before a man climaxes 
keeps a woman from getting HIV during sex 
 
 
407/450  
 
90.4 
 
8/450  
 
1.8 
 
35/450  
 
7.7 
Showering, or washing one’s genitals after sex 
keeps a person from getting HIV 
 
419/449  93.3 1/449  0.2 29/449  6.5 
Eating healthy foods can keep a person from 
getting HIV 
 
392/449  87.3 3/449  0.7 54/449  12.0 
Using a latex condom or rubber can lower a 
person’s chance of getting HIV 
 
444/449  98.9 2/449  0.4 3/449  0.7 
There is a vaccine that can stop adults from 
getting HIV 
 
368/449  82.0 4/449  0.9 77/449  17.1 
There is a female condom that can help 
decrease a woman’s chance of getting HIV 
 
265/447  59.3 46/447  10.3 136/447  30.4 
A person will not get HIV if she or he is taking 
antibiotics 
 
349/447  78.1 1/447  0.2 97/447  21.7 
Using vaseline or baby oil with condoms lowers 
the chance of getting HIV 
 
367/449  81.7 2/449  4.4 81/449  18.0 
Washing drug-use equipment with cold water 
kills HIV 
 
440/449  98.0 1/449  0.2 8/449  1.8 
Douching after sex will keep a woman from 
getting HIV 
 
419/449  93.3 0/449  0.0 30/449  6.7 
Taking vitamins keeps a person from getting 
HIV 
 
403/447  90.2 3/447  6.7 41/447  9.2 
Condoms make intercourse completely safe ** 
 
327/448  73.0 90/448  20.1 31/448  6.9 
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Transmission       
 
A person can get HIV from a toilet seat 
 
 
373/449  
 
83.1 
 
16/449  
 
3.6 
 
60/449  
 
13.4 
Coughing and sneezing do not spread HIV 
 
389/450  86.4 26/450  5.8 35/450  7.8 
HIV can be spread by mosquitoes 
 
162/444  36.5 168/444  37.8 114/444  25.7 
A person can get HIV by sharing a glass of 
water with someone who has HIV 
 
389/446  87.2 22/446  4.9 35/446  7.8 
It is possible to get HIV when a person gets a 
tattoo 
 
327/449  72.8 40/449  8.9 82/449  18.3 
A pregnant woman with HIV can give the virus 
to her unborn baby 
 
401/450  89.1 9/450  2.0 40/450  8.9 
A woman can get HIV if she has anal sex with a 
man 
 
339/447  75.8 18/447  4.0 90/447  20.1 
All pregnant women infected with HIV will 
have babies born with AIDS 
 
249/450  55.3 95/450  21.1 106/450  23.6 
A person cannot get HIV by having oral sex, 
mouth-to-penis, with a man who has HIV 
 
270/445  60.7 63/445  14.2 112/445  25.2 
A person can get HIV even is she or he has sex 
with another person only one time 
 
443/449  98.7 4/449  0.9 2/449  0.4 
People are likely to get HIV by deep kissing, 
putting their tongue in their partner’s mouth, 
if their partner has HIV 
 
334/449  74.4 53/449  11.8 62/449  13.8 
A woman cannot get HIV if she has sex during 
her period 
 
399/449  88.9 7/449  1.6 43/449  9.6 
Having sex with more than one partner can 
increase a person’s chance of being infected 
with HIV 
408/447  91.3 25/447  5.6 14/447  3.1 
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A person can get HIV by sitting in a hot tub or 
a swimming pool with a person who has HIV 
 
381/447  85.2 10/447  2.2 56/447  12.5 
A person can get HIV if having oral sex, mouth 
on vagina, with a woman 
 
203/446  45.5 84/446  18.8 159/446  35.7 
A woman can get HIV if she has vaginal sex 
with a man who has HIV 
 
435/449  96.9 2/449  0.4 12/449  2.7 
Intravenous drug users are at risk for AIDS 
when they share needles ** 
 
440/449  97.8 1/449  0.2 8/449  1.8 
Intravenous drug users become exposed to the 
AIDS virus because the virus is often contained 
in heroin, amphetamines and the injected 
drugs ** 
 
293/449  65.3 54/449  12.0 102/449  22.7 
Donating blood carries no AIDS risk for the 
donor ** 
 
208/448  46.4 170/448  37.9 70/448  15.6 
The HIV virus can be transmitted by: *** 
Saliva 
337/441  76.4 67/441  15.2 37/441  8.4 
Sperm 402/446  90.1 25/446  5.6 19/446  4.3 
Vaginal 341/445  76.6 34/445  7.6 70/445  15.7 
Sweat 408/441  92.5 2/441  0.5 31/441  7.0 
Urine 311/439  70.8 30/439  6.8 98/439  22.3 
Blood 443/446  99.3 1/446  0.2 2/446  0.4 
Tears 405/438  92.5 4/438  0.9 29/438  6.6 
Mother milk 
 
127/442  28.7 128/442  29.0 187/442  42.3 
Treatment       
ART prevents mother-to-child HIV 
transmission * 
 
48/448  10.7 32/448  7.1 368/448  82.1 
HIV can be prevented by ART after rape  
 
29/448  6.5 155/448  34.6 264/448  58.9 
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HIV can be controlled by ART 
 
206/446  46.2 16/446  3.6 224/446  50.2 
HIV can be cured by ART 
 
269/447  60.2 7/447  1.6 171/447  38.3 
Taking ART prevents disease progression 
 
234/447  52.3 11/447  2.5 202/447  45.2 
Antiretroviral medicine can cause side effects 
 
181/448  40.4 2/448  0.4 265/448  59.2 
Missing doses of ART leads to disease 
progression 
 
123/448  27.5 7/448  1.6 318/448  71.0 
Missing doses of ART increases the risk of 
transmitting the virus 
 
31/448  6.9 97/448  21.7 320/448  71.4 
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3.6. HIV disclosure in the workplace 
 
Sophie Degroote, Dirk Vogelaers, Ria Koeck, Ruth Borms, Laurence De Meulemeester and Dominique 
Vandijck 
 
Degroote S et al. HIV disclosure in the workplace. Acta Clinica Belgica (2014) 69(3):191-3 
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Abstract 
 
Introduction: As HIV is currently a chronic and manageable disease, an increasing amount of people 
living with HIV (PLHIV) are (again) active on the labor market. Since research on this topic is scarce, 
this study aimed to explore experiences of PLHIV in the workplace, especially concerning disclosure and 
adherence to antiretroviral therapy.  
 
Methods: A questionnaire was developed and validated in collaboration with Sensoa (the Flemish 
expertise center for sexual health) and participants were recruited using flyers and announcements on 
websites. 
 
Results: A total of 54 PLHIV completed the questionnaire, among whom 50 (92.6%) males. Half of the 
participants did not disclose their HIV status in the workplace mostly due to being afraid of social or 
professional consequences. Those who disclosed, reported no changes in the workplace or even reported 
receiving more empathy. A minority of  participants have to take antiretroviral medication at work and 
they reported no particular  problems related to medication intake. 
 
Conclusion: 
Despite improved solidarity and information campaigns, many PLHIV still do not disclose their HIV 
status in the workplace, most frequently due to fear for discrimination. More actions are warranted, as 
well as addressing possible self-stigma. Adherence to antiretroviral therapy in the workplace posed little 
or no problems. 
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Introduction 
 
Current treatment strategies have turned HIV infection into a chronic disease and life expectancy for 
people living with HIV (PLHIV) continues to increase [1-3]. Moreover, treatment options are still 
expanding and new antiretroviral agents are less toxic and more convenient than earlier antiretroviral 
therapy (ART). As such, the vast majority of PLHIV can currently lead a relatively normal life. 
Consequently, PLHIV can make a professional career or may return to work after a period of disability 
[4].  
Previous research showed that a majority of PLHIV work. Furthermore, employment seemed to 
positively influence health-related quality of life [5]. The present study aimed to explore experiences of 
PLHIV in the workplace concerning disclosure and adherence to ART. 
 
Methods 
 
In collaboration with Sensoa, the Flemish expertise center for sexual health, a research project was 
conceived. Literature research was performed and emerging themes were discussed together with the 
experts of Sensoa, resulting in a scientific and practice-based approach. 
 
Participants 
 
All PLHIV who were currently working or had been working in the past, were eligible for inclusion. The 
target audience was reached by flyers distributed in the Flemish AIDS reference centers in Antwerp, 
Brussels and Ghent and during HIV cafés (informal meetings among peers), by announcements on the 
website of Sensoa, their daughter website ‘www.levenmethiv.be’ (= ‘living with HIV’), their Facebook 
account and the community website ‘HivMix’. 
 
Questionnaire 
 
Results from the literature research were used to outline the structure of the questionnaire [4, 6-9]. In 
consultation with Sensoa, the questions were chosen and formulated, resulting in a tree-structured 
questionnaire examining two main themes: disclosure and medication-intake in the workplace. In 
addition, socio-demographic data (gender, age), date of HIV-diagnosis and information about the work 
situation (work schedule, job type, etc.) were also included. It was decided to use an online 
questionnaire as it is an easy, low-cost and quick method to collect data. 
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Statistical analyses 
 
All results were exported from the questionnaire software (‘Qualtrics’) to SPSS.22 (SPSS, Inc., Chicago 
IL, US). Descriptive analyses were performed and are reported via numbers and percentages. 
Associations were examined via chi-square tests. 
Results 
 
Population 
 
A total of 67 PLHIV participated in the study, among whom 54 fully completed the questionnaire. Of 
participants 50 were men and 4 women, with a median age of 42 years (IQR 33-51 years). Forty-four 
people were currently working (12 blue-collar workers1, 25 white-collar workers1, 5 self-employed and 2 
public servants). Ten people were unemployed and one of them did not return to work after HIV 
diagnosis, rendering other questions no longer applicable. Almost three quarters of the remaining 
participants worked full-time (39/53, 73.6%). 
 
Disclosure 
 
Almost half of the respondents did not inform any of the colleagues about his/her seropositive status 
(23/53, 43.4%). People who disclosed, mostly told close colleagues only (22/53, 41.5%), an official 
trustee (13/53, 24.5%) or executives (12/53, 22.6%). When being asked what hindered disclosure, half 
of people reported to have fear for professional consequences (such as discharge, loss of clients) (28/53, 
52.8%) and to be afraid for social consequences (such as discrimination, nagging) (26/53, (49.1%). 
Twenty-one participants (42.0%) worried about people telling others and 11 respondents (22.0%) 
mentioned to have followed someone’s advice to not disclose at the workplace. 
Those who disclosed, mostly did this of their own free will (23/30, 76.7%). Justifying their changing 
health state (10/30, 33.3%) or the (more frequent) absences (8/30, 26.7%), but also the desire to be 
honest and not to live with a secret were the most cited reasons to disclose (4/30, 13.3%). 
In the majority of the cases, no professional changes appeared after disclosure (18/30, 60.0%), or the 
change was positive (i.e. more understanding from colleagues, 8/30, 26.7%). Nonetheless, 3 participants 
(10%) declare that they got fired after they had disclosed.  
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As compared to blue-collar workers, significantly more white-collar workers had disclosed their 
seropositive status at the workplace (4/12, 33.3% vs. 17/25, 68.0%, p = 0.046). Disclosure was not 
found to be associated with other factors (gender, age, time since diagnosis, disclosure to environment, p 
> 0.05).  
 
Medication intake 
 
Forty-seven participants (88.7%) reported to take ART, among whom 38 (80.9%) once daily. Twenty-one 
participants took their medication in the workplace and none of them reported problems doing so, 
neither towards colleagues, neither towards infrastructure. Half of the 26 others took the decision not to 
take medication at work consciously, in consultation with their physician. Variable work time tables 
were most frequently reported as a hindering factor to adherence (5/21, 23.8%). On the other hand, 
access to food (8/21, 38.1%), drinks (7/21, 33.3%) and the proficiency to quickly take ART (7/21, 
33.3%) were reported to be supporting factors. 
 
Discussion 
 
These findings confirm the general good health among PLHIV in Belgium [10]. For this study 
population,  the fact that being seropositive does not necessarily hinder a professional career, since the 
vast majority of respondents work full-time. Strikingly, almost half of the participants did not disclose in 
the workplace, despite the many solidarity campaigns, etc. This number is almost double as compared to 
French PLHIV (29.9%) [7], but less than British PLHIV (61.5%) [6]. The lower disclosure percentage 
seen in the French study may be partly due to the fact that this study took place in 2002-2003. Ten years 
ago, openness about HIV may have been less frequent. The higher disclosure percentage in the UK 
study is probably biased by the study population, almost completely consisting  of homosexual, white 
men. They are more likely to disclose to employers than heterosexual men/women and homosexual 
men from ethnic minority groups [11].  
Fear for discrimination or discharge is high, and seems to be the main reason to not disclose. Previous 
research among French-speaking Belgians showed that 6.5% of the people who disclosed experienced 
difficulties afterwards (being refused a job, blocked career, etc. [12] The latter demonstrates that 
information and solidarity campaigns from organisations as Sensoa are highly needed. Internalized 
stigma, the fear and shame PLHIV experience from within, remains an increasingly recognized 
additional barrier [13]. Some PLHIV argue that disclosure will not give any added value, or they 
consider it a private affair [6]. Hence, it should be acknowledged that the decision to disclose is a 
personal choice and that achieving 100% disclosure might be an unrealistic goal.  
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Differences in job context may influence the decision to disclose the status. We have found that white-
collar workers disclose more frequently than blue-collar workers. However, this issue should be further 
explored in bigger study samples and confounding factors should be taken into account. Those could be: 
type of working environment, the reputation of the person, colleagues’ knowledge about HIV, 
anticipated negative consequences and awareness of the sexual orientation of the person living with HIV 
(mainly applicable for homosexual people) [6, 8]. 
Data about medication intake in the workplace, on the other hand, revealed that this is less an issue 
than expected. Many PLHIV do not take ART at work, since certain regimens need to be taken before 
sleep or along with the main course, which is mostly in the evening. And if they do, they do not seem to 
encounter difficulties. Availability of accommodations, such as flexible work hours or easy access to food 
and drinks, were reported to be helpful, corresponding with previous research about adherence in the 
workplace [9]. 
Some limitations of this study should be acknowledged. Our relatively small sample size does not fully 
represent the Belgian HIV cohort, since there are more female PLHIV (37% vs. 7%) and a lower 
percentage is on ART (75% vs. 87%) [10]. Our study methodology is also susceptible for recruitment 
bias towards people who are currently working. Moreover, our results should be further studied in depth 
by means of qualitative research (e.g. focus groups). Nevertheless, these first results already show 
tendencies and can inspire further actions and campaigns. 
In conclusion, half of the PLHIV disclosed their seropositive status not in the workplace mainly due to 
fear for discrimination. The potential barriers need to be further explored. 
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4. DISCUSSION 
 
4.1. Main findings 
 
HIV infection has evolved into a chronic disease with hugely improved prognosis thanks to HAART. 
Life expectancy may approach that of HIV-seronegative matched age groups [1]. Nevertheless, the impact 
of HIV infection at both the human and societal level may remain significant.  In any chronic disease 
maximizing HRQoL becomes a major, if not principal, goal and hence identification of manageable 
factors that may be subjected to targeted interventions is mandatory.  
The narrative review on determinants of HRQoL in PLHIV revealed the limitations and difficulties in 
this research field, hampering the translation and implementation of research findings into clinical 
practice: 
1) Many studies identified associations, rather than causal relationships. Studies using methodologies 
such as path analysis are required to investigate and to determine the direction of associations. 
2) Determinants have a dynamic nature as HIV evolved from a lethal to a chronic disease; i.e. they 
impact differently upon PLHIV as prognosis and treatment modalities have significantly improved. 
The first HAART regimens, for example, induced serious side-effects which negatively impacted 
HRQoL. The current regimens, on the other hand, are well tolerated and their benefits positively 
impact HRQoL. 
3) The many instruments available all have their merits and flaws. The dimensions taken into 
consideration differ largely and omission of coping, stigma, body image and resilience are 
problematic. ‘You only get what you look for’… However, and this applies merely to disease-specific 
instruments, it is difficult to define what are elements of HRQoL itself, and what are mechanisms 
(such as coping and adherence) and indicators (such as socio-economic status) influencing HRQoL. 
These should be included in a sort of profile apart from the HRQoL instrument [2].  
4) There is a significant difference between a HRQoL instrument measuring effective mental and 
physical health versus an instrument resulting in a risk score incorporating significant determinants. 
Such a risk score could be used to screen for patients in need of more intensive psychological 
support (similar to screening for cardiovascular risk with the Framingham score). 
5) HRQoL measures could be supplemented with well-being and participation measures. This would 
provide higher-level information that goes beyond persons’ subjective ratings of  health states, but 
rather incorporates outcomes of HRQoL in the social and physical environment [3].  
6) There is a large intra-individual variability and a need for longitudinal assessment of change. Hence 
sensitivity to change is an important characteristic of an optimal HRQoL instrument. 
7) The strong interaction between clinical, psychological and behavioral determinants hampers 
research methodologies which have to explore these interactions in multilevel analysis. 
8) Similar factors determine HRQoL in other chronic diseases: disability, advanced disease stage, 
depression and comorbidity recur as main determinants. 
In a first study, we assessed HRQoL in a single center sample of mainly homosexual PLHIV in Belgium. 
Overall, we have found good HRQoL on the basis of MOS-HIV values. MOS-HIV values in other 
countries are similar to these single-center Belgian values, although Canadian scores are lower (Table 6). 
This may be due to the high percentage (63%) of people in the AIDS stage in that particular sample. 
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Table 6: Comparison of MOS-HIV values of PLHIV in different countries 
Total scores  
(mean ± SD) 
Belgium Spain [4] Greece  [5] Canada [6] China [7] 
Physical health score 53.1± 9.3 50 ± 10.6 49.0 ± 9.3 41 ± 11 / 
Mental health score 50.5 ± 9.6 50 ± 9.6 45.3 ± 10.5 48 ± 10 / 
Subscales       
General health perceptions 63.8 ± 22.8 47.4 ± 25.3 51.2 ± 23.9 39 ± 26 39.63 ± 24.9 
Physical functioning 81.6 ± 21.9 78.2 ± 22.1 73.0 ± 26.7 68 ± 25 78.60 ± 21.8 
Role functioning 84.5 ± 32.6 79.2 ± 36.5 51.9 ± 35.2 38 ± 44 71.32 ± 37.6 
Social functioning 82.0 ± 25.0 83.4 ± 25.4 79.0 ± 25.5 62 ± 29 65.58 ± 33.6 
Cognitive functioning 79.1 ± 20.5 76.9 ± 21.7 77.0 ± 19.4 53 ± 24 74.50 ± 23.0 
Pain 80.1 ± 22.9 72.9 ± 26.3 83.0 ± 22.4 61 ± 26 79.06 ± 25.9 
Mental health 68.2 ± 18.1 62.9 ± 21.2 58.4 ± 22.1 54 ± 23 61.01 ± 25.5 
Energy 65.9 ± 19.2 61.2 ± 22.6 57.8 ± 17.0 40 ± 22 54.03 ± 25.7 
Health distress 77.8 ± 22.0 74.3 ± 23.4 67.9 ± 27.7 63 ± 28 64.13 ± 30.1 
Quality of life 71.8 ± 19.5 58.1 ± 19.6 62.2 ± 22.4 52 ± 24 56.05 ± 19.2 
Health transition 59.1 ± 19.9 59.2 ± 22.5 56.7 ± 24.4 / 54.34 ± 26.9 
 
It could be argued that the disease-specific design of the tool limits comparability with other chronic 
diseases [8]. However, as the MOS-HIV largely corresponds to the SF-36 tool (with only minor 
differences in the items determining ‘Role functioning’ and ‘Social functioning’, and one extra subscale 
‘cognitive functioning’ in MOS-HIV), some explorative comparisons with other chronic diseases and 
with the general population could be made (Table 7). It seems that PLHIV have better scores on all 
subscales as compared to patients with fibromyalgia, chronic fatigue, chronic hepatitis C and COPD, 
with significant differences with the fibromyalgia and chronic fatigue patients. Scores of PLHIV are not 
significantly different from those within the general population. 
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Table 7: Explorative comparison of MOS-HIV values in PLHIV with SF-36 values in other chronically ill 
patients  
Total scores  
(mean ± SD) 
HIV Fibromyalgia 
[9] 
Chronic 
fatigue [10] 
Chronic 
hepatitis C 
(treated with 
antivirals) [11] 
COPD [12] General 
population 
(Netherlands) 
[13] 
Physical health score 53.1± 9.3 28.9 ± 7.4 / 40.78 ± 12.5 38.4 ± 9.9 / 
Mental health score 50.5 ± 9.6 39.1 ± 11.8 / 46.3 ± 12.5 48.6 ± 10.4 / 
Subscales        
General health 
perceptions 
63.8 ± 22.8 37.9 ± 20.7 29.8 ± 14.1 51.8 ± 21.0 46.4 ± 23.0 69.4 ± 19.6 
Physical functioning 81.6 ± 21.9 38.7 ± 22.1 42.7 ± 19.7 75.9 ± 21.9 52.4 ± 25.2 82.5 ± 24.8 
Role functioning 84.5 ± 32.6      
Role limitations physical   7.8 ± 19.7 10.2 ± 21.2 35.9 ± 44.3 30.1 ± 39.6 77.7 ± 37.8 
Role limitations 
emotional 
 45.0 ± 42.6 65.8 ± 42.9 43.2 ± 46.7 48.0 ± 44.5 87.2 ± 30.6 
Social functioning 82.0 ± 25.0 37.5 ± 24.8 44.9 ± 21.9 75.2 ± 24.4 74.4 ± 27.7 84.2 ± 23.1 
Pain 80.1 ± 22.9 24.9 ± 15.2 34.5 ± 19.7 73.3 ± 22.8 63.2 ± 29.3 80.2 ± 23.6 
Mental health 68.2 ± 18.1 55.4 ± 21.7 60.0 ± 18.1 61.0 ± 20.5 73.8 ± 17.9 77.3 ± 17.1 
Energy 65.9 ± 19.2 23.3 ± 18.3 27.5 ± 13.7 50.0 ± 25.1 49.9 ± 21.7 65.9 ± 20.0 
 
The review (3.1) showed that HRQoL in PLHIV is influenced by a variety of determinants. Through the 
diverse studies, a consensus emerged about the negative impact on HRQoL of following factors: a low 
socio-economic status, a poor immunological status, HIV symptoms, (psychiatric) comorbidity, a lack of 
social support and non-adherence to ART. Our experimental studies (3.2 and 3.3) highlight the 
importance of work situation and (neuro)psychological complaints. 
The high (nearly 100%) level of adherence required in HAART with limited forgiveness may translate 
into a lifelong challenge and even burden in a segment of PLHIV. Adherence in our study sample of the 
AIDS Reference Center (ARC) Ghent was studied in 3.4. Most of our study participants reported to be 
adherent, as assessed with the SMAQ and the CASE adherence index. There were, however, significant 
differences according to the instrument that was used. This indicates the complexity and difficulty of 
proper measurement of behavior. Females, smokers and people with neurocognitive complaints had a 
higher risk of non-adherence.  
The studies on HRQoL and adherence revealed that both constructs are associated. Non-adherence was 
associated with declines in both physical and mental health in the follow-up study. However, the true 
relationship between adherence and HRQoL should be studied more in depth to draw conclusions on 
possible causality. It would be necessary to disentangle adherence into its components (initiation, 
implementation, discontinuation) and to identify reasons for non (or late) initiation, suboptimal 
implementation and early discontinuation separately. These could have different patterns of association 
with HRQoL, as it is thought that initiation and implementation are rather person-related aspects and 
discontinuation is rather treatment-related. Moreover, studying the relationship between adherence and 
HRQoL would require a holistic approach in which possible confounders or mediating factors should 
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be included (for example side-effects, HIV symptoms, self-efficacy, maladaptive illness perceptions, 
satisfaction with patient-provider relationship, social network,  lifestyle, …). 
The study on HIV-related knowledge in adolescents (3.5) revealed that globally, knowledge was poor and 
some serious misconceptions about HIV still exist. A better HIV-related knowledge, not limited to this 
target population, could increase understanding and reduce HIV-related stigma. 
Finally, the study on disclosure (3.6) demonstrated that fear of discrimination is still high among 
PLHIV. However, most people who disclosed their seropositivity in the workplace, did not experience 
any negative or positive consequences. One could argue that perhaps people willing to disclose are likely 
to work in a more tolerating workplace. But maybe people who did not disclose would not experience 
any consequences after disclosure neither. As such, it remains possible that their fear of discrimination 
is maintained by anticipated and/or internal stigma. 
 
4.2. Strengths and limitations 
 
A number of limitations of the studies presented need to be acknowledged, as well as their strengths.  
Firstly, a narrative review on determinants of HRQoL in PLHIV is methodologically less sound than a 
systematic review. However, we have provided a transparent overview of the included studies in the 
methods section of the manuscript and in an additional table. 
Secondly, the observational studies on HRQoL and adherence may suffer from recruitment bias. These 
include the monocentric design, limited to the ARC of the Ghent University Hospital, and the open 
recruitment. Within this sample, favoring inclusion of Caucasian MSM, may bias towards a segment 
with better motivation and clinical outcomes. This subpopulation is likely to predispose towards 
participation in clinical studies. These issues of recruitment bias may hamper generalizability of findings. 
Nonetheless, the study population of nearly 250 PLHIV is noteworthy, especially taking into account the 
great detail of the questionnaires. The exploration of a broad set of possible determinants of HRQol, 
including neuropsychological parameters, in contrast to numerous previous studies focusing on more 
specific, limited sets of parameters may be considered a strength of the observational studies. However, it 
would have been interesting to include more data on somatic comorbidities and HIV symptoms. Those 
factors could have influenced HRQoL of our study sample, but were not part of our data acquisition. 
Data on HRQoL in PLHIV are the first in Belgium and values are available for both a generic (EuroQol 
– unpublished) as well as for a disease-specific (MOS-HIV) instrument. This pioneer research is in 
accordance with the recommendation to include HRQoL data at least on a periodical basis and/or 
sample wise (aimed at specific populations) in the Belgian national HIV cohort. This initiative has been 
elaborated by BREACH (Belgium Research on AIDS and HIV Consortium). Data collection will be 
operational as from 2015 and coordinated by the Scientific Institute of Public Health (ISP/WIV). An 
annual collection of HRQoL data within this framework should be considered relevant and desirable 
but feasibility needs to be assessed, both from the patient’s perspective and the associated workloads for 
the health care professionals. 
The follow-up study suffered from the same recruitment bias and the sample for this study included 
even less patients of minority groups due to non-ignorable drop-out. As such, alternative statistical 
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modeling could have been useful, or we could have restricted the analyses to participants who had 
follow-up data (listwise deletion). The participants at T1 seem to roughly represent an ‘upper class’ 
subpopulation within PLHIV followed in the Ghent ARC, limiting generalizability towards the Belgian 
PLHIV cohort. Lower recruitment and higher study discontinuation rates are typically seen in minority 
groups, but existing barriers could have been addressed [14]. Another limitation relates to the short 
follow-up period of one year. Especially in chronic diseases, it is important to follow the patients’ 
HRQoL during a longer period to obtain a true longitudinal perspective. Nonetheless, by conducting a 
follow-up study, we were able to include additional data in our comprehensive dataset, on which still 
supplementary analyses could be made (e.g. the relationship between clinical changes and HRQoL, 
identification of risk groups for declines in HRQoL…). 
Adherence to medication can be assessed through different methods. In this project, it was decided to 
use self-report questionnaires. This method is easy and fast, and by including two questionnaires, we 
could assess differences between the instruments. A disadvantage of self-report is the associated social 
desirability bias (particularly in interviews). It is possible that true adherence is lower than reported. This 
is evidenced by the observed significant difference in the proportion of adherent patients according to 
the SMAQ (79.4% - written self-report) versus the CASE adherence Index (93.6% - interview). 
Nonetheless, the two instruments have a positive correlation (phi coefficient 0.421, p<0.001) and the 
written assessment of the CASE at follow-up did not result in a lower proportion of adherent 
participants as compared to the interview at baseline. As such, in addition to the different assessment 
method, we presume also that substantial features of the SMAQ lead to more people being classified 
non adherent. Firstly, patients are asked ‘Do you ever forget to take your medicine?’. The answer on this 
question rather relies on the integrity of the patient than on the truth. It is – the exception proves the 
rule – impossible to be perfectly adherent [15]. The last question ‘Over the last 3 months, how many 
days have you not taken any medicine at all?’ should be interpreted carefully, keeping in mind the 
advent of single tablet regimens. One missed STR dose corresponds to one day of no medicine at all, 
whereas multi-pill regimens require more missed doses to result in a day without any medicine. We 
therefore suggest to adapt the SMAQ – developed in 1996 – to the current HAART regimens. We have, 
however, also remarks on the more recently developed CASE Adherence Index (2006). To our opinion, 
the instrument is too forgiving, i.e. the cut-off score of 10 (on a maximum of 16) is somewhat low and 
may be interpreted as too liberal.  
The study on HIV disclosure in the workplace was hampered by small sample size, for which different 
explanations could be brought forward. According to Sensoa, PLHIV are (over?)burdened by studies and 
they may have lost their interest and willingness to participate. Moreover, recruitment was done during a 
holiday period leading to suboptimal recruitment opportunities (and less motivated participants). 
Additionally, the flyer calling for the completion of the online questionnaire was not successful enough 
(i.e. questionnaire could not be completed immediately). We must also acknowledge a selection bias 
towards MSM, as sexual orientation and white-collar workers as type of job may influence disclosure. 
The results can therefore probably not be generalized.  
The last limitation relates to the HIV-related knowledge study. Knowledge was only assessed in 
university students. It would have been valuable to ask the same questions to other target groups (health 
care professionals, migrants, MSM…). However, by focusing on one target group – with presumed high 
knowledge levels – our study included a relatively homogenous group, which increases generalizability of 
our findings towards similar populations. 
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4.3. Future research projects 
 
There is a further potential for analysis of the HIV CARE project data, e.g. through analysis of sleep, 
fatigue and personality questionnaires. This will be performed in collaboration with the sleep research 
unit, at our department of General Internal Medicine, Ghent University Hospital. 
Further in-depth research about STRs will be performed from January 2016 on. The design of the 
project is partly based on the HIV CARE study (through using the same questionnaires). A cost-
effectiveness study will be conducted, based on real life data. A detailed list of costs and outcomes will 
be collected and results will be interesting for the different stakeholders: the patients, the clinicians, 
other health-care professionals, policy makers and the pharmaceutical industry. 
The link towards societal aspects of HIV will be further maintained through projects in collaboration 
with Sensoa. HIV disclosure was one of their main topics of 2014. However, disclosure is only one 
component in the complex web of stigma, discrimination, misconceptions, attitudes, prejudices and 
different situations of social interaction (in the workplace, on the street, in familial context…). It is 
necessary to further explore disclosure from a more comprehensive point of view, e.g. by using 
qualitative research methods and discrimination between internal and external stigma. The relevance of 
Sensoa’s progress towards an HIV@work framework is shown by our explorative study. Finally, 
knowledge was only assessed in university students, but it would be valuable to explore the same 
questions to other target groups as mentioned in the HIV plan (health care professionals, migrants, 
MSM…). 
And finally, interventional projects to improve HRQoL and/or adherence in our single center cohort or 
in larger multicenter cohorts may be considered. These could include: 
- Implementing screening for depressive symptoms and neurocognitive complaints in the HIV 
care path, to be repeated periodically. The screening must be accompanied by appropriate 
treatment options, if necessary. 
- Investigating non-adherence more analytically, in order to identify subgroups of non-adherent 
patients. More detailed questionnaires, or other methods (such as electronic monitoring 
systems) may be employed. The identification of subgroups (for example: patients taking drug 
holidays versus patients missing evening doses), could lead to more tailored adherence 
counseling. 
- Patients’ and physicians’ possible needs to improve the patient-physician relationship could be 
inventoried and possible organizational changes or courses could be implemented. 
 
4.4. Clinical and policy implications 
 
HRQoL, adherence and HIV care model 
In general, HRQoL of our study sample was good. This indicates a significant gain in QALY’s, as the life 
years gained are characterized by high HRQoL. Hence this increases the relevance of the improved 
survival in PLHIV [16]. However, long-term effects of ART, and/or long-term effects of delayed ART are 
not entirely known yet, and could certainly decrease HRQoL [16, 17]. Large and long lasting cohort 
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studies are needed to further understand the mechanisms and the interaction between ART and the 
infection [18]. In this regard, i.e. relating HRQoL and life-expectancy, insights on ‘HIV aging’ should 
also be incorporated. PLHIV have a higher risk to develop comorbidities (myocardial infarction, end-
stage renal disease and non-AIDS defining cancers) as compared to HIV-negative people. However, these 
comorbidities occur at a similar age as in HIV-negative people [19]. As such, this supports the concept of 
‘accentuated aging’, rather than ‘accelerated aging’, which represents new challenges in HIV care [19]. 
This highlights the increased importance of prevention, early detection and treatment of these 
comorbidities, even more so as compared to the general population in order to preserve high HRQoL 
throughout the increased longevity established with improvements in HAART. 
Both instruments, EuroQol and MOS-HIV, demonstrate a better physical than mental health in our 
sample. This reflects the current good clinical outcomes in most PLHIV due to effective and tolerable 
antiretroviral treatment. On the other hand, it also adverts to the fact that mental health – although 
correlated with physical health– does not simply ‘follow’ those physical advances [20]. Perceptions about 
health status include more than only physical aspects [21, 22]. Additionally, in PLHIV, implications of 
the infection itself (e.g. symptoms, fear of transmission, chronic medication burden…), but also other 
factors may hinder mental health. It should be noted that the two main populations living with HIV in 
Belgium, i.e. homosexual men and Sub-Saharan African migrants, can suffer from additional stigma as 
they are members of minority groups (homophobia, racism, lower socio-economic status…[23-25]). 
Current guidelines on HIV mainly focus on the clinical management of the disease (e.g. [26, 27]). 
However, as HRQoL in PLHIV is influenced by a variety of factors, the management should be broad 
and multidimensional. In Belgium, many PLHIV are treated and followed in an ARC, in which a 
multidimensional approach is assured by the presence of a multidisciplinary team. This facilitates 
possible interventions to improve HRQoL, such as the involvement of social nurses in return-to-work 
programs or the (neuro)psychological screening and treatment by psychologists and psychiatrists. 
Additionally, physicians, as well as the other health care providers, should take part in courses and 
training sessions about the patient-provider relationship. The different disciplines could exchange skills 
and experiences they have acquired though their work with this patient group.   
This multidimensional approach could still be intensified by systematically including patient-reported 
outcomes in clinical practice. The first steps in that area have been taken within the framework of the 
national AIDS plan and the planned periodical assessment of HRQoL in the Belgian cohort [28]. 
Patient-reported outcomes can, however, only be fully valuable if they are actually used as a guidance 
tool through the management [29]. Based on our findings, we consider the EuroQol-5D a valuable 
candidate as an instrument to monitor HRQoL in clinical practice. Scores are informative, the EuroQol-
5D is responsive to change when the visual analogue scale is included [30] and is predictive for mortality 
[31]. Additionally, the EuroQol-5D yields one score to describe HRQoL, which is simple and evades the 
(artificial) use of separate scores for physical and mental health  [32, 33]. Further, the EuroQol-5D can 
be used for cost-effectiveness analyses and comparability with other populations is assured [34]. The 
simplicity of the instrument is, however, also considered its biggest limitation. Ceiling effects blur 
differentiation in HRQoL in people considered in ‘perfect health’. HRQoL variations within those 
group are incontrovertibly present and important, but apparently not captured by the five domains of 
the EuroQol-5D. Therefore, a more extensive questionnaire (e.g. MOS-HIV, or more recent instruments 
developed in collaboration with patients e.g. PRO-QOL) could further inspire high-quality management 
as they result in a broader, more detailed picture of health status [34, 35]. Those questionnaires have a 
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higher face-validity for patients and clinicians as they can valuate disease-specific aspects impacting 
HRQoL [36]. 
Still some other adaptations could be made to the current care model for HIV in Belgium. Care  should 
become more embedded in the patient’s environment, through a better collaboration with the general 
practitioner (GP), the patient’s significant others, associations etc. [28]. This questions the need for all 
PLHIV to be followed in an ARC. Perhaps there are indeed arguments to ‘shift’ the clinically stable 
patients (i.e. undetectable viral load, stable or rising CD4-count, no signs of medication toxicity) to 
primary care, to preserve secondary/tertiary care for patients who need it and to organize at least part of 
the clinical follow-up through e-Health services [37, 38]. Moreover, with the current longevity of HIV 
and associated age-related comorbidities, the GP could fulfill a coordinating role in the HIV 
management, as it is the case for other chronic diseases such as diabetes or arthritis [37]. In African 
countries, which are confronted with less resources and more PLHIV, task-shifting has shown to be a 
good strategy towards more efficiency [39]. More involvement of primary care in HIV care could perhaps 
also improve the continuum of care in Belgium due to improvements in accessibility [37]. Although the 
majority of PLHIV are in medical care, an unknown number of people are not aware of their 
seropositivity and about 20% are not retained in medical care [40].  
Nevertheless, the need for multidisciplinary care remains and appropriate resource shifts should be 
provided. Further, there would be a need for education among general practitioners, a protocol 
stipulating the coordination and the task division between primary and secondary/tertiary care and 
assuring a good communication between different caregivers [41]. However, a Belgian survey exploring 
the readiness/willingness of general practitioners and PLHIV to shift routine HIV care towards primary 
care showed that only a minority of the participating PLHIV (5/27, 18.5%) would consult their GP for 
HIV-related follow-up, while the majority of the participating GPs was willing to do so (61/97, 62.5%) 
[41].  
Within the adapted care model, the development of self-management should also be incorporated [28]. 
This is especially important to improve adherence, as this responsibility ultimately lies with the patient. 
Health care providers should be aware of possible risk groups for suboptimal adherence, but should 
always further examine the underlying reasons.  
HIV and society 
A common theme arose from the disclosure and knowledge studies: up till now, HIV integration in 
society seems insufficient.  
Among the PLHIV who responded to our online questionnaire, many were still afraid to be 
discriminated at the workplace and this proved the main reason not to disclose their seropositivity. 
Disclosure is a double-edged sword for PLHIV: with disclosure, they can experience negative 
consequences, but if they do not disclose, they involuntarily maintain the taboo around HIV [42]. 
Therefore, investing in solidarity campaigns, as well as in a framework ‘HIV@work’ (for PLHIV, 
employers, employees…), is crucial. Even so, disclosure is a main theme for PLHIV in daily life and in 
different social settings. It remains a personal choice and it is mostly the result of a process with many 
influencing factors [43, 44]. One of those, sometimes forgotten or minimized, could be the discussions 
and counseling about disclosure with health care providers. They should have proficient knowledge and 
skills to help the patient make the best choices. They could also enable the patient to set approach-
focused goals, which would facilitate the disclosure process [44]. 
 159 
 
The second study in this framework showed that HIV-related knowledge in university students is still 
unsatisfactory. It seems that they are not informed enough about sexual risk behavior. In order to reach 
as many young people as possible, this topic could be included in their curriculum (and should not be 
restricted to the ‘facts’ as in biology lessons). Other options are information campaigns through 
television programs, social media, events… Our findings appeal also to clinicians: they should be aware 
of the rather poor knowledge of HIV in young people. General practitioners could inquire and inform 
about sexual risk behavior and specialists who see young NONOPEP (non-occupational post-exposure 
prophylaxis) or HIV patients, could shortly probe and, if necessary, increase HIV-related knowledge so 
future risk behavior could be reduced. 
As this study was performed among highly educated people, it could be deduced that HIV-knowledge in 
the general population is even lower [45]. Increasing the knowledge about HIV could aim at tackling 
one of the most important underlying reasons of HIV stigma, namely ignorance. When people would 
endorse HIV truths (e.g. correct transmission routes, effective treatment which lowers transmission risk) 
instead of HIV myths, HIV stigma could be reduced [46, 47]. Up till now, however, there is almost no 
literature on the effectiveness of such interventions. Firstly, small and short-term interventions have 
been described, such as increasing tolerance by supply of factual information about HIV, but they have 
little (long-term) effectiveness [48]. Secondly, community-based interventions (e.g. mass media 
campaigns), which have the possibility to be effective, have rarely been developed and described 
scientifically [48]. It is recommended that stigma-reduction starts at the intrapersonal level. As such, 
internalized stigma is tackled and empowered PLHIV can help in the development and implementation 
of ‘higher level’ interventions on the governmental and structural level such as legal aid services to 
report discrimination [49]. Increasing the knowledge about HIV could also contribute to preventing new 
HIV infections, although this is only one of the numerous and mutually reinforcing strategies [47, 50]. 
 
Conclusion 
 
In general, research on HRQoL in PLHIV suffers from methodological difficulties. Instruments which 
are easy and fast to administer in clinical practice, which are at the same time detailed enough to be 
sensitive for change and last but not least, which capture the currently relevant and appropriate 
determinants of HRQoL should be developed. 
Determinants of HRQoL identified in our single-center study population of PLHIV overlap with those 
discussed in the narrative review. A broad spectrum of determinants – from socio-economic status to 
comorbidity – should be monitored and therefore, in HIV care, a multidimensional, holistic approach is 
valuable. 
A good HRQoL was found in our single-center sample. Current good clinical outcomes in many PLHIV, 
due to significant improvements in HAART tolerability, translate into good physical health scores. As 
HIV has become a chronic condition, HIV management requires adaptations to the chronic care model 
in which a partial shift of care to and shared responsibility of caregivers, including primary care, are 
mandatory and advocated. In particular, mental health deserves special attention, as it still may come 
under pressure due to e.g. HIV stigma. 
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HIV stigma is fueled by ignorance, which remains present in society, in spite of numerous solidarity 
campaigns. The study among university students proved that their HIV knowledge is unsatisfactory. 
Stigma hampers real and thorough integration of PLHIV. Hence, it was found that fear of 
discrimination limits disclosure of PLHIV in our study. Counseling about coping with HIV stigma and 
disclosure is an important aspect within the management of HIV. 
Other patient-reported outcomes, such as adherence, are equally indispensable to monitor. Similar to 
HRQoL, however, is the need for an updated and reliable self-report questionnaire. 
In summary and conclusion, HRQoL appears high in PLHIV followed in a Belgian AIDS Reference 
Center as compared to other chronic medical conditions, with a wide range of determinants. New 
adapted measurement tools are needed to assess different dimensions of HRQoL and adherence. 
Knowledge levels need to be improved as a prerequisite to reduce stigma and facilitate a more positive 
approach-based autonomous and individual choice for disclosure, in the patient environment, including 
the workplace. 
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SUMMARY 
 
Background 
HIV and AIDS remain a major issue in global health. Worldwide, although the incidence of new 
infections seems to decrease or at least stabilize, the prevalence of HIV infection remains a huge health 
burden. In Belgium, similar trends are observed. With improved survival, a significant number of people 
are living with HIV (PLHIV). There are about 14.000 PLHIV in medical care in Belgium. 
Since the advent of highly active antiretroviral therapy (HAART), HIV has turned from a lethal into a 
chronic disease. This evolution entails new challenges for the medical world (a) and for the people living 
with HIV (PLHIV) (b), but also for society (c).  
(a) The management of a chronic disease requires a multidisciplinary approach and a long-term 
vision in which the health-related quality of life (HRQoL) of the patient is crucial.  
(b) The vast majority of PLHIV takes lifelong medication, which requires strict adherence. 
PLHIV are still confronted with stigma. 
(c) HIV stigma should be tackled. 
 
Aims 
In this study, five main goals were identified: 
1. Conducting a literature review on determinants of health-related quality of life (HRQoL) in 
PLHIV 
2. Assessing HRQoL over time and searching for determinants of HRQoL over time, in a single 
center sample of PLHIV from an AIDS Reference Center in Belgium 
3. Assessing adherence and its determinants in PLHIV, in the same single center sample 
4. Assessing knowledge levels on HIV in university students 
5. Assessing disclosure and adherence of PLHIV at the workplace 
 
Methods 
A longitudinal study was set up in the AIDS Reference Center of Ghent to collect socio-demographic-, 
quality of life-, and adherence data. Two studies were performed outside this setting, in collaboration 
with Ghent University and Sensoa. 
 
Results 
1. Determinants of HRQoL in PLHIV are diverse. The negative association between HRQoL and 
a low socio-economic status, a poor immunological status, HIV symptoms, (psychiatric) 
comorbidity, a lack of social support and non-adherence to ART emerged. 
2. We have found good HRQoL in our study sample, comparable to controls and better than 
other chronic diseases. HRQoL in PLHIV is influenced and predicted by a variety of 
determinants, including many non-clinical determinants.  
3. A vast majority of the study sample reports to be adherent; risk groups for non-adherence were 
identified. 
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4. HIV-related knowledge in university students was rather poor and some serious misconceptions 
about HIV still exist. 
5. Fear of discrimination after disclosure in the workplace is high. However, most people who 
announced their seropositivity, did not experience any consequences. Adherence in the 
workplace does not seem to be a problem. 
 
Recommendations 
1. The management of HIV should draw particular attention to (non-clinical) determinants of 
HRQoL. 
2. Information campaigns for young people about HIV are warranted to improve their HIV-related 
knowledge and to help reduce HIV stigma. 
3. PLHIV would benefit from an HIV@work framework and this could also decrease potential 
ignorance and misconceptions in employers and colleagues.  
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SAMENVATTING 
 
Achtergrond 
 
Hiv en aids staan nog steeds hoog op de wereldagenda. Hoewel het aantal nieuwe infecties stabiel blijft, 
en zelfs een dalende trend vertoont, blijft de hoge prevalentie van hiv een groot gezondheidsprobleem. 
In België zijn een gelijkaardige evoluties merkbaar: hiv-incidentie blijft stabiel (de laatste cijfers tonen 
zelfs een daling) maar door de verbeterde overleving leven meer en meer mensen met het virus. In België 
worden er ongeveer 14.000 personen met hiv medisch opgevolgd.  
Na de komst van hoog actieve antiretrovirale therapie (HAART), evolueerde hiv van een dodelijke naar 
een chronische ziekte. Deze evolutie brengt nieuwe uitdagingen met zich mee voor de medische wereld 
(a), voor de personen met hiv (b), maar ook voor de maatschappij (c). 
 
(a) Het management van een chronische zieke patiënt vereist een multidisciplinaire aanpak en een 
langetermijnvisie, waarbij de levenskwaliteit van de patiënt van cruciaal belang is. 
(b) De grote meerderheid van de patiënten neemt levenslang medicatie, die strikte inname vereist.  
Personen met hiv krijgen nog steeds te maken met hiv-stigma. 
(c) Hiv-stigma moet worden aangepakt. 
 
Doelstellingen van het proefschrift 
 
In deze studie werden drie doelstellingen beoogd: 
1. Het verrichten van een literatuurstudie over determinanten van gezondheidsgerelateerde 
levenskwaliteit bij personen met hiv 
2. Het meten van de gezondheidsgerelateerde levenskwaliteit en het bepalen van de 
determinanten ervan in een studiepopulatie van personen met hiv afkomstig uit een 
aidsreferentiecentrum in België 
3. Het meten van therapietrouw en het bepalen van determinanten ervan in dezelfde 
studiepopulatie 
4. Het meten van de hiv-kennis bij universiteitsstudenten 
5. Het bevragen de bekendmaking van de hiv-status en de therapietrouw op het werk 
 
Methodologie 
 
Er werd een longitudinale studie opgezet in het aidsreferentiecentrum van Gent. Hierbij werden socio-
demografische data, alsook data omtrent gezondheidsgerelateerde levenskwaliteit en therapietrouw  
verzameld. Twee studies werden elders uitgevoerd, in samenwerking met de Universiteit Gent en 
Sensoa. 
 
Resultaten 
 
1. Gezondheidsgerelateerde levenskwaliteit wordt beïnvloed door diverse determinanten. Er is een 
consensus over het negatief verband tussen gezondheidsgerelateerde levenskwaliteit en een lage 
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socio-economische status, a zwakke immunologischel status, HIV symptomen, (psychiatrische) 
comorbiditeit, gebrek aan sociale steun en therapie-ontrouw voor antiretrovirale medicatie. 
2. In het algemeen rapporteert de studiegroep een goede kwaliteit van leven. Kwaliteit van leven 
wordt beïnvloed door een verschillende factoren, waaronder vele niet-klinische factoren. 
3. Een meerderheid van de studiegroep zegt therapietrouw te zijn; risicogroepen voor 
therapieontrouw werden geïdentificeerd. 
4. Kennis over hiv bij universiteitsstudenten is eerder onvoldoende en er heersen enkele 
hardnekkige misvattingen over hiv. 
5. De angst voor discriminatie na het bekendmaken van de serostatus op het werk is hoog. De 
meeste mensen die hun seropositiviteit bekendmaken, ondervinden echter geen gevolgen. 
Therapietrouw op het werk vormt voor de meeste personen geen probleem. 
 
Aanbevelingen 
 
1. Bij de behandeling van hiv zou bijzondere aandacht moeten gegeven worden aan (niet-klinische) 
determinanten van kwaliteit van leven. 
2. Voorlichtings- en informatiecampagnes bij adolescenten over hiv zijn noodzakelijk om hun hiv-
kennis te verhogen en hiv-stigma te verminderen. 
3. Personen met hiv zouden baat hebben bij een raamwerk ‘HIV@work’. Dat kan ook de 
potentiële onwetendheid en misvattingen bij werkgevers en collega's wegnemen. 
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EQ-6D 
This questionnaire asks about your idea about your health. With this information we can record how you are feeling and how 
well you are able to do your daily activities. Thank you for filling in this questionnaire!  
Answer each of the following questions by putting a cross  in the space after the answer that corresponds the best to your 
health status today.  
 
1. Mobility 
I have no problems in walking around          
I have some problems in walking around         
I am confined to bed           
 
2. Self-Care 
I have no problems with self-care          
I have some problems washing or dressing myself         
I am unable to wash or dress myself          
 
3. Usual activities (e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities        
I have some problems with performing my usual activities        
I am unable to perform my usual activities         
 
4. Pain/Discomfort 
I have no pain or discomfort           
I have moderate pain or discomfort          
I have extreme pain or discomfort          
 
5. Anxiety/Depression 
I am not anxious or depressed          
I am moderately anxious or depressed          
I am extremely anxious or depressed          
 
6. Cognition 
I have no problems with my cognitive functioning (e.g. memory, concentration, IQ, …)     
I have some problems with my cognitive functioning (e.g. memory, concentration, IQ, …)     
I have severe problems with my cognitive functioning (e.g. memory, concentration, IQ, …)    
 
 III 
 
7. To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the best 
state you can imagine is marked 100 and the worst state you can imagine is marked 0.  
We would like you to indicate on this scale how good or bad your own health is today, in your opinion. Please do this by 
drawing a line from the box below to whichever point on the scale indicates how good or bad your health state is today. 
 
Best imaginable health state                                                                                                 
 
Worst imaginable health state   
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MOS-HIV 
We would like you to answer some questions about how you are feeling and the kinds of things you are able to do. Your 
answers will help us understand the effects of the medication you are taking.  
Answer each of the following questions by putting a cross  in the space after the answer that corresponds the best to your 
health status today.  
 
1. In general, would you say your health is: 
Excellent            
Very good            
Good            
Fair             
Poor            
 
2. How much bodily pain have you generally had during the past 4 weeks? 
None            
Very mild            
Mild            
Moderate            
Severe            
Very severe            
 
3. During the past 4 weeks, how much did pain interfere with your normal work (or your normal activities, including 
work outside and housework)? 
Not at all            
A little bit            
Moderately            
Quite a bit            
Extremely            
 
4. The following questions are about activities you might do during a typical day. Does you health now limit you in these 
activities? If so, how much?  
 Yes, limited a lot Yes, limited a little No, not limited 
a. The kinds or amounts of vigorous 
activities you can do, like lifting heavy 
objects, running of participating in 
strenuous sports. 
   
b. The kinds of amounts of moderate 
activities you can do, like moving a table, 
carrying groceries or bowling 
   
c. Walking uphill or climbing (a few flights 
of stairs). 
   
d. Bending, lifting or stooping    
e. Walking one block    
f. Eating, dressing, bathing or using the 
toilet 
   
 
5. Does your health keep you from working at a job, doing work around the house or going to school? 
Yes             
No             
 
6. Have you been unable to do certain kinds or amounts of work, housework or schoolwork because of your health?  
Yes             
No             
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7. How much of the time, during the past 4 weeks, has your health limited your social activities (like visiting with friends 
or close relatives)? 
All of the time           
Most of the time           
A good bit of the time          
Some of the time           
A little of the time          
None of the time           
 
8. For each of the following questions, please check the box for the one answer that comes closest to the way you have 
been feeling during the past 4 weeks. 
How much of the time, during the 
past 4 weeks: 
All of the 
time 
Most of 
the time 
A good bit 
of the 
time 
Some of 
the time 
A little of the 
time 
None of the 
time 
a. Have you been a very nervous 
person? 
      
b. Have you felt calm and 
peaceful? 
      
c. Have you felt downhearted 
and blue? 
      
d. Have you been a happy 
person? 
      
e. Have you felt so down in the 
dumps that nothing could 
cheer you up? 
      
 
9. For each of the following questions, please check the box for the one answer that comes closest to the way you have 
been feeling during the past 4 weeks. 
 
How often, during the past 4 
weeks: 
All of the 
time 
Most of 
the time 
A good bit 
of the 
time 
Some of 
the time 
A little of the 
time 
None of the 
time 
a. Did you feel full of pep?       
b. Did you feel worn out?       
c. Did you feel tired?       
d. Did you have enough energy 
to do the things you wanted to 
do? 
      
e. Did you feel weighed down by 
you health problems? 
      
f. Were you discouraged by your 
health problems? 
      
g. Did you feel despair over your 
health problems? 
      
h. Were you afraid because of 
you health? 
      
10. For each of the following questions, please check the box for the one answer that comes closest to the way you have 
been feeling during the past 4 weeks. 
 
How much of the time, during the 
past 4 weeks: 
All of the 
time 
Most of 
the time 
A good bit 
of the 
time 
Some of 
the time 
A little of the 
time 
None of the 
time 
a. Did you have difficulty 
reasoning and solving 
      
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problems, for example, making 
plans, making decisions, 
learning new things? 
b. Did you forget things that 
happened recently, for 
example, where you put things 
and when you had 
appointments? 
      
c. Did you have trouble keeping 
your attention on any activity 
for long? 
      
d. Did you have difficulty doing 
activities involving 
concentration and thinking? 
      
 
11. Please check the box that best describes whether each of the following statements is true or false for you. 
 Definitely 
true 
Mostly true Not sure Mostly false Definitely false 
a. I am somewhat ill 
 
     
b. I am as healthy as 
anybody I know 
     
c. My health is excellent      
d. I have been feeling bad 
lately 
     
 
12. How has the quality of your life been during the past 4 weeks? That is, how have things been going for you? 
Very well, could hardly be better          
Pretty good            
Good and bad parts about equal          
Pretty bad            
Very bad, could hardly be worse          
 
13. How would you rate your physical health and emotional condition now compared to 4 weeks ago? 
Much better            
A little better            
About the same           
A little worse            
Much worse            
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SMAQ 
 
Do you take antiretroviral therapy? (HIV-medication) 
No             
Yes  
            
If so: 
1. Do you ever forget to take your medicine?  
No            
Yes            
2. Are you careless at times about taking your medicine? 
No            
Yes            
3. If sometimes you feel worse when taking the medicine, do you stop taking it? 
No            
Yes            
4. Thinking about the last week. How often have you  not taken your medicine?              …. times 
 
5. Did you take all of your medicine over the last weekend? 
Yes            
No            
6. Over the past 3 months, how many days have you not taken any medicine at all?                          … times 
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CASE Adherence Index 
 
1. How often do you feel that you have difficulty taking your HIV medications on time? By ‘on time’ we mean no more 
than two hours before or two hours after the time you doctor told you to take it. 
Never      (4) 
Rarely      (3) 
Most of the time    (2) 
All of the time    (1) 
 
5. On average, how many days per week would you say that you missed at least one dose of your HIV medication? 
Every day     (1) 
4-6 days per week    (2) 
2-3 days per week    (3) 
Once a week    (4) 
Less than once a week    (5) 
Never      (6) 
 
6. When was the last time you missed at least one dose of your HIV-medication? 
 
Within the last week    (1) 
1-2 weeks ago     (2) 
3-4 weeks ago    (3) 
Between 1 and 3 months ago    (4) 
More than 3 months ago    (5) 
Never      (6)    
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Beck Depression Inventory 
This questionnaire consists of 21 groups of statements. Please read each group of statements carefully, and then pick out the 
one statement in each group that best describes the way you have been feeling during the past two weeks, including today. Put a 
cross in the space beside the statement you have picked. If several statements in the group seem to apply equally well, put a 
cross in the space beside the statement with the highest number for that group. Be sure that you do not choose more than one 
statement for any Group, including item 16 (changes in sleeping pattern) or item 18 (changes in appetite). 
1. 0.     I do not feel sad          
1. I feel sad much of the time         
2. I am sad all the time         
3. I am so sad or unhappy that I can’t stand it       
 
2. 0.   I am not discouraged about my future        
1. I feel more discouraged about my future than I used to be      
2. I do not expect things to work out for me       
3. I feel my future is hopeless and will only get worse      
 
3. 0.   I don’t feel like a failure         
1. I have failed more than I should have        
2. As I look back, I see lot of failures        
3. I feel I am a total failure as a person        
 
4. 0.  I get as much pleasure as I ever did from the things I do      
1. I don’t enjoy things as much as I used to do       
2. I get little pleasure from the things I used to enjoy      
3. I can’t get any pleasure from the things I used to enjoy      
 
5. 0.  I don’t feel particularly guilty         
1. I feel guilty about many things I have done or should have done     
2. I feel guilty most of the time         
3. I feel guilty all of the time         
 
6. 0.  I don’t feel I am being punished        
1. I feel I may be punished         
2. I expect to be punished         
3. I feel I am being punished         
 
7. 0.   I feel the same about myself as ever        
1. I have lost confidence in myself        
2. I am disappointed in myself         
3. I dislike myself          
 
8. 0.  I don’t criticize or blame myself more than usual       
1. I am more critical of myself than I used to be       
2. I criticize myself for all of my faults        
3. I blame myself for everything bad that happened       
 
9. 0. I don’t have any thoughts of killing myself       
1. I have thoughts of killing myself, but I would not carry them out     
2. I would like to kill myself         
3. I would kill myself if I had the chance        
10. 0.  I don’t cry anymore than I used to        
1. I cry more than I used to         
2. I cry over every little thing         
 X 
 
3. I feel like crying, but I can’t         
 
11. 0.  I am no more restless or wound up than usual        
1. I am more restless or wound up than usual       
2. I am so restless or agitated that it’s hard to stay still      
3. I am so restless or agitated that I have to keep moving or doing something    
      
12. 0.   I have not lost interest in other people or activities.      
1. I am less interested in other people or things than before      
2. I have lost most of my interest in other people or things .     
3. It’s hard to get interested in anything  .      
 
13. 0.   I make decisions as well as ever        
1. I find it more difficult to make decisions than usual      
2. I have much greater difficulty in making decisions than I used to     
3. I have trouble making any decision        
 
14. 0.  I do not feel I am worthless          
1. I don’t consider myself as worthwhile and useful as I used to do     
2. I feel more worthless as compared to other people      
3. I feel utterly worthless         
 
15. 0.  I have as much energy as ever         
1. I  have less energy than I used to have        
2. I don’t have enough energy to do very much       
3. I don’t have enough energy to do anything       
      
16. 0.   I have not experienced any change in my sleeping pattern       
1. I sleep somewhat more than usual        
I sleep somewhat less than usual        
2. I sleep a lot more than usual         
I sleep a lot less than usual         
3. I sleep most of the day          
I wake up 1-2 hours early and can’t get back to sleep      
 
17. 0.   I am no more irritable than usual        
1. I am more irritable than usual        
2. I am much more irritable than usual        
3. I am irritable all of the time         
 
18. 0.   I have not experienced any change in my appetite      
1. My appetite is somewhat less than normal       
My appetite is somewhat greater than usual       
2. My appetite is much less than before        
My appetite is much greater than usual        
3. I have no appetite at all         
I crave food all the time         
 
19. 0.  I can concentrate as well as ever         
1. I can’t concentrate as well as usual         
2. It’s hard to keep my mind on anything for very long      
3. I find I can’t concentrate on anything        
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20. 0.  I am no more tired or fatigued than usual        
1. I get more tired or fatigued more easily than usual      
2. I am too tired or fatigued to do a lot of things I used to do      
3. I am too tired or fatigued to do most of the things I used to do     
 
21. 0.  I have not noticed any recent change in my interest in sex      
1. I am less interested in sex than I used to be       
2. I am much less interested in sex now        
3. I have lost interest in sex completely        
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3 Neurocognitive screening questions 
 
1. Do you experience frequent memory loss?         
(for example: do you forget the occurrence of special events even the more recent ones,  
appointments etcetera?) 
            yes/no 
 
2. Do you feel that you are slower when reasoning, planning activities, or solving problems?  
            yes/no 
 
3. Do you have difficulties paying attention?    
(for example: to a conversation, a book, or a movie) 
yes/no 
 
 
